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Visual impairment (VI) is a public health problem with substantial disease burden 
worldwide. With the aging population, the prevalence of VI will increase dramatically, 
leading to a much heavier disease burden on individuals and society in the coming 
future. In order to alleviate the burden of VI, studies comprehensively and precisely 
measuring the disease burden from the economic and humanistic perspectives are 
essential for policy makers in resource allocation and preventative programs design. 
 
For the economic burden of VI, majority of the studies are conducted in western 
countries, while in Asia, such studies are limited. Considering the high prevalence of 
VI in Asia that about 180.7 million people were visually impaired in 2010, it is 
necessary to explore the economic burden of VI. Meanwhile, generic health-related 
quality of life (HRQOL) is useful in the comparison between multiple health 
conditions and could be used in the cost-utility analysis (CUA), while studies 
exploring the impact of vision problems on generic HRQOL are limited. Compared 
with vision-specific quality of life, the limited usage of generic HRQOL instruments 
could be due to its general insensitivity.   
   
Within this framework, several research questions concerning the economic and 
humanistic burden of vision problems were addressed. First, we estimated the direct 
medical costs from VI in Singapore. We found that VI imposed considerable direct 
costs at both individual and population levels in Singapore. Meanwhile, the direct 
ii 
 
medical costs due to VI and four major eye diseases were likely to increase 
dramatically in the next decades. Second, we estimated the out-of-pocket expenditure 
and productivity loss of VI in Singapore. We found that VI had significant economic 
burden to the visually impaired patient and their families. Third, we measured the 
health burden associated with VI and compared the burden of VI with other four 
health conditions in Singapore. We found that VI was associated substantial health 
burden among Asians in Singapore. Fourth, we explored the effect of visual acuity 
(VA) on generic HRQOL among patients with VI in Singapore. We found that VA of 
the worse-seeing eye may have larger impact than that of the better-seeing eye on the 
health utility of visually impaired individuals. Fifth, we explored the effect of a vision 
‘bolt-on’ item on the sensitivity of EQ-5D to the impact of vision problems. We found 
that the vision ‘bolt-on’ EQ-5D appeared to be more discriminative than the standard 
EQ-5D in measurement of vision problems.  
 
These studies have provided new knowledge about the economic and humanistic 
burden of VI in Singapore. First, the economic and health burden of VI is substantial 
to visually impaired patients and their caregivers at both individual and population 
level in Singapore. The findings highlight the importance of VI prevention programs 
and provide detail information that could be used in the CUA of eye disease 
interventions in the future. Second, VA of the worse-seeing eye should be also used in 
the HRQOL studies, considering the larger impact of VA of the worse-seeing eye than 
that of the better-seeing eye on the health utility of visually impaired individuals. 
iii 
 
Third, the vision ‘bolt-on’ EQ-5D shows more discriminative more than standard 
EQ-5D in measurement of vision problems and the sensitivity of the vision ‘bolt-on’ 
EQ-5D to vision change in interventional studies needs to be further investigated.    
iv 
 
List of Tables 
Table 2.1 Socio-demographic characteristics and costs for visual impairment in 
Singapore (n=500) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .34 
Table 2.2 Annual costs per capita in categories of major eye diseases and visual 
impairment (n=500) . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . 35 
Table 2.3 Projection of the number of individuals with major eye diseases and visual 
impairment in 2015 to 2040. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36 
Table 2.4 Projection of the direct medical costs of major eye diseases and visual 
impairment in 2015 to 2040. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37 
Table 3.1 Characteristics of participants with and without visual impairment 
(n=1,000) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .50 
Table 3.2 Annual health service utilization and out-of-pocket expenditure of 
individuals with and without visual impairment (n=1,000) . . . . . . . . . . . . . . . . . . . . 51 
Table 3.3 Annual absenteeism and productivity loss of individuals with and without 
visual impairment (n=1,000) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .52 
Table 4.1 Socio-demographic and health characteristics of the participants 
(n=10,009) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .66 
Table 4.2 Prevalence and EQ-5D index score for different severities of unilateral and 
bilateral visual impairment (n=10,009). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 
Table 4.3 Effects of different severities of unilateral and bilateral visual impairment 
on EQ-5D index score in multivariate regression analysis (n=10,009). . . . . . . . . . . .68 
Table 4.4 Odds ratios (95% confidence interval) of different severities of unilateral 
v 
 
and bilateral visual impairment in predicting EQ-5D health problems 
(n=10,009) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .69 
Table 4.5 Annual quality-adjusted life-years (QALYs) loss per 100,000 persons 
associated with visual impairment and other health conditions. . . . . . . . . . . . . . . . . .71 
Table 5.1 Socio-demographic characteristics, visual acuity measure and EQ-5D index 
score for participants in the study (n=3,183) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83 
Table 5.2 Unadjusted effects of VA measures on EQ-5D index score in participants 
with bilateral VI (n=1,179) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86  
Table 5.3 Unadjusted effects of VA measures on EQ-5D index score in participants 
with bilateral VI by age group and by ethnicity (n=1,179) . . . . . . . . . . . . . . . . . . . . .87 
Table 5.4 Unadjusted effects of VA measures on EQ-5D index score in participants 
with bilateral VI by social-economic status (n=1,179) . . . . . . . . . . . . . . . . . . . . . . . .88 
Table 5.5 Unadjusted effects of VA measures on EQ-5D index score in participants 
with bilateral VI by socio-economic status and age group (n=1,179). . . . . . . . . . . . . 89 
Table 5.6 Odds Ratios (95% confidence interval) of VA measures on each EQ-5D 
domain in participants with bilateral VI by socio-economic status and age group 
(n=1,179). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 
Table 5.7 Unadjusted effects of VA measures on EQ-5D index score in participants 
with unilateral VI (n=2,004) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91  
Table 5.8 Unadjusted effects of VA measures on EQ-5D index score in participants 
with unilateral VI by age group (n=2,004) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 
Table 5.9 Unadjusted effects of VA measures on EQ-5D index score in participants 
vi 
 
with unilateral VI by social-economic status (n=2,004) . . . . . . . . . . . . . . . . . . . . . . .93 
Table 5.10 Unadjusted effects of VA measures on EQ-5D index score in participants 
with unilateral VI by socio-economic status and age group (n=2,004). . . . . . . . . . . . 94 
Table 5.11 Odds Ratios (95% confidence interval) of VA measures on each EQ-5D 
domain in participants with unilateral VI by socio-economic status and age group 
(n=2,004). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 
Table 6.1 Characteristics of the EQ-5D value sets used in the study . . . . . . . . . . . . 105 
Table 6.2 Characteristics of participants with and without visual impairment 
(n=836). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .110 
Table 6.3 Mean (SD) EQ-5D index scores for different visual impairment groups 
(n=836) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114 
Table 6.4 Mean (SD) EQ-5D index scores for groups with and without a vision 




List of Figures 
Figure 6.1 Unadjusted mean differences in EQ-5D index scores between different 
visual impairment groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .117 
Figure 6.2 Adjusted mean differences in EQ-5D index scores between different VI 
groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .118 
Figure 6.3 Unadjusted mean differences in EQ-5D index scores between groups with 
and without a vision problem assessed by the VF-14 . . . . . . . . . . . . . . . . . . . . . . . .119 
Figure 6.4 Adjusted mean differences in EQ-5D index scores between groups with 
and without a vision problem assessed by the VF-14 . . . . . . . . . . . . . . . . . . . . . . . .120 
Figure 6.5 F-statistic ratios of unadjusted mean difference in EQ-5D index scores 
between different visual impairment groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121 
Figure 6.6 F-statistic ratio of adjusted mean difference in EQ-5D index scores 
between different VI groups. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .122 
Figure 6.7 F-statistic ratios of unadjusted mean differences in EQ-5D index scores 
between groups with and without a vision problem assessed by the VF-14. . . . . . . 123 
Figure 6.8 F-statistic ratio of adjusted mean differences in EQ-5D index scores 




List of Acronyms 
AMD Age-related macular degeneration 
BMI Body mass index 
BMVA Better eye-weighted mean visual acuity 
BP Blood pressure 
BVA Visual acuity in the better-seeing eye 
CI Confidence interval 
CUA Cost-utility analysis 
DALY Disability-adjusted life years 
DR Diabetic retinopathy 
EQ-5D European Quality of Life-5 Dimensions 
HRQOL Health-related quality of life 
HUI Health  Utilities Index 
ICD-10 International Classification of Diseases 
IOP Intraocular pressure 
LogMAR Logrithm of the minimum angle of resolution 
MVA Mean of visual acuity 
MVH Measurement and Valuation of Health Study 
NEI-VFQ National Eye Institute Visual Function Questionnaire 
NICE National Institute for Health and Care Excellence 
OECD Economic Co-operation and Development 
OOP Out-of-pocket  
OR Odds ratio 
PACG Primary angle-closure glaucoma 
POAG Primary angle-open glaucoma 
QALY Quality-adjusted life years 
RE Refractive error 
SCES Singapore Chinese Eye Study 
SD Standard deviation 
iii 
 
SE Standard error 
SEED Singapore Epidemiology of Eye Disease 
SES Socio-economic status 
SF-6D Short form 6 Dimensions 
SG Singapore 
SiMES Singapore Malay Eye Study 
SINDI Singapore Indian Eye Study 
UCRE Under-corrected refractive error 
VA Visual acuity 
VF-14 Visual Function Index-14 
VI Visual impairment 
VSQOL vision-specific quality of life 
WHO World Health Organization 
WMVA Worse eye-weighted mean visual acuity 
WVA Visual acuity in the worse-seeing eye 
YLD Years lost due to disability 






List of Publications 
Published papers 
Wang X, Lamoureux E, Zheng Y, et al. Health burden associated with visual 
impairment in Singapore: the Singapore epidemiology of eye disease study. 
Ophthalmology. 2014; 121: 1837-42. 
 
Luo N*, Wang X*, Ang M, et al. A vision ‘bolt-on’ item could increase the 
discriminatory power of the EQ-5D index score. Value in Health. 2015; 18: 1037-42. 
*Contributions to the manuscript are equal. 
  
Award 
Student Travel Grant Winner for ISPOR 20
th














1 Visual Impairment 
Visual impairment (VI) is a public health problem, which exerts substantial burden worldwide. 
According to the estimate from the World Health Organization (WHO), in 2010, about 285.39 
million people were visually impaired worldwide, among whom 246.02 million people were in 
low vision and 39.37 million blindness (Pascolini and Mariotti, 2012). In Southeast Asia alone, 
about 27.91 million people were visually impaired in 2010, accounting for 9.8% of the total 
population in this area. Moreover, VI is the most prevalent cause of moderate and severe 
disability in the population aged 60 year and above, compared with other health conditions 
associated with disability (United Nations Population Fund, 2012). A study in Europe showed 
that VI, after memory loss, is the second top health concern in aging (International Federation on 
Aging, 2012).   
 
VI is common in the elderly, because most eye diseases are age-related. People aged 40 and 
above constitute the majority of the VI population (Buhrmann et al., 2007). The prevalence rate 
of VI has been found to increase in each decade over the age of 40 in the Baltimore Eye Survey 
and the Los Angeles Latino Eye Study in the US (Tielsch et al., 1990; Varma et al., 2004). 
Similar trend has been found in studies in both eastern and western populations (Baasanhu et al., 
1994; Zhao et al., 2010; Hyman et al., 2001; Wang et al., 2000; Iwase et al., 2006; Wong et al., 
2008; Zheng et al., 2011). An Australia study even showed that the number of people with low 
vision and blindness increased by three-folds in each decade in people over the age of 40 (Taylor, 
2006). With the rapid aging population, the burden of VI will increase dramatically. According 
to a Canadian Study, the prevalence of VI and number of people with VI is estimated to increase 
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by 56% and 97% from 2006 to 2031, respectively (Buhrmann et al., 2007). Even though the 
global age-standardized prevalence of blindness and VI in old people decreased from 3.0% and 
14.3% in 1990 to 1.9% and 10.4% in 2010, due to the increasing population aging, the total 
number of people with VI and blindness remains increased (Stevens et al., 2013). For example, 
the number of old people with low vision has increased from 172 million in 1990 to 191 million 
in 2010 (Stevens et al., 2013).   
 
1.2 Definition of Visual Impairment 
VI is defined based on the presenting or best-corrected visual acuity (VA) in the better-seeing 
eye according to the US and the modified WHO definition (Tielsch et al., 1990; WHO, 2006). In 
the US definition, blindness is defined as VA of 20/200 or worse in the better-seeing eye and low 
vision as VA worse than 20/40 but better than 20/200 in the better-seeing eye. According to the 
modified WHO definition of VI or the International Classification of Diseases - 10 (ICD-10), 
there are 4 levels of vision status: normal vision (VA better or equal to 20/60), moderate VI (VA 
worse than 20/60 but better than or equal to 20/200), severe VI (VA worse than 20/200 but better 
than or equal to 20/400), and blindness (VA worse than 20/400). Moderate and severe VI could 
be combined as low vision. 
 
1.3 Cause of Visual Impairment 
Visual impairment is mainly caused by five eye conditions: cataract, glaucoma, diabetic 
retinopathy (DR), macular degeneration and under-corrected refractive error (UCRE). Globally, 
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the five eye diseases account for about 70% and 80% of low vision and blindness, respectively 
(Pascolini and Mariotti, 2012). The leading causes of low vision are UCRE (52.9%), cataract 
(18.4%), macular degeneration (3.1%), glaucoma (2.2%) and DR (1.9%). Cataract (33.4%) 
remains the leading cause of blindness, followed by UCRE (20.9%), glaucoma (6.6%), macular 
degeneration (6.6%) and DR (2.6%).  
 
There are large differences in the causes of VI and blindness between regions. In 2010, the 
proportion range of blindness caused by cataract is from less than 15% in the high-income 
regions to more than 40% in South and Southeast Asia, and Oceania (Bourne et al., 2013; Keeffe 
et al., 2014). The proportion of blindness caused by macular degeneration is higher in regions 
with older populations, such as high-income regions (e.g. Asia Pacific, high income: 19.5%; 
North America, high income: 16.4%), Southern Latin America (19.5%), and Central (15.4%) and 
Eastern Europe (15.4% and 16.6%), while lower in regions such as south Asia (2.6%).  The 
proportion of blindness caused by glaucoma is higher in tropical Latin America (15.5%) and 
lower in South Asia (4.7%), East and West Sub-Saharan Africa (4.0% and 4.4%), and Oceania 
(4.2%).The proportion of blindness caused by DR, ranging from 1.1% in east Asia to 4.3 % in 
high income Asia Pacific, does not notably vary among different regions. In terms of the causes 
of low vision, the proportion of low vision caused by UCRE is larger in south Asia (65.4%) than 
in other regions (43.2% to 48.1%). Meanwhile, cataract caused the smallest proportion of low 
vision in the highest-income regions (13.0% to 13.8%) and largest in south Asia (21.4%) and 




1.3.1 Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is a deterioration of an eye’s macula, a small oval-
shaped pigmented area near the center of the retina in the human eye, and therefore leads to 
patient’s central vision loss (Lim et al., 2012). With the aging process, small yellow deposits, 
which are called drusen, present beneath the retina. In the early AMD, medium sized drusen 
could be found and it does not much affect the vision status. In the late AMD, large drusen and 
damage to the macula leads to vision loss. There are two types of late AMD: dry (atrophic / non-
neovascular) AMD and wet (exudative / neovascular) AMD. In dry AMD, the thinning macula 
leads to gradual vision loss. Currently, there is no treatment or medication for dry AMD. In wet 
AMD, with the growth of abnormal blood vessels underneath the retina and macular, fluid and 
blood may leak and cause damage to the macula. Compared with dry AMD, wet AMD may 
cause rapid and severe vision loss. Certain medication and treatment (e.g. anti-vascular 
endothelial growth factor injection therapy, and photodynamic therapy) have been developed to 
stop further vision loss. Nevertheless, current medication and treatment could not cure AMD or 
preclude recurrence. The risk factors of AMD mainly include age, smoking, genetic 
susceptibility and family history. For example, in the US, people aged 75 years and above are 
three times more likely to develop AMD, compared with those aged between 65 to 74 years old 
(Klein et al., 1991). Meanwhile, in UK, the risk of AMD related vision loss is two-fold in current 
smokers compared with that in non-smokers (Evans et al., 2005).  
 
 1.3.2 Cataract 
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Cataract refers to the clouding of the lens in the eye and the most common symptoms are blurry 
vision, faded colors, glare over light and double vision or multiple images (Asbell et al., 2005). 
Most cataracts are age-related that in Americans age 80 above, the percentage of people with 
cataract or cataract surgery is higher than 60% (Congdon et al., 2004). Apart from age, the risk 
factors of cataract mainly include smoking, diabetes, and ultraviolet exposure. In the treatment of 
cataract, cataract surgery has been proven to be cost-effective and therefore is widely used as the 
way to cure cataract (Baltussen et al., 2004; Frampton et al., 2014).   
 
1.3.3 Diabetic Retinopathy 
Diabetic retinopathy (DR) is the most common eye disease related with diabetes mellitus. It is 
caused by the micro aneurysms developed on the blood vessels inside the retina (Cheung et al., 
2010). The fragile abnormal blood vessels could leak blood and fluid into the center of the eye, 
causing blurring vision. Meanwhile, the fluid leaking into the center of the macular leads to the 
swell of the macula, which is called macular edema. The severity of DR could be classified into 
five levels: mild non-proliferative DR, moderate non-proliferative DR, severe non-proliferative 
DR, proliferative DR, and clinically significant macular oedema. In the first 3 levels, blood 
vessels nourishing the retina are blocked, while in the latter two levels, abnormal, fragile new 
blood vessels grow along the retina and the surface of the vitreous gel. Nevertheless, macular 
edema could occur at any stage of DR and is more likely to occur with the progression of the 
disease. To prevent the progression of DR, treatment is mainly conducted for proliferative DR 
and clinically significant macular oedema. Proliferative DR is treated with laser surgery and a 
vitrectomy might be necessary in case of severe and persistent bleeding. Both treatment could 
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effectively reduce, but not cure the vision loss due to DR. The risk factors mainly include the 
presence of diabetes and the uncontrolled glucose or blood pressure level. 
 
1.3.4 Glaucoma 
Glaucoma is a group of diseases that damage the eye’s optic nerve and, are often associated with 
increased intraocular pressure and decreased peripheral vision (Quigley, 2011). There are three 
types of glaucoma in adults: primary open-angle glaucoma (POAG), primary close-angle 
glaucoma (PACG), and secondary glaucoma. POAG is the most common type of glaucoma and 
is due to the slow fluid flow through the meshwork drain and the consequent increased 
intraocular pressure that damages the optic nerve and causes vision loss. The progression of 
POAG is slow and often has no symptoms until advanced stage. POAG is mainly treated with 
medication or surgery (laser surgery or conventional surgery) to lower the intraocular pressure. 
Unlike the open normal anterior chamber angle in POAG, in PACG, the anterior chamber angle 
is closed, leading to a sudden spiked intraocular pressure (IOP) elevation and subsequent damage 
to optic nerve and vision. Meanwhile, PACG is commonly associated with sudden intense eye 
pain, redness, nausea and vomiting, and therefore treated as a medical emergency that 
medication and laser surgery should be used immediately to prevent the disease progression, 
lower the IOP, prevent the damage to optic nerve, and protect vision (Schacknow and Samples, 
2010). Secondary glaucoma is mainly a complication of other medical conditions (e.g. surgery, 
advanced cataract, eye injuries, and eye tumors). Medication and surgery are the common 
treatment for secondary glaucoma. Currently, there is no cure for glaucoma and the effect of 
glaucoma on people’s life could be life-long, while early diagnosis and treatment may do help to 
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protect vision from severe vision loss. The risk factors of glaucoma include age, family history, 
and ethnicity, and may be slightly different among different types of glaucoma. 
  
1.3.5 Under-Corrected Refractive Error 
Refractive error (RE) refers to unappropriated light focusing on the retinal due to the optical 
defects and is a leading cause of vision loss. RE includes four types: myopia, hyperopia, 
astigmatism and presbyopia. Myopia refers to the too strong optical power of the eye for the 
corresponding axial length that light focuses in front of the retina, and is the most common type 
of RE (Morgan et al., 2012). The risk factors of myopia include genetics and environmental 
factors, such as reading and socioeconomic status. Hyperopia refers to the too weak optical 
power of the eye that light focuses behind the retina. Astigmatism refers to the optical defect 
caused by the differential refractive power along different ocular meridians. In people with 
astigmatism, the lines in particular direction appear to be less clearly, compared with lines at 
right angles. Presbyopia refers to the age-related decline in accommodation to lenses due to 
reduced focusing ability and is commonly seen in population older than 40. All types of RE 
could be easily corrected by eyeglasses, contact lenses and refractive surgery (Sakimoto et al., 
2006).  
  
1.4 Visual Impairment in Singapore 
Singapore is a multi-ethnic country, in which Chinese, Indians and Malays comprise 96.7% of 
the total population in 2014 (Department of Statistics, 2014). Chinese constitute the majority of 
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the Singapore population at 74.3%, followed by 13.3% of Malays and 9.1% of Indians. Though 
the prevalence of major eye diseases (e.g., glaucoma and AMD) differs in ethnicities (Sommer et 
al., 1991), no significant differences in the prevalence of VI were found among the 3 ethnic 
groups. For Chinese, in the Tanjong Pagar Survey, the age-standardized prevalence rate of 
bilateral VI is 1.6% (low vision: 1.1%; blindness: 0.5%), according to the WHO definition of 
best-corrected visual acuity (Saw et al., 2004). For Malays, in the Singapore Malay Eye Study, 
the age-standardized prevalence rate of bilateral VI is 1.11% (low vision: 1.03%; blindness: 
0.08%) and 0.52% (low vision: 0.47%; blindness: 0.05%), according to the US and WHO 
definition of best-corrected visual acuity, respectively (Wong et al., 2008). For Indians, in the 
Singapore Indian Eye Study (SINDI), the age-standardized prevalence rate of bilateral VI is 3.8% 
(low vision: 3.4%; blindness: 0.4%) and 1.8% (low vision: 1.6%; blindness: 0.2%), according to 
the US or WHO definition of best-corrected VA, respectively (Zheng et al., 2011). Compared 
with the prevalence rate of VI in populations in other countries, the prevalence rate of VI in 
Singapore is relatively row. For example, the prevalence rate of VI in Indians in Singapore is 
similar to those in the whites and Japanese, but lower than those in blacks, Chinese, Mongolians, 
and Indians living in Indian (Baasanhu et al., 1994; Zhao et al., 2010; Hyman et al., 2001; 
Tielsch et al., 1990; Varma et al., 2004; Wang et al., 2000; Iwase et al., 2006; Sapkota et al., 
2006). Despite of the variations in methodologies and definitions among these studies, one 
possible reason for the relatively lower prevalence rate of VI in Singapore is the better 
knowledge and awareness of vision problems, better accessibility and affordability of the eye 




In Singapore, cataract, glaucoma, DR, AMD and UCRE are the leading causes of VI, which is in 
consistence with the findings in studies in Asia (Baasanhu et al., 1994; Li et al., 1999; Murthy et 
al., 2001; Dandona et al., 2001; Michon et al., 2002; Zainal et al., 2002). Cataract is the main 
cause of bilateral low vision in Chinese (58.8%) and Indians (60.0%), and bilateral blindness in 
Malays (65.2%) and Indians (65.7%). Meanwhile, UCRE is the main cause of bilateral low 
vision (52.2%) in Malays and glaucoma of bilateral blindness in Chinese (60.0%).    
 
2 Disease Burden of Vision Problems 
Disease burden refers to the burden that a disease imposes on society and is generally measured 
from clinical, economic and humanistic perspective (Reeder, 1995; Gunter, 1999; Kemp, 2006). 
Clinical burden is mainly measured by epidemiological indicators, such as prevalence, incidence, 
morbidity and mortality. Economic burden refers to direct, indirect and intangible costs 
associated with the disease. The economic burden studies are meaningful in that they may help to 
identify appropriate actions or strategies to reduce the cost of disease or injury (WHO, 2009). 
Humanistic burden refers the consequences of a disease on patient’s functional status or quality 
of life (e.g. physical functioning, social functioning, well-being, and life satisfaction).  
 
2.1 Economic Burden of VI 
The economic burden of a health condition is measured by cost-of-illness study. In the cost-of-
illness study, both the direct and indirect costs of the health condition are measured. In terms of 
vision problems, the economic burden of vision problems is significant and increases 
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dramatically over time. The worldwide economic burden of vision problems in 2010 is estimated 
to be $3.0 trillion (direct costs: $2.3 trillion; indirect costs: $652 billion). By the year 2020, the 
economic burden of vision problems is projected to be 3.6 trillion (direct costs: $2.8 trillion; 
indirect costs: $760 billion) (Access Economics, 2010). Same trends exist in regions and 
countries. In the US, the annual economic burden of vision problems among the population aged 
40 and above is estimated to be $51.4 billion in 2004 and it increases to $111.1 billion in 2013 
(Wittenborn and Rein, 2013). Meanwhile, in Australia, the annual economic burden of vision 
problems is estimated to increase from $9.8 billion in 2004 to $16.6 billion in 2009. In Canada, 
the annual economic burden of VI is estimated to be $15.8 billion in 2007, accounting for 1.19% 
of Canada’s GDP, and is projected to be as much as $30.3 billion by 2032. 
 
2.1.1 Cost-of-Illness Study 
Cost-of-illness study measures the economic burden of diseases. The information from the cost-
of-illness study highlights the magnitude of the impact of a disease on society (Finkelstein et al., 
2003; Taylor and Sloan, 2000) and can help policy makers in resource allocation and strategy 
identification to better prevent or treat diseases (Miller et al., 1998; Warner et al., 1999). Cost-of-
illness study generally measures direct and indirect costs. The definitions of direct and indirect 
costs are not consistent across studies. Generally speaking, direct costs measure the actual costs 
of resources related with a disease in the health care sector (Drummond et al., 2005), such as the 
costs due to inpatient and outpatient service, pharmaceuticals, vision care (optometry, 
ophthalmology and lenses), assistance program and research. Indirect costs measure the value of 
the lost productivity and mainly include costs due to productivity loss, informal care, tax 
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deduction, and transfer deadweight loss. Moreover, cost-of-illness study could be done from 
different perspective and reach different results. The perspectives may include society, health 
care system, business, government, and participants and families (Gold et al., 1996; Hodgson et 
al., 1994). Appropriate prospective identification should be based on research questions. For 
example, a study measuring the percentage of the costs of a disease on the government 
healthcare budget should be conducted from the perspective of the government, while another 
study concerning the individual costs of a disease to the patients or their families should be 
conducted from the perspective of patients and their families. Nevertheless, the most 
comprehensive measurement of the costs of a disease is estimated from the societal perspective. 
 
There are two types of cost-of-illness studies: incidence-based and prevalence-based studies 
(Tarricone, 2006). Incidence-based studies estimate the lifetime costs, which measure the costs 
of a disease from onset to termination. Prevalence-based studies estimate the annual costs, which 
measure the costs of a disease in a period, regardless of the onset time. The prevalence-based 
studies are suitable to measure the current economic burden of a disease, while incidence-based 
studies are suitable to measure the cost changes when preventative programs are implemented.  
In comparison of the two kinds of studies, prevalence-based studies are more common in use, 
because less data, fewer assumptions, and less money are required to conduct the prevalence-
based studies. 
  
2.1.2 Direct Costs  
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Direct costs could be further classified as direct medical costs and direct non-medical costs 
(Drummond et al., 2005). Direct medical costs refer the costs of resources used for treating a 
particular disease, such as the costs due to inpatient and outpatient costs, while direct non-
medical costs refer to the costs of the disease but not due to medical treatment. In patients with 
VI, direct non-medical costs include costs in supporting services, assistive devices, home care, 
residential care and transportation. The direct costs of VI are considerable. For example, the 
direct costs for vision problems in Australia are higher than those of coronary heart disease, 
stroke, depression, diabetes and asthma (Taylor et al., 2006). In Canada, the direct costs of VI 
($8.6 billion) rank 1
st 
in comparison of the direct costs of all kinds
 
of diseases (Cruess et al., 
2011). 
 
2.1.2.1 Direct Medical Costs 
Previous studies have shown that direct medical costs of VI are mainly due hospitalization, and 
medical service use in consultation, diagnosis and treatment (Clarke et al., 2003; Cruess et al., 
2011; Frick et al., 2007; Frick et al., 2008; Morse et al., 1999; Roberts et al., 2010). In 
comparison, drug costs are not a major contributor to direct medical costs. For example, in Japan, 
the medical costs ($8.10 billion), composed of inpatient ($1.81 billion) and outpatient ($6.29 
billion) medical expenditure, add up to 73% of the total health care costs ($11.09 billion) and 
11.1% of the total economic costs ($72.81 billion). Comparatively, the costs of drugs ($1.40 
billion) account for 12.6% of the total health costs and 1.9% of the total economic costs. 
Moreover, direct medical costs of VI are positively associated with the severity of VI that 
blindness has the largest costs. For example, the study measuring the impact of VI on costs in 
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Medicare beneficiaries with glaucoma shows that the annual mean costs per patient in 2007 are 
$8,157 for no vision loss, $13,162 for moderate VI, $15,312 for severe VI, and $18,670 for 
blindness.  
 
The direct costs of eye diseases vary in different countries, considering the different prevalence 
rate of eye diseases and unit cost in diagnosis, consultation and treatment. According to the 
economic burden study in the US, UCRE ($16.1 billion) has the highest direct medical costs in 
2011, followed by cataract ($10.7), physical disorders ($8.9 billion), retinal disorders ($8.7 
billion) and glaucoma ($5.8 billion). In Canada, UCRE ($3.48 billion) remains to have the 
highest direct medical costs in 2007, while AMD ($898.9 million) has the second highest direct 
medical costs, followed by glaucoma ($549.0 million), cataract ($481.0 million) and DR ($205.7 
million). 
 
2.1.2.2 Direct Non-Medical Costs 
In terms of the direct non-medical costs, home care assistance including assistive devices/aids, 
home modifications, and home-based nursing, is the main component (Frick et al., 2007; Rein et 
al., 2006; Schmier et al., 2009; Cruess et al., 2011; Wong et al., 2008; Roberts et al., 2010; Porz 
et al., 2010; Lafuma et al., 2006). Meanwhile, direct non-medical costs also increase with the 
severity of VI. For example, in the US study, the home health care costs from paid independent 
provider for blindness are $1200 more than that for low vision (Frick et al, 2007; Schmier et al., 
2006; Schmier et al., 2009; Keeffe et al., 2009; Wong et al., 2008; Lafuma et al., 2006). Similar 




2.1.3 Indirect costs 
Previous studies have shown that the substantial indirect costs of VI are even higher than the 
direct costs in some studies (Wittenborn, et al., 2013; Royal National Institute of Blind People, 
2009). The indirect costs of VI are mainly due to productivity loss and informal care (Rein et al., 
2006; Roberts et al., 2010; Lafuma et al., 2006; Brezin et al., 2005; Cruess et al., 2011, Frick et 
al., 2007). For example, in Japan, the costs due to productivity losses ($4.67 billion), including 
lower employment ($4.23 billion) and absenteeism ($0.38 billion), account for 35.6% of the 
indirect costs ($13.12 billion) and 6.4% of total economic costs ($72.81 billion). Meanwhile, the 
costs of informal care ($6.61billion) are even higher than productivity loss and together with 
productivity loss add up to 85.9% of the indirect costs and 16.5% of the total economic costs. 
Same as direct costs, indirect costs of VI also increase with the severity of VI, with the highest 
for blindness. For example, in the US, the annual informal care costs for blindness are $242 
million, compared with $124 million for low vision (Frick et al., 2007).   
 
2.2 Health-Related Quality of Life 
VI, as a serious health condition, affects people’s functioning and well-beings (Goldzweig et al., 
2004; Ong et al., 2012; Lamoureux et al., 2008). Previous studies have shown that VI increases 
the risks of depression, falls, and injuries such as hip fractures (Dargent et al., 1996; Lamoureux 
et al., 2010). Notably, VI may also increase the risk of mortality by increasing the risks of injury, 
accident, or social and emotional problems leading to early death (McCaty et al., 2001; Freeman 
et al., 2005). To measure the impact of VI on people’s functioning and well-beings, health 
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related quality of life (HRQOL) is widely used. HRQOL has a number of definitions and 
according to WHO, HRQOL is defined as “the optimum levels of mental, physical, role (e.g. 
work, parent, career, etc.) and social functioning, including relationships, and perceptions of 
health, fitness, life satisfaction and well-being” (Bowling, 1999). Compared with clinical 
outcome measure, HRQOL provides the unique information from patients’ perspective about 
their perception of the effect of certain health conditions on multiple aspects of life. Meanwhile, 
HRQOL could improve patient care by widening the parameters of benefit, indicating the need 
for interventions, acting as prognostic indicators, aiding decision-making, and assisting resource 
allocation and healthcare policy (Fayers and Machin, 2007). HRQOL usually contains multi-
dimensional assessments, such as physical, functional, psychological/emotional and 
social/occupational domains. There are three types of HRQOL scales: disease or condition 
specific measures, general or generic health profiles, and preference-based measures (Drummond 
et al., 2005).  
 
Disease or condition specific measures concentrate on health outcomes specific to an individual 
disease, medical conditions, or patient population and thus have the advantages of better 
responsiveness to changes in the patient’s condition and high acceptance of patients and 
physicians in a study. Nevertheless, disease or condition specific measures have two main 
disadvantages. First, specific measures could not be used to compare the effectiveness of 
programs in different disease areas. Second, the narrow focus of specific measures may 
sometimes fail to assess all the relevant dimension of the HRQOL of life of a certain disease. In 
terms of VI, vision-specific quality of life measures are widely used to measure the impact of VI 
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on HRQOL. The commonly used vision-specific HRQOL measures include the Visual Function 
Index (VF-14) and National Eye Institute visual Function Questionnaire (NEI-VFQ). 
 
In comparison with disease or condition specific measures, general or generic health profiles 
comprehensively measure the HRQOL and could be applied across different patient population 
and disease areas. The widely used general health profiles include the Nottingham Health Profile, 
the Short Form (SF) 36 and the Sickness Impact Profile (Brazier et al., 1993; Bergner et al., 1981; 
Hunt et al., 1981). The main advantages of the widely used general health profiles are their 
proven validity and reliability. However, general health profiles couldn’t be used to compare 
across different programs producing different types of outcomes, because they produce a profile 
of scores across different domains of the instrument rather than a single quality of life score, 
except the Sickness Impact Profile. Moreover, in the general health profile, the association 
between higher scores and preferred outcomes is not clear, because the scoring methods of the 
instruments are not based on individuals’ preferences for the outcomes. Meanwhile, the score 
from general health profiles is not calibrated as death = 0 and perfect health = 1, and thus could 
not be combined with quantity of life.      
 
Preference-based measures or utilities are the principal values representing the strength of an 
individual’s preferences for specific health-related outcomes. Compared with specific measures 
and general health profiles, preference-based measures could generate a single index measure 
with death = 0 and perfect health = 1, and thus are widely used in the economic analysis, 
especially the cost-utility analysis (CUA). The preference / utility evaluation includes direct and 
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indirect methods. In direct method, utilities are measured directly from the individuals. There are 
three widely used techniques: the rating scale and its variants, the standard gamble, and the time 
trade-off. In indirect method, utilities are mainly assessed by generic HRQOL measures, such as 
Quality of Well-Being (QWB) (Kaplan et al., 1997), Health Utilities Index (HUI) (Feeny et al., 
2004), European Quality of Life-5 Dimensions (EQ-5D) (Dolan, 1997), and Short Form 6 
Dimensions (SF-6D) (Brazier et al., 1998). Among the generic HRQOL measures, EQ-5D has 
the advantage of simplicity and is recommended by National Institute for Health and Care 
Excellence (NICE, 2008) in the UK. Therefore, EQ-5D is used as the measure in majority of the 
studies exploring the impact of VI on generic HRQOL. 
 
The health utility gained from generic HRQOL measures could be used in quality-adjusted life 
years (QALYs) calculation and further applied in the CUA. QALYs integrate the quantity of life 
and the quality of life into a single index and allow the comparison of the outcomes from 
different programs and interventions. QALYs are calculated as the time in the health state 
weighted by the utility score for the health state. For example, one intervention leads to a health 
state valued as 0.75 for four year and thus generates 3 QALYs. Similarly, another intervention 
leads to a health state valued as 0.50 for four years and thus generates 2 QALYs. Therefore, the 
first intervention generates additional 1 QALY. Apart from QALYs, disability-adjusted life years 
(DALYs) are also widely used as an alternative to QALYs (Murray, 1994). DALYs for a disease 
or health conditions include the Years of Life Lost (YLL) due to premature mortality and the 
Years Lost due to Disability (YLD) for people living with the disease or health condition. In the 
global burden of disease study, YLL is calculated as the number of death multiplied by standard 
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life expectancy at age of death in years, and YLD is calculated as the number of prevalent cases 
multiplied by the disability weight (Murray et al., 2012). 
 
2.2.1 Impact of VI and Eye Diseases on Generic Health-Related Quality of Life 
Previous studies have shown a substantial impact of VI on generic HRQOL. Studies in the 
Netherlands show that the effect of VI on generic HRQOL is larger than that of type 2 diabetes, 
coronary syndrome, and hearing impairment (Nispen et al., 2009; Langelaan et al., 2007). 
Moreover, increased severity of VI is significantly associated with the worsening EQ-5D index 
score and patients with VI are more likely to report problems in each dimension compared with 
the general Dutch population (Nispen et al., 2009; Langelaan et al., 2007). Similar findings are 
also found in other studies, mainly using EQ-5D as the generic HRQOL measure (Polack et al., 
2007; Lotery et al., 2007; Polack et al., 2010; Thygesen et al., 2008; Smith et al., 2008). The 
impact of eye diseases on generic HRQOL is also explored in previous studies, in majority of 
which EQ-5D is used as the HRQOL measure.  
 
For cataract, significant differences are observed between patients with cataract and the controls 
with normal vision (Polack et al., 2007; Polack et al., 2008; Polack et al., 2010). Nevertheless, 
the benefit of cataract surgery on generic HRQOL measured by EQ-5D index score varies. Some 
studies showed the responsiveness of the EQ-5D to the benefit of cataract surgery (Harwood et 
al., 2005; Sach et al., 2007; Ang et al., 2013), while others failed (Conner-Spady et al., 2005; 
Browne et al., 2007). In terms of the convergent validity, two studies have found a significant 
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association between VA and the higher probability of reporting problems in all EQ-5D 
dimensions except anxiety, while in the other two studies, no such finding was observed. 
 
In terms of glaucoma, previous studies have shown that the EQ-5D index score is negatively 
associated with the severity levels of glaucoma and VI (Kobelt et al., 2006; Thygesen et al., 
2008), even though the associations are not always significant (Aspinall et al., 2008 Montemayor 
et al., 2001). No other generic HRQOL measures have been used to measure the impact of 
glaucoma on generic HRQOL.  
 
For AMD, patients with AMD have a significant reduction in generic HRQOL compared with 
general population (Lotery et al., 2007; Ruiz-Moreno et al., 2008; Soubrane et al., 2007). 
Moreover, significant difference in EQ-5D index score is found between patients with unilateral 
and bilateral AMD (Kim et al., 2010), while inconsistent finding exists in the difference in EQ-
5D index score across different severity levels of VI. One study even shows that the EQ-5D 
index score for participants with normal vision is the worst, compared with that for participants 
with mild, moderate, and severe AMD (Soubrane et al., 2007). Nevertheless, studies exploring 
the association between the severity of AMD and the EQ-5D index score are limited.  
 
Two studies show that EQ-5D index score has a significant difference between the two extreme 
groups (normal vision and blindness); however, the differences between the neighbor groups are 
frequently inconsistent (Lloyd et al., 2008; Smith et al., 2008). For example, the EQ-5D index 
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score in the VI group of 6/12 – 6/18 is worse than that in the neighbor groups of 6/6 – 6/9 and 
6/24 – 6/36.  Meanwhile, a study in Indian shows that only blindness is independently associated 
with the decline in EQ-5D index score, while other severity groups are not (Polack et al., 2015). 
 
In conclusion, the results of studies using EQ-5D to measure the impact of VI and eye diseases 
on generic HRQOL are mixed. Most studies show that EQ-5D could successfully distinguish the 
differences between patients and controls (Tosh et al., 2012). Nevertheless, for construct validity, 
most of the studies show the little or no difference of EQ-5D index score across VI severity 
groups. Moreover, previous studies have identified the difference before and after the 
intervention, though most of them are not statistically significant. In terms of convergent validity, 
the results about the association between EQ-5D index score and VA measure are also mixed.           
 
2.2.2 Vision-Specific Quality of life (VSQOL) 
With the increasing emphasis on the full impact of VI on people’s daily life, VSQOL is widely 
used. Among the various VSQOL instruments, the Visual Function Index (VF-14) and National 
Eye Institute Visual Function Questionnaire (NEI-VFQ) are most frequently used. VF-14 is 
originally developed to measure the functional impairment due to cataract (Steinberg et al., 1994) 
and afterward validated for VI (Chiang et al., 2013; Lamoureux et al., 2009; Lamoureux et al., 
2008) and other eye diseases, including DR, UCRE, glaucoma, AMD and dry eye (Milne et al., 
2012; Pan et al., 2014; Chan et al., 2013; Tong et al., 2010). VF-14 has also been translated and 
validated in multiple populations (Khadka et al., 2014; Chiang et al., 2011; Mousa et al., 2012). 
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All the studies have shown the significant association between the presences of vision problems 
and the deterioration of the VSQOL measured by VF-14 index score.  
 
The original NEI-VFQ questionnaire contains 51 items and is firstly developed to provide a 
comprehensive visual function assessment (Mangione et al., 1998). Both VF-14 and NEI-VFQ 
require patients to rate their difficulties in performing the vision-related activities. Compared 
with VF-14, NEI-VFQ not only emphasizes patients’ difficulty with tasks and symptoms, but 
also measures the effect of vision problems on other aspects of quality of life, such as 
dependency, emotional well-being, and social function. Nevertheless, the 51-item NEI VFQ 
questionnaire has a disadvantage of the long length, which may diminish participant rates and 
response reliability, and increase the data collection and management costs. To solve the 
problem, a shorter, 25-item version  is developed to measure the most important dimensions of 
vision-related health status (Mangione et al., 2001). The NEI VFQ-25 contains 25 questions, 
related with 11 vision-related constructs and an additional single-item general health question. 
The NEI-VFQ-25 has been validated and widely used as the measure of VSQOL in the 
evaluation of the impact of multiple eye diseases or disease interventions, such as cataract, 
glaucoma, and retinal diseases, and in multiple populations (Stock et al., 2015; Abe et al., 2015; 




3 Research Objectives 
Vision problems have been shown to impose substantial economic and humanistic burden to the 
individuals and society; however such studies are limited in Singapore. Although understanding 
the economic burden of vision problems in Singapore is helpful to resource allocation and vision 
problem prevention, there are only three studies of direct medical costs of specific eye diseases, 
including acute PACG and myopia, found in literature. Apart from direct medical costs, 
productivity loss has been shown to account for a large amount of economic burden of vision 
problems, while no study has been done to measure the productivity loss of vision problems in 
Singapore. Moreover, the economic burden of a heath condition could be conducted from 
different perspective, providing unique cost information to each particular group. Therefore, the 
present project aims to address the economic burden of vision problems in Singapore from the 
perspective of healthcare system, and patients and their families. 
 
In terms of humanistic burden, previous studies mainly focus on the impact of vision problems 
on VSQOL. There is a lack of studies on the impact of vision problems on generic HRQOL and 
the comparison between the health burdens of vision problems with other health conditions. EQ-
5D is widely used as the measure of generic HRQOL because of its simplicity and is 
recommended by NICE. Nevertheless, EQ-5D is found to be insensitive to the impact of vision 
problems. Therefore, adding a vision ‘bolt-on’ item to the standard EQ-5D may solve the 
problem. Previous studies mainly focused on the valuation of the health utilities of all possible 
health states defined by the ‘bolt-on’ descriptive system, while the impact of the ‘bolt-on’ EQ-
5D on sensitivity has not been conducted. Therefore, the present project aims to address the 
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health burden of vision problems in Singapore and evaluate a vision ‘bolt-on’ item on the 
sensitivity of EQ-5D to vision problems.    
 
The specific objectives of the projects are summarized as below: 
1. to measure the annual direct medical costs of VI in Singapore; 
2. to measure the out-of-pocket (OOP) expenditure and productivity loss of VI in Singapore; 
3. to assess the health burden associated with VI in Singapore; 
4. to investigate the effect of VA on generic HRQOL in patients with VI; 










4 Organization of the Thesis 
The thesis is organized in such a way that each of the subsequent chapters addresses each of the 




  chapter reports the annual direct medical costs from VI and major eye diseases in Asian 
population. In this study, the annual direct medical costs of VI from the four major eye diseases 
in Singapore were described from the individual and national level using data from hospital 
financial department. The direct medical costs of VI and major eye diseases were also projected 




 chapter reports the medical service utilization, OOP expenditure and productivity loss of 
VI in Singapore. In this study, data of the medical service utilization, OOP expenditure and 





 chapter reports the health burden associated with VI in Singapore. In this study, EQ-5D 
data from the Singapore Epidemiology of Eye Disease (SEED) were used to measure the 







 chapter reports the effect of VA on HRQOL among patients with VI in Singapore. In this 
study, generic HRQOL data from SEED study were analyzed using regression models to assess 
the effects of 5 different VA measures (VA in the better-seeing eye , better-weighted mean VA, 
mean VA, worse-weighted mean VA, and VA in the worse-seeing eye on visually impaired 





 chapter reports the effect of adding a vision dimension to the EQ-5D descriptive system, 
using data from the above economic burden of VI study. In the study, 16 pairs of mutually 
exclusive subgroups of individuals known to differ in vision status were defined and compared 
pairwise. The absolute mean difference and F-statistic were used as the measured of relative 
sensitivity in the comparisons of the EQ-5D index scores.  
 
In the last chapter, the major findings of the project are summarized. Future work to address the 









The Rising Economic Cost of Visual Impairment Due to 
Four Major Eye Disease in Asians: A Prospective Study of 








Visual impairment (VI) is a public health problem worldwide. According to the estimate from the 
World Health Organization (WHO) in 2010, about 285.39 million people were visually impaired, 
including 246 million with mild/moderate VI and 39.37 million with severe VI (Pascolini and 
Mariotti, 2012). Studies from Australia, Canada, Europe, Japan and the United States of America 
(USA) have described the heavy economic burden of VI on their society (Taylor et al., 2006; 
Cruess et al., 2011; Brezin et al., 2005; Roberts et al., 2010; Rein et al., 2006; Frick et al., 2007; 
Wittenborn, 2013). In Australia, for example, the economic costs of VI were estimated to be 
AUD$ 9.85 billion in 2006, higher than coronary heart disease, stroke, diabetes mellitus, or 
depression (Taylor et al., 2006). 
 
In Asia, where about 45 million people were estimated to have significant VI in the southeast 
Asia region alone, few studies have described the economic burden of VI (Dilokthornsakul et al., 
2014; Awan et al., 2012; Shamanna et al., 1998). With the aging population, the economic 
burden of VI is expected to increase in the near future, which highlights the importance to 
understand the economic burden of VI and plan for preventive programs. Singapore, a developed 
country with a multi-racial population comprising three major racial groups in Asia (i.e. Chinese, 
Indian, and Malay), represents a unique setting to study the economic burden of VI in Asians. To 
date, only direct costs of specific eye diseases such as acute primary angle-closure glaucoma 
(PACG) and myopia have been studied in Singapore (Wang and Chew, 2004; Lim et al., 2009; 
Zheng et al., 2013).   
 
Therefore, in this study, we aimed to describe the annual direct medical costs of VI due to the 
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major eye diseases in Singapore and project the direct medical costs from 2015 to 2040. 
 
2.2 Methods 
Study subjects and procedures 
Individuals with VI 
Five hundred individuals with VI were recruited from the outpatient clinics in Singapore 
National Eye Center, the tertiary medical center for eye diseases in Singapore. The inclusion 
criteria were: 1) a clinical diagnosis of cataract, glaucoma, diabetic retinopathy (DR), or age-
related macular degeneration (AMD) for at least 3 months; 2) visually impaired in both eyes; 3) 
40 years old or above; 4) Singaporean or permanent resident; 5) able to communicate in English 
or Chinese, presence of a caregiver in case of language barrier; and 6) written informed consent. 
Quota sampling was used to recruit equal number of individuals with each of the four eye 
diseases. Patients, who were with VI and underwent cataract surgery within 1 year, were also 
eligible for the study. Patients of 40 years old or above were recruited because the investigated 
eye diseases in this study were not typical in younger persons.  
 
 The visually impaired individual’s service utilization and expenditure data from the date of 
his/her first visit to SNEC till the date of interview were retrieved from the SNEC financial 
department (mean: 59.9 months; medium: 62.5 months; range: 3-136 months). Notably, the costs 
were estimated in dependent of government subsidy. This study for VI followed the principles of 
Declaration of Helsinki and the ethical approval was obtained from the Centralized Institutional 




Definitions of VI 
In this study, presenting visual acuity (VA) was measured for each participant with a Snellen 
chart. The Snellen chart contains symbols to test VA (Chen et al., 2014). VI was classified into 
two levels according to the VA in the better-seeing eye: (1) mild/moderate VI (VA ≤6/12 to 
VA >6/60; and (2) severe VI (VA ≤6/60) (Tielsch et al., 1990).  
 
Statistical Analysis 
Annual direct medical costs of eye diseases and VI were estimated based on the cost data for the 
patients with VI. If the patients’ costs data were available for more than 1 year, it would be traced 
back for 1 year from the date of interview. If the patients’ costs data were available for less than 
1 year, the annual costs were derived by multiplying the average costs per month by 12. Based 
on the data from the hospital financial department, the direct medical costs included three 
components: (1) consultation and examination; (2) treatment and procedure; and (3) medication. 
For total and each part of the costs, the ANOVA test was used to compare the costs across 
participants with different eye diseases, while the 2-sample t-test was used to compare the costs 
between mild/moderate and severe VI groups.  
 
The annual direct medical costs of each major eye disease and VI in Singapore were calculated 
as the mean direct medical costs per capita multiplied by the projected number of individuals (i.e. 
population) with the condition in 2015 to 2040. The projected populations were estimated from a 
local study in which age- and ethnicity-specific prevalence data from the Singapore 
Epidemiology of Eye Diseases (SEED) study (Lavanya et al., 2009) and projected general 
population data were used to project the number of people seeking medical care due to various 
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eye conditions (Ansah et al., 2015). For each projected eye disease population, we adjusted its 
size by multiplying the prevalence rate of VI estimated from the SEED data. This is necessary as 
the study population of this study is patients with both eye diseases and VI. Further, we estimated 
the prevalence rates for subtypes of AMD (neovascular and non-neovascular AMD), glaucoma 
(primary open-angle glaucoma [POAG], PACG and secondary glaucoma), and DR (non-
proliferative and proliferative DR) using the SEED data, and used them to determine the 
subpopulations of the eye diseases. We re-estimated the direct medical costs per capita for each 
subtype of the eye diseases and multiplied them with the corresponding subpopulation to derive 
the national-level direct medical costs. Costs for subtypes of the eye diseases were aggregated to 
provide the estimates for costs of the eye diseases. This subtype-weighted approach was used in 
the costs estimation because the prevalence rates of the eye disease subtypes in our sample and 
the projected future populations were different. Previous studies showed that costs of different 
subtypes or severities of the eye diseases varied (Lim et al., 2012; Cantor et al., 2010; Cheung et 
al., 2010; Happich et al., 2008).      
 
An inflation rate of 3% and the average US dollar/Singapore dollar exchange rate of 1.25 in 2013 
were used in the analysis. I was responsible for both the data collection and data analysis. All the 
analyses were conducted using SAS software version 9.2 (SAS Inc., Cary, NC) at a significance 
level of 0.05.  
 
2.3 Results 
The socio-demographic and health characteristics of recruited subjects are shown in Table 2.1. 
The mean ± standard deviation (SD) age of participants was 71.6 ± 9.8 years old. The proportion 
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of males was 47.6%. Majority of the patients was Chinese (88.0%). The mean ± SD VA in the 
better-seeing eye was 0.49 ± 0.31 and 76.6% of the participants were with mild/moderate VI. 
The mean ± SD total annual direct medical, consultation and examination, treatment and 
procedure, and medication costs per capita of those with VI in 2013 were S$7,090 ± 29,441, 
S$626 ± 845, S$2,114± 3,255, and S$4,350 ± 27,896, respectively.  
 
Annual costs per capita for eye diseases and categories of VI are shown in Table 2.2. The direct 
medical costs of AMD (S$16,644 ± 56,406) were higher than those of glaucoma (S$6,222 ± 
11,559), DR (S$2,767 ± 5,864) and cataract (S$2,727 ± 2,757) (p=0.0003). Medication costs 
were the major driver of direct medical costs for AMD and glaucoma, while treatment and 
procedure costs for cataract and DR. The annual direct medical costs of mild/moderate VI 
(S$5,449 ± 29,927 per capita) were significantly lower than those of severe VI (S$12,461 ± 
38,431 per capita, p<0.0001). Medication costs accounted for the majority of direct medical costs 
for both mild/moderate VI (56.3%; S$3,068 out of S$5,449) and severe VI (68.6%; S$8,548 out 
of S$12,461). The treatment costs for both mild/moderate VI (S$1,796 per capita) and severe VI 
(S$3,153 per capita) were also considerable.  
 
Projections of the number of individual with major eye diseases and VI for Singapore in 2015 to 
2040 are shown Table 2.3. The number of individuals with major eye disease and VI would 
increase by at least 1.5 times in 2015 to 2040 (e.g. number of individuals with cataract and VI by 
about 1.7 times).  In 2015, the number of individuals with cataract (20,846) was the highest, 
followed by AMD (17,738), DR (14,195), and glaucoma (7,940). Nevertheless, the increase rate 
of cataract was lower than that of the other three eye diseases and in 2040, the number of 
 33 
 
individuals with DR (52,271) and AMD (52,105) was the highest, followed by cataract (35,456) 
and glaucoma (23,344).   
 
Projections of the direct medical costs of major eye diseases and VI for Singapore in 2015 to 
2040 are shown in Table 2.4. AMD had much higher direct medical costs than cataract, glaucoma 
and DR in this period. For example, in 2015, the direct medical costs of AMD (S$176.0 million) 
would be more than two times higher than those of cataract (S$60.3 million), glaucoma (S$44.4 
million) and DR (S$56.5 million). The direct medical costs of each eye disease would increase 
by at least 3 times from 2015 to 2040 (e.g. direct medical costs of cataract by about 3.6 times). 
The direct medical costs of mild/moderate VI would be much larger than those of severe VI. For 
example, in 2015, the direct medical costs of mild/moderate VI would be S$333.3 million, 8.3 
times more than those of severe VI (S$40.4 million). With the aging process, the medical costs of 
total VI costs would increase by about 5.6 times from S$373.8 million in 2015 to S$2103.0 




Table 2.1 Socio-demographic characteristics and costs for visual impairment in Singapore 
(n=500) 
Age  
 Mean (SD); Median (Range) 71.6 (9.8); 73.0 (41.0 - 98.0) 
Gender  
 Male 47.6% 
Ethnicity  
 Chinese 88.0% 
 Indian 5.4% 
 Malay 5.4% 
 Others 1.2% 
Education  
 No formal education 34.6% 
 Primary education 29.6% 
 Secondary education 35.8% 
Employment status  
 Working 19.8% 
 Not working 80.2% 
Marital status  
 Single 6.6% 
 Married 86.2% 
 Separated/divorced 1.4% 
 Widow 5.8% 
Visual acuity in the better-seeing eye 
 Mean (SD); Median (Range) 0.49 (0.31); 0.40 (0.30 - 3.00) 
 Mild/moderate VI 76.6% 
 Severe VI 23.4% 
Annual total costs per capita (S$)  
 Mean (SD); Median (Range) 7090 (29,441); 2,573 (58 - 474,951) 
Annual consultation & examination costs per capita (S$) 
 Mean (SD); Median (Range) 626 (845); 441 (0 - 8868) 
Annual treatment & procedure costs per capita (S$)  
 Mean (SD); Median (Range) 2,114 (3,255); 0 (0 - 29,443) 
Annual medication costs per capita (S$)  
  Mean (SD); Median (Range) 4,350 (27,896); 76 (0 - 453,731) 




Table 2.2 Annual costs per capita in categories of major eye diseases and visual impairment (n=500) 
 






 Medication costs 
Mean SD  Mean SD  Mean SD  Mean SD 
Diagnosis            
 Cataract 2,727 2,757  606 724  1,949 2,398  172 475 
 Glaucoma 6,222 11,559  757 994  1,630 3,358  3,835 8,982 
 Diabetic retinopathy 2,767 5,864  500 674  1,526 2,454  740 4,522 
 Age-related degeneration 16,644 56,406  640 934  3,350 4,177  12,655 54,127 
  P value 0.0003  0.1168  <0.0001  0.001 
Visual impairment             
  Mild/moderate VI 5,449 25,927  585 782  1,796 3,019  3,068 24,361 
  Severe VI 12,461 38,431  762 1,017  3,153 3,762  8,548 37,014 
  P value <0.0001  0.0002  0.0021  <0.0001 
All costs are in thousand Singapore dollars;  
SD = standard deviation; VI = visual impairment; 
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Table 2.3 Projection of the number of individuals with major eye diseases and visual impairment in 2015 to 2040 
  2015 2020 2025 2030 2035 2040 
Diagnosis             
  Cataract  20,846 32,218 35,424 35,748 35,737 35,456 
 Glaucoma 7,940 11,752 15,605 18,899 21,521 23,344 
  Diabetic retinopathy 14,195 22,855 31,568 39,416 46,325 52,271 
  Age-related degeneration 17,738 29,070 38,228 44,786 49,359 52,105 
Visual impairment  
        Mild/moderate VI 57,662 91,066 114,742 131,857 145,241 154,960 
  Severe VI 3,057 4,829 6,084 6,991 7,701 8,216 
VI = visual impairment;  
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Table 2.4 Projection of the direct medical costs of major eye diseases and visual impairment in 2015 to 2040 
 2015 2020 2025 2030 2035 2040 
Diagnosis              
 Cataract  60.3 108.1  137.7  161.1  186.7  214.8  
 Glaucoma 44.4  82.8  132.6  192.0  261.5  342.1  
 Diabetic retinopathy 56.5  96.9  149.2  209.4  276.5  347.7  
 Age-related degeneration 176.0 334.4  509.8 692.4  884.7  1,082.6  
Visual impairment              
  Mild/moderate VI 333.3 610.3 891.4 1,187.6 1,516.4 1,875.6 
  Severe VI 40.4 74.0 108.1 144.0 183.9 227.4 
  Total costs 373.8 684.3 999.5 1,331.5 1,700.3 2,103.0 
All in million Singapore dollars; Annual inflation rate: 3%; 




To our knowledge, this is the first study to estimate the economic burden of VI and major eye 
diseases at both individual and national levels in Singapore, a developed urban-state in Asia. Our 
study showed that VI imposed a substantial economic burden to the healthcare system of 
Singapore. For example, the median annual direct medical cost of VI per capita accounted for 9.5% 
of the median annual personal income in resident employed households in 2013 (Department of 
Statistics, 2013). The finding about the substantial economic burden of VI is consistent with the 
situations in other countries (Taylor et al., 2006; Cress et al., 2011; Brezin et al. 2005; Roberts et 
al., 2010; Rein et al., 2006; Frick et al., 2007). In our study, direct medical costs were estimated 
as costs for outpatient services, including consultation and examination, treatment and procedure, 
and medication. It should be noted that, because only direct medical costs occurred in the tertiary 
medical center were captured in the study, our cost estimates were lower than those estimates 
from previous studies, all of which investigated both direct and indirect costs (Taylor et al., 2006; 
Cruess et al., 2011; Roberts et al., 2010; Frick et al., 2007; Wittenborn, 2013). If only the direct 
medical costs of VI from outpatient service were considered, the costs of VI per capita estimated 
in our study were higher than those in studies conducted in other Asian countries (Roberts et al., 
2010; Wang et al., 2013, Park et al., 2015). For example, the direct medical costs of VI per 
capital in Japan were $3,842 (equivalent to approximately S$4,802), account for 88.7% and 38.7% 
of the direct medical costs of mild/moderate and severe VI. 
 
The findings in our study also provided a unique view of the economic burden of eye diseases in 
Singapore or broadly Asia. At the individual level, AMD had higher direct medical costs 
compared with cataract, DR and glaucoma. The high direct medical costs of AMD should be 
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mainly due to the high medication costs for neovascular AMD. The result is consistent with the 
finding in a Thailand study (9), but different from that in a French study in which consultation 
and examination costs were the major cost drivers (Bonastre et al., 2003). One possible reason 
for the difference was that the French study was conducted in 2000, which was before the 
approval of the expensive Anti-vascular Endothelial Growth Factor (VEGF) medications (e.g. 
ranibizumab and aflibercept). Similarly, medication costs accounted for the majority of the direct 
medical costs of glaucoma (Varma et al., 2011) and the higher medication costs of glaucoma than 
treatment costs should be due to the high costs of eye drops (Wong et al., 2008). Nevertheless, 
for both cataract and DR, treatment and procedure costs were the main cost drivers, because 
surgery, including laser and conventional surgery, is the main treatment for these two eye 
diseases (Cheung et al., 2010; Lundstrom et al., 2001). At the national level, the projected direct 
medical costs of AMD could remain at least two times higher than those of cataract, glaucoma 
and DR in 2015 to 2040. The result could not be simply compared with findings from other 
studies that the economic burden of eye diseases was estimated from the healthcare system 
perspective in our study, while the society perspective in majority of other studies (Taylor et al., 
2006; Cruess et al., 2011; Wittenborn, 2013). Nevertheless, our study was consistent with a 
Canadian study that the estimated health system expenditure in people with vision loss was 
highest for AMD, followed by glaucoma, cataract and DR (Cruess et al., 2011). Apart from the 
high costs of medications, the high direct medical costs of AMD could also be due to late self-
detection. Early AMD is painless and could progress slowly without self-detection until it 
progresses to late AMD, with obvious vision loss and symptoms (Cruess et al., 2011). Hence, 
patients with AMD seeking medical care are mainly those with late AMD which causes higher 
medical costs. The direct medical costs increased with the severity of VI, which was consistent 
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with the findings in previous studies (Frick et al., 2007; Bramley et al., 2008; Javitt et al., 2007).  
The results in our study highlight the importance of public health programs or strategies for early 
detection of major eye diseases and VI. Systematic screening and early treatment, which could 
delay or prevent the progression of eye diseases, are shown to be cost-effective means in 
healthcare resource utilization for eye diseases (Maberley et al., 2003; James et al., 2000). 
Moreover, more generous investment into research on more effective treatment or management 
strategies may also be a possible way to reduce the substantial economic burden of eye diseases 
and VI. For example, a new treatment of glaucoma was found to reduce the economic burden by 
delaying the disease progression from early stage ($623 per capita) to late stage ($2,511 per 
capita) (Lee et al., 2006).     
 
There are some limitations in our study. First, only medical costs occurred in one tertiary medical 
center where participants were followed up were considered. Visually impaired individuals who 
were not seeking medical care were not included and, for those who were included, the medical 
costs occurred in other medical centers or primary care clinics were not captured. Therefore, the 
true medical costs per capita may be over- or under- estimated. Second, in calculating the 
medical costs of the eye diseases, only visually impaired individuals were considered. Therefore, 
the actual national-level direct medical costs for the studied eye diseases would be higher 
because those not visually impaired individuals would also seek medical care. Third, in 
calculating the medical costs of VI at the national level, only individuals whose VI was due to 
cataract, glaucoma, DR, or AMD were considered, failing to consider the individuals with VI 
caused by other eye diseases. Fourth, the number of patients with eye diseases between 2015 and 
2040 in Singapore was projected using imperfect data available from 2012 to 2015 and thus 
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might not be accurate. Meanwhile, the inaccuracy could be also due to the innovations or 
breakthroughs in treatment of eye diseases and VI in the future (Kannnan et al., 2015; Gemenetzi 
et al., 2012).  
 
In summary, the direct medical costs of VI are substantial at both individual and national levels 
in Singapore. Moreover, the economic burden due to the four major eye diseases and VI is likely 









Out-of-pocket Expenditure and Productivity Loss of Visual 





Visual impairment (VI) is a public health problem worldwide. According to World Health 
Organization, about 285.39 million people were visually impaired in 2010, among whom 39.37 
million were blind (Pascolini and Mariotti, 2012). Previous studies have shown that VI causes a 
substantial economic burden to the society (Wittenborn, 2013; Rein, 2013; Taylor et al., 2006; 
Roberts et al. 2010; Cruess et al. 2011; Economics 2009). In the United States, the annual costs 
of vision problems in 2013 were estimated to be $65.1 billion, which were only slightly lower 
than those of heart conditions, trauma, cancer and mental health disorders (Wittenborn, 2013; 
Rein, 2013). In Australia, the direct costs of vision problems were AUD$ 9.85 billion, ranking 
the 7th among various health conditions (Taylor et al., 2006).  
 
Moreover, previous studies have shown that productivity loss, defined as the labor costs of lower 
income and reduced workforce participation, accounts for a large amount of economic burden of 
VI (Wittenborn, 2013; Rein, 2013). For example, in Australia, the productivity loss of 
individuals with VI was estimated to be AUD$1.78 billion in 2004, which was almost equal to 
the direct cost (AUD$ 1.82 billion) (Taylor et al., 2006).  
 
The economic burden of VI estimated in previous studies is mainly from the perspectives of 
health care system, government and society, while the studies of out-of-pocket (OOP) 
expenditure of VI, defined as the expenditure borne by patients and their families, are limited 
(Organization for Economic Co-operation and Development, 2001; O'Connor et al., 2008; Wong 
et al., 2008). Compared with expenditure from other perspectives, OOP expenditure provides 
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more accurate and concise information of the health burden to the households, reflecting the 
affordability and equity of the health systems (Carpenter et al., 2015; Corrieri et al., 2010).      
 
VI is also a serious public health issue in Singapore. According to the Singapore Epidemiology 
of Eye Disease study (SEED), the prevalence of VI was 4.4% and 3.8% in Malays and Indians 
aged 40 years and above, respectively (Wong et al., 2008; Zheng et al., 2011). With the aging 
population, the number of people with VI will increase dramatically. Studies investigating the 
economic burden of VI in Singapore were rare and mainly focused on the direct medical cost of 
specific eye diseases (Wang et al., 2004; Lim et al., 2009; Zheng et al., 2013). Our recent study 
showed that the direct medical costs of VI could be S$373.8 million in 2015 and increase by 5.6 
times to S$2.10 billion in 2040 (Wang et al., 2015). Nevertheless, the heavy economic burden 
revealed in the study was from the perspective of healthcare system; no study has been 
conducted to estimate the OOP expenditure of VI or any eye disease. Moreover, no study has 
estimated the productivity loss of VI or any eye disease in Singapore.  
 
In this study, we aimed to estimate the OOP expenditure and productivity loss of VI in Singapore.  
  
3.2 Methods 
A cross-sectional, questionnaire-based survey was conducted to assess the economic burden of 
500 Singaporeans with VI and 500 Singaporeans without VI in the study. Individuals with VI 
were recruited from the outpatient clinics in Singapore National Eye Center, the tertiary medical 
center for eye diseases in Singapore, following certain inclusion criteria. Quota sampling was 
used to recruit equal number of individuals with each of the four eye diseases. After recruitment, 
45 
 
each individual and/or his/her caregiver was interviewed face-to-face in hospital by a trained 
research assistant using a set of standardized questionnaires including, in the order of 
administration, the vision ‘bolt-on’ EQ-5D questionnaire, the 14-item visual function 
questionnaire (VF-14), a healthcare utilization and expenditure questionnaire, and an 
employment questionnaire. Data collected using the EQ-5D and VF-14 questionnaires were used 
in a different study (see Chapter 6). 
 
Among the 500 individuals without VI, 336 individuals were recruited from participants of the 
2013 National Eye Care Day which provided free ophthalmologic examinations to registered 
members of the general public. The inclusion criteria were: 1) clinically confirmed absence of 
cataract, glaucoma, diabetic retinopathy (DR) and age-related macular degeneration (AMD); 2) 
aged 40 years or above; 3) Singapore citizen or permanent resident; 4) normal vision in both eyes; 
5) able to communicate in English or Chinese; and 6) written informed consent. After 
recruitment, each individual or his/her caregiver was home visited and interviewed face-to-face 
by a trained interviewer using the same set of standardized questionnaires for individuals with VI. 
The remaining 164 individuals without VI were recruited from a convenience sample of 
communities and interviewed using the same inclusion criteria and procedures mentioned above 
except that normal vision and absence of the four eye diseases were based on self-report rather 
than clinical examination. 
 
Data on the self-reported healthcare utilization, expenditure and the employment status were 
used in the analysis in Chapter 3. This study for VI followed the principles of Declaration of 
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Helsinki and the ethical approval was obtained from the Centralized Institutional Review Board 
(CIRB) of SingHealth. 
 
Definitions of Visual Impairment and Eye Diseases  
In the study, presenting VA was measured for each participant using a Snellen chart. VI was 
defined as VA ≤6/12 in the better-seeing eye (Tielsch et al. 1990, Zheng et al. 2011, Wong, 
Chong, et al. 2008). Four most common eye diseases including cataract, glaucoma, DR, and 
AMD were clinically diagnosed by the ophthalmologists and included in the study.  
 
Healthcare Utilization and Expenditure 
The standardized healthcare utilization and expenditure questionnaire used in this study assessed 
the healthcare utilization and expenditure information of individuals with and without VI in the 
past 3 months. The questionnaire consisted of 5 sections including  inpatient services, emergency 
department services, outpatient services, other health care (e.g. message, acupuncture, bone 
setting), and health equipment. In each section, detailed information of healthcare utilization 
including reasons for seeking or using the services, healthcare service providers, and frequency 
of usage, was collected. Afterwards, information about the payment and payment type including 
health scheme and insurance, cash or credit card, and others, was collected. OOP expenditure 
was inquired for each healthcare service reported by the participants or their caregivers using the 





The employment status of participants and their caregivers in the past 1 month was assessed. For 
those who were working, their monthly wages, working hours, and absenteeism due to any 
health condition (for patients) or taking care of their clients (for caregivers) were inquired. For 
those who changed their employment status (from full-time to part-time, one job to another, 
stopping work) due to health reasons or caregiving responsibility, their last drawn monthly 
wages from the previous job were also inquired.  
 
Statistical Analysis 
The annual utilization and OOP expenditure due to any health problem were calculated for each 
individual as the healthcare utilization and expenditure in the past 3 months collected from the 
interview multiplied by 4. The calculation was conducted for each type of services and their total. 
Productivity loss was calculated as the percentage of the time of absenteeism due to health 
problems, multiplied by their monthly wages, and multiplied by 12. If an individual or his/her 
caregiver was unemployed or retired due to non-health reasons, the productivity loss was 
assumed to be 0. The utilization and OOP expenditure between individuals with and without VI 
were compared using the 2-sample t-test. 
 
A 2-part model was used to estimate the healthcare utilization and OOP expenditure due to VI 
separately (Cantoni and Ronchetti, 2006). The first part was a logistic model that predicted the 
probability of positive utilization or expenditure, while the second part was a generalized linear 
model (GLM) with gamma family and log link for estimating the utilization or expenditure 
among those individuals who reported utilization or expenditure. In both the logistic regression 
model and GLM model with gamma family and log link, the independent variables included age 
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(40-59/60-79/80 above), gender (male/female), ethnicity (Chinese/non-Chinese), education (no 
formal education/primary education/secondary education), employment status (working/not 
working), marital status (married/not married), interview language (English/Chinese/others), and 
VI status (yes/no).  
 
The average Canadian dollar/Singapore dollar and US dollar/Singapore dollar exchange rate of 
1.21 and 1.25 in 2013 were used in the analysis, respectively. I was responsible for data 
collection and data analysis in the study. All the analyses were conducted using SAS software 
version 9.2 (SAS Inc., Cary, NC) at a significance level of 0.05.  
3.3 Results 
Characteristics of individuals with and without VI are shown in Table 3.1. For individuals with 
VI, the mean  standard deviation (SD) age was 71.6  9.8 years old and the proportion of males 
was 47.6%. Most individuals with VI were Chinese (88.0%), with primary or no formal 
education (64.2%), not working (80.2%), and married (86.2%). For individuals without VI, the 
mean  SD age was 65.2  7.5 years old and the proportion of males was 44.8%. Most 
individuals without VI were Chinese (87.2%), with secondary education (57.6%), not working 
(59.4%), and married (71.0%), and interviewed in Chinese (51.6%). Compared with individuals 
with VI, those without VI were younger, better educated, and more likely to work. 
 
Annual healthcare utilization and OOP expenditure of individuals with and without VI are shown 
in Table 3.2. The annual healthcare utilization of individuals with VI was higher than that of 
individuals without VI. For example, the mean annual inpatient hospital admission number in 
individual with and without VI was 0.130 and 0.034, respectively (p<0.0001). After the 
49 
 
adjustment of covariates, the annual medical service utilization attributed to VI as indicated by 
the difference between individuals with and without VI was mainly due to outpatient clinic visits 
(marginal number of visits per person: 1.123) and other health care (marginal number of use per 
person: 0.394) (Table 3.2). The annual OOP expenditure of individuals with VI (S$3,047.40) was 
higher than those of individuals without VI (OOP expenditure: S$1,033.3), respectively 
(P<0.0001). Same trends were shown for all types of services (Table 3.2). After the adjustment of 
covariates, the annual OOP expenditure attributed to VI (S$2017.1) was mainly due to outpatient 
service costs (S$1259.4) and inpatient service costs (S$713.8). 
 
Annual productivity loss of individuals with and without VI is shown in Table 3.3. The mean 
annual absenteeism time due to health problems in individuals with VI (89.4 hours) and their 
caregivers (136.9 hours) was higher than that in individuals without VI (5.0 hours) and their 
caregivers (1.0 hour), respectively (P<0.0001 for both). After adjusting for covariates, the 
productivity loss attributed to VI for patients and caregivers was 113.6 hours and 114.5 hours, 
respectively. Compared with patients (S$243.9), caregivers (S$555.1) had higher productivity 
loss due to VI.    
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Table 3.1 Characteristics of participants with and without visual impairment (n=1,000)  
Characteristic 
Individual with VI 
(n=500)  
Individual without 
VI (n=500)  
P value 






       
 






       
 




















       
 
















       
 










       
 




















       
 















SD = standard deviation; VI = visual impairment; yrs = years
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Table 3.2 Annual health service utilization and out-of-pocket expenditure of individuals with and without visual impairment (n=1,000) 
Category 
Individual with VI 
(n=500)  
Individual without 
VI (n=500)  






Medical service utilization 
       



































  Emergency department service cost 77.0 1097.7  7.6 70.4  38.3 (1.4) 
 Outpatient service cost 1711.8 3521.4  512.3 2833.9  1259.4 (14.6) 
 Other health care 240.7 1702.6  171.2 923.5  64.3 (1.2) 
 Health equipment 64.7 287.3  16 167.3  9.4 (0.5) 
No. = number; SD = standard deviation; SE = standard error; S$ = Singapore dollar; VI = visual impairment. 
52 
 
Table 3.3 Annual absenteeism and productivity loss of individuals with and without visual 
impairment (n=1,000) 
Category 
Individual with VI 
(n=500)  
Individual Without 
VI (n=500)  
Marginal effect 
of VI (SE) 
Mean SD 
 
Mean SD   
Absenteeism, hours         
  Individual 89.4 301.9  5.0 25.5  113.6 (5.8) 
  Caregiver* 136.9 281.3  1.0 18.0  114.5 (2.5) 















SD = standard deviation; SE = standard error; S$ = Singapore dollar; VI = visual impairment 





Our study showed that VI imposes substantial economic burden to the individuals and their 
families in Singapore – the annual OOP expenditure and productivity loss per capita due to VI 
was S$2017.1 and S$915.3, respectively, in 2013. To our knowledge, this is the first study to 
estimate the OOP expenditure and productivity loss of VI in Singapore. Moreover, previous cost-
of-illness studies simply collected cost data from the individuals with the relevant condition. For 
example, in a study estimating the economic costs of myopia in Singapore, data were collected 
from adults aged over 40 years and with myopia (Zheng et al., 2013). In contrast, our study 
collected data from both the individuals with and without VI, thus providing more accurate 
estimates. This is because the economic burden due to VI is not limited to direct medical costs 
for vision problems. There are also medical costs for other health problems due to vision 
problems. Studies have demonstrated that poor vision increased the chance of falls, fractures and 
depression (Ivers et al., 2003; Noran et al., 2009; Ivers et al., 2002). Therefore, expenditures on 
other health problems caused by VI should also be considered when estimating the economic 
costs of VI. Nevertheless, it would be difficult for investigators or respondents to determine 
whether specific self-reported service utilization that occurred in the past is ascribed to VI. Thus, 
it is necessary to use individuals without VI as the reference group.  
 
The result in our study that inpatient and outpatient services caused the majority of the OOP 
expenditure is consistent with previous studies (Kumar et al., 2015; Choi, 2015). The OOP 
expenditure of VI shown in our study is considerable. The mean annual OOP expenditure of VI 
is lower than that of VI (equal to SG$4,355) in Australia (Wong et al., 2008). In the Australian 
study, 150 visually impaired individuals completed diaries to record their daily personal vision-
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related expenditure for up to a year. A large proportion of the OOP expenditure was related to 
transportation in the Australian study, which is not surprising as Australia has a much larger 
territory than Singapore which is an urban state with an area of 718.3 square kilometers only. 
The burden of the OOP expenditure measured by its percentage of the total household income or 
expenditure can be used to make cross-country comparisons (Organization for Economic Co-
operation and Development, 2011). Based on our study and the published annual household 
expenditure (Singapore Department of Statistics, 2014), the OOP expenditure of VI accounts for 
3.6% of household expenditure in Singapore, which is about the same as the average (3.2%) for 
the Organization for Economic Co-operation and Development (OECD) countries (Organization 
for Economic Co-operation and Development, 2011). Nevertheless, the economic burden of VI 
in Singapore is likely to increase dramatically in the future due to the rapidly aging population. 
According to Singapore Ministry of Health, the outpatient attendance rate of government-
subsidized patients to department of ophthalmology in the major public hospitals increased 39.1% 
from 2002 to 2006 (Di, 2007). Therefore, policy makers might consider policies that will provide 
more subsidies for the inpatient and outpatient services for individuals with VI, especially those 
with low household income. 
 
Our study shows that caregivers suffer from much more productivity loss compared with 
individuals with VI. The result is consistent with the finding in the Japanese study (Roberts et al. 
2010). We found that the productivity loss of VI in Singapore is mainly due to absenteeism 
rather than completely loss of productivity. The estimated annual productivity loss of VI due to 
absenteeism (S$243.9 per capita) in Singapore is similar to that in Canada (Can$283.6, 
equivalent to approximately S$343.2) and Japan (US$234.6, equivalent to approximately 
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S$293.3) (Roberts et al., 2010, Cruess et al. 2011). In both the Canadian and Japanese studies, a 
human capital approach was used to estimate the productivity loss for individuals with VI for the 
entire population.   
 
The major limitation of the study is the use of self-reported data. It is likely that respondents 
underreported service utilization due to recall bias. The use of a control group may not overcome 
this problem because individuals with VI should have underreported more than individuals 
without VI. Hence, the OOP expenditure and productivity loss due to VI might be 
underestimated in this study. Second, the healthy controls in the study were recruited from 
participants of a health screening event. They might be more health conscious and healthier than 
average members of the general population. As a result, the sampling bias might widen the actual 
difference in health service utilization and expenditure between individuals with and without VI. 
Third, only the productivity loss of the primary caregiver, defined as the caregiver who spent 
most time taking care of the patients, was considered, which might cause underestimation. 
Nevertheless, the vast majority of the patients had only one caregiver. Fourth, though 2-part 
model was used to adjust the covariates (e.g. age, gender and comorbidities) in the analysis, their 
effect on the OOP expenditure and productivity loss could not be completely ruled out.   
 
In conclusion, our study demonstrated that VI has caused significant economic burden to patients 
and their families in Singapore. The significant economic burden of VI highlights the importance 









Health Burden Associated with Visual Impairment in 






Visual impairment (VI) is an important public health issue in Asia (Bourne et al., 
2012). In Southeast Asia alone, about 45 million people have VI, among whom 12 
million are blind (Resnikoff et al., 2004; Dandona et al., 2006). With the aging of the 
population, the burden of VI is anticipated to increase (Chiang et al., 2012; Gordois et 
al., 2012). Previous studies have shown that VI not only affects people’s visual status 
but also has an impact on people’s functioning and well-being (Goldzweig et al., 2004; 
Ong et al., 2012; Lamoureux et al., 2008). Hence, apart from visual acuity (VA), 
health-related quality of life (HRQOL) should also be measured in order to achieve a 
comprehensive assessment of the impact of VI on patients. 
 
Both vision-specific and generic HRQOL instruments are used to measure the health 
burden of VI. Vision-specific quality of life (VSQOL) instruments such as the Vision 
Function Index Questionnaire (VF-14) (Steinberg et al., 1994) are more sensitive to 
vision problems than generic instruments such as the European Quality of Life 
Questionnaire (EQ-5D) (Brooks, 1996; Lotery et al., 2007). However, VSQOL 
instruments cannot generate a utility-based index score for calculation of 
quality-adjusted life years (QALYs) or comparison of the health burden associated 
with vision problems and other health conditions. The health burden of VI has been 
estimated using EQ-5D in several western and eastern populations (Lotery et al., 2007; 
Langelaan et al., 2007; van Nispen et al., 2009; Lin and Yu, 2012; Polack et al., 2008); 
however, the sample sizes of those studies are relatively small and therefore the 
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findings in those studies may not be generalizable to Asians in Singapore. In this 
study, we aimed to measure the impact of VI on generic HRQOL and to compare it 
with commonly seen health conditions in the three major ethnicities in Singapore. 
 
4.2 Methods 
4.2.1 Study Population 
In this study, data from the Singapore Epidemiology of Eye Disease (SEED) Study 
were used, comprising three population-based eye studies: the Singapore Chinese Eye 
Study (SCES), the Singapore Indian Eye Study (SINDI), and the Singapore Malay 
Eye Study (SiMES). The three studies have been described in detail previously 
(Foong et al., 2007; Lavanya et al., 2009). In brief, an age-stratified random sampling 
was used to select ethnic Chinese, Indians, and Malays aged 40-80 years living in 
Singapore. The overall response rate was 75.6%: 72.8% for Chinese, 75.6% for 
Indians, and 78.7% for Malays. The SEED study adhered to the principles of 
Declaration of Helsinki and ethical approval was obtained from the Singapore Eye 
Research Institute Institutional Review Board. 
 
4.2.2 Health-Related Quality of Life Measure 
EQ-5D was used to assess the generic HRQOL. The EQ-5D contains five dimensions: 
mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. 
Participants rated their health status in those dimensions on the day of survey as one 
of the three levels: no problems, some problems, or extreme problems. To measure the 
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utility or value of the health status of the participants, we used their responses to the 
five dimensions to calculate an index score ranging from -0.59 for the worst health 
state to 1.00 for perfect health (Dolan, 1997). In this interval scale used by the EQ-5D, 
the score of 0 means the value of the corresponding health states is as bad as death 
and negative scores indicate the corresponding health states are worse than death. In 
the three studies, trained research assistants conducted face-to-face interview in 
English, Chinese, Tamil, or Malay, depending on the participant’s preference. 
Previous studies tested the validity and reliability of the EQ-5D questionnaire in 
English-speaking and Chinese-speaking Asian patients with rheumatic diseases in 
Singapore (Luo et al., 2003; Luo et al., 2003) as well as in local Malay- and Tamil- 
speaking patients
 
(Wee et al., 2007). The EQ-5D demonstrated satisfactory validity 
and reliability in both local general and patient populations (Wee et al., 2007; Lee et 
al., 2013; Varma et al., 2006; Luo et al., 2009) including persons with vision problems 
(Au Eong et al., 2012; Ang et al., 2013). 
 
4.2.3 Definitions of Visual Impairment (VI) 
In all three eye studies, participants underwent extensive visual examinations, 
including VA testing and a detailed clinical slit lamp examination. The presenting VA 
for each participant was measured with a logarithm of the minimum angle of 
resolution (logMAR) chart (Lighthouse International, New York, NY) at a distance of 
4m, with the participants wearing their habitual optical correction (e.g. spectacles or 
lenses). If the participants could read no number at 4m, they moved to 3, 2, or 1m, 
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consecutively. If they could read no number on the chart, the VA was measured as 
Counting Fingers, Hand Movement, Perception of Light, or No Perception of Light. 
 
VI was classified as unilateral and bilateral VI and as mild/moderate, and severe. 
Mild/moderate VI was defined as VA <20/40 but >20/200 (logMAR >0.30 to <1.00) 
and severe VI as VA ≤20/200 (logMAR ≥1.00) (Tielsch et al., 1990). Unilateral VI was 
defined based on the VA of the better-seeing eye and classified the severity of bilateral 
VI into 6 categories (Zheng et al., 2011): (1) normal vision in both eyes, (2) normal 
vision in one eye, and mild/moderate VI in the other, (3) normal vision in one eye, and 
severe VI in the other, (4) mild/moderate vision impairment in both eyes, (5) severe VI 
in one eye, and mild/moderate VI in the other, (6) severe VI in both eyes. 
 
4.2.4 Other Health Conditions  
The presence or absence of four health conditions, including obesity, hypertension, 
diabetes, and hyperlipidemia, was determined for each participant. Obesity was 
defined as body mass index (BMI) ≥30; diabetes as random glucose ≥200mg/dl 
(11.1mmol/L), use of diabetic medication, or self-reports of physician diagnosis; 
hyperlipidemia as a total cholesterol level ≥239.4mg/dl (6.2mmol/L) or use of 
lipid-lowering drugs; and hypertension as systolic blood pressure (BP) ≥140mmHg, 
diastolic BP ≥90mmHg, or current use of antihypertensive medications. Blood 
pressure (BP) was measured twice (5 minutes apart). If there was more than 10mm 
Hg (systolic) and 5mm Hg (diastolic) difference in the BP measures, a third 
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measurement was performed and considered the BP as the mean between the 2 closest 
readings.   
 
4.2.5 Statistical Analysis 
Both univariate and multivariate analyses were performed to examine the association 
between the EQ-5D index score and VI. Firstly, ANOVA and chi-square tests were 
used to compare the socio-demographic characteristics across the three ethnicities and 
the EQ-5D index score across different subgroups of individuals with and without 
unilateral/bilateral VI. Secondly, multivariate linear regression models were used to 
examine the effect of unilateral/bilateral VI on the EQ-5D index score by controlling 
for socio-demographics that were found to be associated with HRQOL in a previous 
study
14
. As the distribution of the EQ-5D index score was skewed, the robust standard 
error estimator (Pullenayegum et al., 2010) was used in the multivariate linear 
regression analysis. In order to detect the differential effect of VI across ethnicities, a 
pooled analysis was performed with cross-product interaction terms between VI and 
ethnicity being added to the regression models. Thirdly, a binary logistic regression 
analysis was used to examine the association between the presence of EQ-5D health 
problems and the severities of unilateral/bilateral VI. In this analysis, responses to 
each EQ-5D item were coded into a binary variable (with problems/without problems) 
and analyzed it in a separate model. Lastly, the effects of VI and other health 
conditions (obesity, hypertension, diabetes, and hyperlipidemia) on the EQ-5D index 
score were estimated simultaneously in a multivariate linear regression model. In this 
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model, VI was classified into two categories (with VI/without VI) according to the VA 
of the better-seeing eye. In order to assess the total burden of VI and the other health 
conditions at the population level, the annual quality-adjusted life years (QALYs) loss 
per 100,000 persons were calculated for each condition using the formula below: 
QALYs loss = disutility score X 1 year X 100,000 X prevalence rate, where disutility 
was the regression coefficient for the condition in the above-mentioned model and the 
prevalence rate was the observed proportion of cases with the condition in the SEED 
study. QALYs is an outcomes measure calculated as life years a person lives weighted 
by the person’s quality of life measured by a utility-based measure such as the EQ-5D 
(Bravo et al., 2008; Jia et al., 2010). For example, one year in perfect health is one 
QALY, while two years in a health state of 0.75 is 1.5 QALYs.  
 
Each ethnicity (Chinese, Indian, and Malay) was analyzed separately, using SAS 
software (version 9.2, SAS Institute, Inc., Cary, NC) at the significance level of 0.05. 
 
4.3 Results 
After excluding 3 Indian and 21 Malay participants with missing responses to EQ-5D, 
3,353 Chinese, 3,397 Indian, and 3,259 Malay participants were included in the study. 
The socio-demographic and health characteristics of each ethnic group are described 
in Table 4.1. The mean  SD age of Chinese, Indian and Malay subjects were 59.7  
9.9, 57.8  10.1, and 58.7  11.0 years, respectively. The proportion of males was 
49.6%, 50.1%, and 48.8% in Chinese, Indians, and Malays, respectively. Significant 
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difference across the three ethnicities existed for all socio-demographic and health 
characteristics, except gender (P = 0.1671). The mean  SD EQ-5D index score for 
Chinese (0.92  0.12) was significantly higher than that for Indians (0.82  0.23) and 
Malays (0.83  0.19) (P< 0.0001).  
 
The prevalence and EQ-5D index scores of participants with different severities of 
unilateral and bilateral VI are shown in Table 4.2. EQ-5D index score decreased with 
increasing severity of unilateral and bilateral VI in all three ethnicities (P <0.001 for 
all three ethnicities). For example, there was statistically significant difference in the 
EQ-5D index score between Chinese with normal vision in the better-seeing eye (0.93 
 0.11), unilateral mild/moderate VI (0.90  0.15), and unilateral severe VI (0.82  
0.22). 
 
The effects of unilateral and bilateral VI on the EQ-5D index score after adjustment of 
covariates are described in Table 4.3. In terms of bilateral VI, Indians with 
mild/moderate VI in one eye and severe VI in the other (difference = -0.064, 95% 
confidence interval [CI] = -0.125 - -0.003), Indians with severe VI in both eyes 
(difference = -0.127, 95%CI = -0.237 - -0.017), and Malays with severe VI in both 
eyes (difference = -0.085, 95%CI = -0.148 - -0.022), had lower EQ-5D index score 
than their respective counterparts without VI. In terms of unilateral VI, Indians with 
mild/moderate VI (difference = -0.027, 95%CI = -0.052 - -0.002), Indians with severe 
VI (difference = -0.126, 95%CI = -0.236 - -0.016), and Malays with severe VI 
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(difference = -0.078, 95%CI = -0.137 - -0.019), had significantly lower EQ-5D index 
score than their respective counterparts without VI. Similar differences in the EQ-5D 
index score were also found in Chinese, although those were not statistically 
significant. For example, Chinese with unilateral severe VI (difference = -0.043, 
95%CI = -0.086 - 0.001) and those with unilateral mild/ moderate VI (difference = 
-0.020, 95%CI = -0.047 - 0.007) had lower EQ-5D index score than those without VI. 
In the models testing for interaction between VI and ethnicity, significantly greater 
impact on Indians and Malays as compared to Chinese was observed for both bilateral 
VI (P = 0.0011) and unilateral VI (P = 0.0001).  
 
The multivariate logistic regression analysis results for the EQ-5D dimensions of 
mobility, usual activities, pain/discomfort, and anxiety/depression are shown in Table 
4.4. Self-care was not analyzed because very low proportion of participants reported 
such problems (1.1% in Chinese; 3.1% in Indians; 2.2% in Malays). After the 
adjustment of covariates, bilateral and unilateral VI were significantly associated with 
the reporting of problems with mobility and usual activities in all three ethnicities. For 
example, in Singapore Chinese, unilateral mild/moderate VI (OR = 2.08, 95%CI = 
1.23-3.50), unilateral severe VI (OR = 4.94, 95%CI = 1.28-19.10), and bilateral 
severe VI (OR = 6.51, 95%CI = 1.59-29.58), were significantly associated with the 
reporting of problems in usual activities. In addition, bilateral (OR = 2.68, 95%CI = 
1.11-6.50) and unilateral (OR = 2.54, 95%CI = 1.05-6.13) severe VI were also 




The health burden of VI and four other health conditions measured by disutility and 
annual quality-adjusted life-years (QALYs) loss per 100,000 people are shown in 
Table 4.5. For all three ethnicities, the disutility score of VI (Chinese: 0.0239; Indian: 
0.0297; Malay: 0.0272) was larger than that of obesity, hypertension, diabetes and 
hyperlipidemia. For example, in Chinese, the disutility score of VI was larger than 
that of obesity (0.0143), hypertension (0.0090), diabetes (0.0140), and hyperlipidemia 
(0.0027). The annual QALYs loss per 100,000 persons associated with VI (Chinese: 
511.8; Indian: 608.8; Malay: 706.7) was higher than that of other conditions for all the 
three ethnicities. For example, in Chinese, the annual QALYs loss due to VI was 
larger than that of obesity (75.7), hypertension (506.4) and diabetes (212.2), and 




Table 4.1 Socio-demographic and health characteristics of the participants (n=10,009) 
Variable 
Chinese 
(n = 3,353) 
 Indian 
(n = 3,397) 
 Malay 
(n = 3,259) 
 
P value 
Age   
 
    
 
Mean (SD) 59.7  (9.9)  57.8  (10.1)  58.7  (11.0)  <0.0001 
Gender    
 
      
 
Male 49.6  (1662)  50.1 (1703)  48.0 (1563)  0.1671 
BMI (kg/m
2
)    
 
      
 
Mean (SD) 23.7  (3.7)  26.2  (4.7)  26.4  (5.1)  <0.0001 
Marital status           
 
Married 79.6 (2668)  78.2 (2656)  74.4 (2431)  <0.0001 
Employment           
 
Employed  57.6 (1929)  57.8 (1963)  43.2 (1407)  <0.0001 
Smoking status           
 
Current smokers 13.2 (442)  14.7 (499)  20.3 (661)  <0.0001 
Education           
 
No formal education 22.6 (756)   17.9 (608)   29.8 (972)   
<0.0001 
 
Primary education 31.0 (1038)   37.7 (1280)   43.2 (1409)   
 
Secondary education 46.5 (1559)   44.4 (1508)   27.1 (883)   
Monthly personal income (S$)         
 
<1000 47.6 (1547)   49.3 (1631)   69.1 (2246)   
<0.0001  
1000-2000 22.6 (736)   24.5 (810)   20.2 (654)   
 
2000-3000 12.0 (390)   12.1 (399)   7.3 (237)   
 
>3000 17.8 (580)   14.2 (471)   3.4 (110)   
Other health conditions  
 
      
 
Obesity 5.3 (177)   17.1 (578)   20.9 (681)   <0.0001 
 
Hypertension 59.2 (1984)  56.9 (1931)  69.2 (2256)  <0.0001 
 
Diabetes 15.2 (487)  34.6 (1129)  24.5 (769)  <0.0001 
 
Hyperlipidemia 47.2 (1527)  47.9 (1554)  41.2 (1328)  <0.0001 
EQ-5D index score    
 
      
 
Mean (SD)  0.92 .(0.12)  0.82..(0.23)  .0.83 .(0.19)  <0.0001 
BMI = body mass index; EQ-5D = European Quality of Life-5 Dimensions; SD = 
standard deviation; S$ = Singapore dollar
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Table 4.2 Prevalence and EQ-5D index score for different severities of unilateral and bilateral visual impairment (n=10,009) 
Vision Category 
Chinese 
(n = 3353) 
 Indian 
(n = 3397) 
 Malay 
(n = 3259) 
Prevalence Mean (SD)  Prevalence Mean (SD)  Prevalence Mean (SD) 
Bilateral VI         
 Normal vision in both eyes 53.9 (1805) 0.94 (0.10)  58.3 (1982) 0.84 (0.21)  53.6 (1753) 0.86 (0.16) 
 Mild or moderate VI in 1 eye, normal 
vision in the other 
22.5 (754) 0.92 (0.13)  19.0 (646) 0.81 (0.23)  18.7 (612) 0.82 (0.20) 
 Severe VI in 1 eye, normal vision in the 
other  
2.2 (75) 0.92 (0.13)  2.2 (76) 0.78 (0.29)  1.7 (55) 0.80 (0.19) 
 Mild or moderate VI in both eyes 18.0 (603) 0.90 (0.14)  16.5 (561) 0.78 (0.27)  19.7 (645) 0.80 (0.22) 
 Mild or moderate VI in 1 eye, severe VI 
in the other 
2.7 (920 0.86 (0.21)  3.2 (108) 0.72 (0.34)  4.4 (144) 0.78 (0.22) 
 Severe VI in both eyes 0.7 (22) 0.82 (0.22)  0.8 (27) 0.63 (0.30)  1.8 (60) 0.72 (0.23) 
 P value <0.0001  <0.0001  <0.0001 
Unilateral VI – better-seeing eye    
 Normal vision 78.6 (2634) 0.93 (0.11)  79.5 (2704) 0.83 (0.21)  74.0 (2420) 0.84 (0.17) 
 Mild or moderate VI 20.7 (695) 0.90 (0.15)  19.7 (669) 0.77 (0.28)  24.1 (789) 0.80 (0.22) 
 Severe VI 0.7 (22) 0.82 (0.22)  0.8 (27) 0.63 (0.30)  1.8 (60) 0.72 (0.23) 
 P value <0.0001  <0.0001  <0.0001 
EQ-5D = European Quality of Life-5 Dimensions; SD = standard deviation; VI = visual impairment. 
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Table 4.3 Effects of different severities of unilateral and bilateral visual impairment on EQ-5D index score in multivariate regression analysis 
(n=10,009) 
Vision Category 
Chinese  Indian  Malay 
Beta 95% CI  Beta 95% CI   Beta 95% CI  
Bilateral VI*       
 Normal vision in both eyes (reference)         
 Mild or moderate VI in 1 eye, normal vision in 
the other 
-0.009 -0.023 - 0.005  -0.003 -0.025 - 0.019  -0.016 -0.034 - 0.002 
 Severe VI in 1 eye, normal vision in the other -0.011 -0.035 - 0.013  -0.015 -0.046 - 0.016  -0.023 -0.056 - 0.010 
 Mild or moderate VI in both eyes -0.016 -0.036 - 0.004  -0.021 -0.045 - 0.003  -0.019 -0.039 - 0.001 
 Mild or moderate VI in 1 eye, severe VI in the 
other 
-0.031 -0.068 - 0.006  -0.064 -0.125 - -0.003  -0.028 -0.059 - 0.003 
 Severe VI in both eyes -0.044 -0.089 - 0.001  -0.127 -0.237- -0.017  -0.085 -0.148 - -0.022 
Unilateral VI – better-seeing eye*       
 Normal vision (reference)         
 Mild or moderate VI -0.020 -0.047 - 0.007  -0.027 -0.052 - -0.002  -0.023 -0.052 - 0.006 
 Severe VI -0.043 -0.086 - 0.001  -0.126 -0.236 - -0.016  -0.078 -0.137- -0.019 
CI = confidence interval; EQ-5D = European Quality of Life-5 Dimensions; VI = visual impairment.  




Table 4.4 Odds ratios (95% confidence interval) of different severities of unilateral and bilateral visual impairment in predicting EQ-5D health problems 
 Vision Category 

























    
 
    
 
    
 Normal vision in 
both eyes 
(reference) 
              
 Mild/moderate VI 
in 1 eye, normal 
vision in the other 
 1.52  
(0.99-2.31) 
 1.66  
(0.82-3.35) 
 1.09  
(0.87-1.36) 
 1.23  
(0.94-1.62) 
  1.12 
(0.84-1.48) 
 1.33  
(0.85-2.80) 
 0.92  
(0.75-1.12) 
 1.13  
(0.91-1.40) 
  1.26  
(0.97-1.65) 
 1.29  
(0.87-1.91)  
 1.04  
(0.84-1.27) 
 1.09  
(0.88-1.34) 
 Severe VI in 1 eye, 
normal vision in 
the other  
 2.19  
(0.93-5.15) 
 1.72  
(0.37-7.93) 
 0.75  
(0.40-1.42) 
 0.71  
(0.30-1.69) 
  2.19  
(1.21-3.95) 
 0.71  
(0.21-2.41) 
 0.59  
(0.35-1.00) 
 1.39  
(0.82-2.36) 
  0.43  
(0.17-1.13) 
 2.80  
(1.24-6.29) 
 1.55  
(0.86-2.80) 
 1.37  
(0.75-2.50) 
 Mild/moderate VI 
in both eyes 
 1.26  
(0.81-1.97) 
 2.59  
(1.32-5.07) 
 0.90  
(0.70-1.16) 
 1.06  
(0.77-1.45) 
  1.49  
(1.12-1.97) 
 1.62  
(1.05-2.49) 
 0.85  
(0.68-1.05) 
 1.18  
(0.93-1.48) 
  1.26  
(0.97-1.65) 
 1.86  
(1.29-2.68) 
 1.06  
(0.86-1.31) 
 1.03  
(0.82-1.28) 
 Mild/moderate VI 
in 1 eye, severe VI 
in the other 
 1.55  
(0.73-3.28) 
 3.53  
(1.31-9.55) 
 1.53  
(0.63-1.78) 
 1.26  
(0.67-2.36) 
  1.76  
(1.08-2.89) 
 2.76  
(1.48-5.18) 
 0.75  
(0.48-1.16) 
 1.32  
(0.84-2.06) 
  1.85  
(1.21-2.82) 
 1.41  
(0.78-2.55) 
 0.79  
(0.54-1.16) 
 1.16  
(0.78-1.71) 






 0.68  
(0.22-2.15) 
 1.62  
(0.51-5.14) 
  3.85  
(1.57-9.44) 






  2.61  
(1.44-4.72) 
 6.80  
(3.86-12.88) 
 1.44  
(0.82-2.53) 
 1.16  
(0.65-2.40) 
Unilateral VI – better-seeing eye*              
 Normal vision 
(reference) 
              
 Mild/moderate VI  1.02  
(0.71-1.46) 
 2.08  
(1.23-3.50) 
 0.90  
(0.72-1.13) 
 1.01  
(0.76-1.33) 
  1.42  
(1.11-1.81) 
 1.66  
(1.17-2.37) 
 0.87  
(0.71-1.05) 
 1.14  
(0.93-1.40) 











EQ-5D = European Quality of Life-5 Dimensions; VI = visual impairment.  
*Adjustment of age, gender, body mass index, income, education, employment status, smoking status and other health conditions; only EQ-5D items 
significantly associated with VI included; boldness: P < 0.05. 
&
Odds ratio from logistic regression analysis. 
 Severe VI  2.87  
(0.89-9.25) 
 4.94  
(1.28-19.10) 
 0.66  
(0.21-2.08) 
 1.50  
(0.48-4.71) 
  3.55  
(1.45-8.66) 
 8.54  
(3.29-22.18) 
 1.60  
(0.65-3.94) 
 2.54  
(1.05-6.13) 










Table 4.5 Annual quality-adjusted life-years (QALYs) loss per 100,000 persons associated 
with visual impairment and other health conditions 








Obesity -0.0143   5.3  75.7 
Hypertension -0.0090  56.2 506.4 
Diabetes -0.0140  15.2 212.2 
Hyperlipidemia
$
 -0.0027  47.2 127.4 
Unilateral VI -0.0098 24.7 242.06 
Bilateral VI -0.0239  21.4 511.8 
     Indian 
(n=3,397) 
Obesity -0.0133  17.1 228.2 
Hypertension -0.0105  56.9 599.3 
Diabetes -0.0169  34.6 585.4 
Hyperlipidemia
$
 -0.0064  47.9 306.6 
Unilateral VI -0.0073 21.3 155.49 






Obesity -0.0124  20.9 258.3 
Hypertension -0.0101  69.2 697.6 
Diabetes -0.0166  24.5 407.8 
Hyperlipidemia
$
 -0.0013  41.2  53.6 
Unilateral VI -0.0187 20.5 383.35 
Bilateral VI -0.0272  26.0 706.7 
VI = visual impairment 
*Regression coefficient with adjustment of age, gender, body mass index, income, education, 
employment status and smoking status 
#
Calculated using data from the three ethnic cohorts 
$






To our knowledge, this is the first study to use EQ-5D instrument and QALYs to 
estimate the impact of VI on generic HRQOL and to compare the burden of VI and 
other health conditions in Singapore. Our study showed that unilateral and bilateral VI 
had an impact on generic HRQOL, which was also revealed in previous studies 
(Varma et al., 2006; Chia et al., 2003). Our study also showed that people with VI 
were more likely to experience problems in mobility and usual activities. This finding 
was consistent with the finding in Australia that visually impaired individuals’ ability 
to maintain mobility and independence significantly decreased (Wang et al., 2003) 
and their need for community and family support was significantly high (Wang et al., 
1999). We found that Singapore Indians with unilateral/bilateral severe VI reported 
more emotional problems than those without VI, similar to previous studies in India 
(Nirmalan et al., 2005; Fletcher et al., 1998). However, no such association was found 
in Chinese or Malays, suggesting that these two ethnicities might have better 
psychosocial adoption to vision problems than Indians. Previous studies of elderly 
with visual disorders found that psychosocial adaptation status was associated with 
mental health symptoms (Tolman et al., 2005; Wang and Chan., 2009). 
 
Our study also demonstrated that the health burden of VI was larger than that of 
obesity, hypertension, diabetes, and hyperlipidemia. Similar results were found in two 
previous studies using EQ-5D as the measure of disease burden (Sullivan and 
Ghushchyan, 2006; Sullivan et al., 2011). In a US study, the disutility of VI was equal 
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to that of obesity, while much larger than that of the other three health conditions 
investigated here. In a UK study, the disutility of VI was smaller but close to that of 
obesity and diabetes, while much larger than that of hypertension and hyperlipidemia. 
Our finding that VI is a leading cause of disease burden is also supported by studies 
using WHO’ s healthy years loss due to disability or ill health (YLDs) as the measure 
of disease burden (Murray, 1994). According to the Global Burden of Disease Study 
2010, VI and diabetes mellitus were both the important causes of global health burden, 
while the other three health conditions were not (Vos et al., 2012). In a Dutch study, 
the burden of VI ranked the 2
nd
 among the 47 diseases, much higher than diabetes 
mellitus (Melse et al., 2000). In Singapore, diabetes mellitus and vision problems, 




 leading causes 
of disability burden (in YLDs) while obesity, hypertension and hyperlipidemia were 
not among the 20 leading specific causes (Phua et al., 2009). This body of consistent 
evidence on the heavy burden of VI relative to other health conditions suggests that 
more resources could be allocated to programs and interventions likely to prevent VI.  
.  
A major strength of our study is that our multi-ethnic Asian study population allowed 
us to study the ethnic difference in the impact of VI on generic HRQOL. VI seemed to 
impose higher burden on Indians and Malays than on Chinese. Bilateral severe VI had 
a significant impact on generic HRQOL in both Indians and Malays, while such 
impact was not found in Chinese. The annual QALYs loss per 100,000 people 
associated with VI for Indians and Malays was higher than that for Chinese. Moreover, 
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VI was associated with anxiety/depression in Indians but not in Chinese and Malays. 
The ethnic difference in the impact of VI on HRQOL suggests that eye health 
professionals in Singapore should pay more attention to visually impaired Indians as 
they may be at a higher risk of suffering from depression/anxiety than Singaporean 
Chinese and Malays. Our study findings also highlight the importance of developing 
public health strategies to promote awareness, prevention, and management of eye 
diseases among Indians and Malays, the two main minority groups of Singapore 
(Department of Statistics, Singapore, 2013). Last, the ethnic difference exhibited in 
our study suggests that ethnic difference should be examined when analyzing 
self-reported health outcomes related to vision problems in the multi-ethnic Singapore. 
Otherwise, important ethnic-specific differences might be overlooked. 
 
The strength of this study includes the large samples of the three major Asian 
ethnicities and the clinical diagnoses of VI and other health conditions. There are 
some limitations in our study. First, due to the lack of visual field data, we only used 
the visual acuity to define VI. However, in most population-based studies, VA 
criterion only, and not the peripheral visual field criteria, is used to define VI (Ong et 
al., 2012; Varma et al., 2006; Zheng et al., 2011; Rahmani et al., 1996). Second, the 
health burden of only four health conditions were compared with that of VI, as only 
those four health conditions were clinically diagnosed in the SEED study. Third, using 
the UK scoring method for the EQ-5D might over- or under-estimate the burden of 
the studied conditions in absolute terms. There was no an EQ-5D scoring method 
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based on the health preferences of Singaporeans at the time of our study. However, it 
did not invalidate the comparisons across conditions or ethnicities. Fourth, although 
we controlled for the effects of some variables such as income level, education, and 
marital status in the multivariate analysis, confounding effects or selection bias could 
not be completely ruled out.  
 
In summary, our study demonstrated that visual impairment is associated with 
substantial health burden in all the three Asian ethnicities living in Singapore. The 
relatively high burden of VI highlights the importance of VI prevention. The ethnic 












The Effect of Visual Acuity Measures Based on the Better- 
and Worse-seeing eyes on Health-related Quality of Life 
among Visually Impaired Individuals: the Singapore 






The visual acuity (VA) of an individual’s better-seeing eye is usually used to indicate the 
overall severity of visual impairment (VI) in outcomes research of eye disease (Varma et al., 
2006; McClure et al., 2009; Lin and Yu, 2012). This practice is probably based on the 
assumption that an individual’s level of vision function is primarily determined by the 
individual’s better-seeing eye. VA of the better-seeing eye is found to be positively 
associated with self-reported vision functioning (Varma et al., 2006; McClure et al., 2009; 
Lin and Yu, 2012).  
 
VA of the better-seeing eye alone, however, may not be the optimal indicator for the effect of 
VI severity on general health related quality of life (HRQOL) which represents a broader 
health construct than vision function. This may be particularly true when the HRQOL 
measure used is utility-based, or reflecting the health preferences of patients or the general 
public. The published literature has shown that, while the better-seeing eye had a greater 
effect on self-rated health utility than the worse-seeing eye in some studies (Finger et al., 
2013; Brown et al., 2001; Sahel et al., 2007), the opposite result was observed in other studies 
(Nease et al., 2000; Jampel et al., 2001). For example, health utility had a stronger correlation 
with VA in the worse-seeing eye than in the better-seeing eye in a study of patients with VI 




Therefore, in this study, we aimed to ascertain the VA measure that best indicates the effect 
of VI on individuals’ health utility. We compared the effect sizes of five VA measures based 
on the VA in the better- and worse-seeing eyes of visually impaired individuals on the 




This study drew data from the Singapore Epidemiology of Eye Disease (SEED, 2004-11) 
study which comprised three ethnicity-specific eye studies: the Singapore Malay Eye Study 
(2004-2006), the Singapore Indian Eye Study, (2007-2009) and the Singapore Chinese Eye 
Study (2009-2011). Details of the study design have been described elsewhere (Foong et al., 
2007; Lavanya et al., 2009). Briefly, an age-stratified (by 10-year age groups) random 
sampling methodology was used to select ethnic Chinese, Indians, and Malays 40 to 80 years 
of age living in Singapore. Participants went through a clinical examination and an interview 
to collect socio-demographic and medical data. The overall response rate was 75.6%: 72.8% 
for Chinese, 75.6% for Indians, and 78.7% for Malays. The SEED study adhered to the 
Declaration of Helsinki and was approved by the Singapore Eye Research Institute 




In the present study, the inclusion criteria were: 1) VI in at least one eye; 2) difference by at 
least one line in the VA of the two eyes; and 3) no missing data on the EQ-5D questionnaire. 
After excluding participants with normal vision or vision impaired to the same degree in both 
eyes, 3,183 participants were included in this study.   
 
Measurement of Visual Acuity and Definitions of Visual Impairment (VI) 
VA was measured using logarithm of the minimum angle of resolution (logMAR) number 
chart (Lighthouse International, New York, NY) at a distance of 4 meters and presenting VA 
was measured in the condition that participants wore their habitual optical correction (e.g. 
spectacles or lenses). If no number could be read at 4m, the participant was moved to 3, 2, or 
1m, consecutively. If no number could be read on the chart, VA was assessed as Counting 
Fingers, Hand Movement, Perception of Light, or No Perception of Light. Based on 
presenting VA, VI was defined as logMAR >0.30 in either eye (Tielsch et al., 1990). 
Unilateral VI was defined as VI in one eye and normal vision on the other, while bilateral VI 
was defined as VI in both eyes. 
 
Health-Related Quality of Life Measure 
The EQ-5D questionnaire consists of 2 parts: a descriptive system and the EQ visual analog 
scale (VAS). The EQ-5D descriptive system comprises 5 items, each targeting a different 
health dimension including mobility, self-care, usual activities, pain/discomfort and 
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anxiety/depression. For each dimension, health problems that a respondent experiences on the 
day of survey are described as one of three levels: no problems, some problems and extreme 
problems. Hence, the EQ-5D-3L descriptive system defines a total of 243 (3
5
) unique health 
states. Multiple algorithms are available for generating a utility-based index score for each of 
the EQ-5D described health states (Lee et al., 2009; Shaw et al., 2005; Tsuchiya et al., 2002; 
Dolan, 1997). In this study, we used the most widely used algorithm which reflects the health 
preferences of the generate UK population (Dolan, 1997). The score ranges from -0.59 to 
1.00, with negative scores, 0, and 1 corresponding to health states considered worse than 
death, dead, and full health, respectively. The validity and reliability of the EQ-5D 
questionnaire have been previously tested in Singapore (Luo et al., 2003; Wee et al., 2007; 
Luo et al., 2009; Au et al., 2012; Ang et al., 2013). 
 
Statistical Analyses 
The effect of 5 VA measures on the EQ-5D index score was estimated using separate linear 
regression models. The measures were based on the VA of the better- and/or worse-seeing 
eyes, including VA in the better-seeing eye (BVA), VA in the worse-seeing eye (WVA), the 
mean VA of the two eyes (MVA), the better eye-weighted mean VA (BMVA, 0.75 * VA in 
the better-seeing eye + 0.25 * VA in the worse-seeing eye), and the worse-eye weighted 
mean VA (WMVA, 0.25 * VA in the better-seeing eye + 0.75 * VA in the worse-seeing eye), 
all measured on the logMAR scale. For each VA measure, the EQ-5D index score was 
regressed on the VA measure in a simple linear regression model. The regression coefficients 
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of the VA measures and the corresponding 95% confidence intervals (CIs) were used to 
compare the effect size of the VA measures.  
 
The above mentioned linear regression analyses were conducted for individuals with 
unilateral and bilateral VI separately and, within each subgroup, for individuals with different 
ethnicity (Chinese, Indian, and Malay), age (≥ 65 years and <65 years) and socio-economic 
status (SES) (low and high). Low SES was defined as no formal education plus monthly 
personal income <S$1000.  
 
In addition, logistic regression models were used to examine the association between the VA 
measures and reporting of health problems with the EQ-5D items. The response to each of the 
EQ-5D items was coded into a binary variable (1=moderate/extreme problems; 0=no 
problems) and was used as the dependent variable in the logistic regression models. For each 
EQ-5D item, five models in which only one of the VA measures was the independent 
variable were used to estimate the individual effect of the VA measures on self-reported 
problems in that dimension. I was responsible for data analyses in the chapter. Statistical 





The mean ± standard deviation (SD) age of participants was 63.3 ± 10.2 years, the proportion 
of males was 49.6%, the mean ± SD of BVA was 0.30 ± 0.21, and WVA 0.71 ± 0.46. The 
mean ± SD of EQ-5D index score was 0.84 ± 0.21. Participants with unilateral VI (n=2,004) 
and bilateral VI (n=1,179) differed in all socio-demographic characteristics, VA measures, 




Table 5.1 Socio-demographic characteristics, visual acuity measure and EQ-5D index score 






Bilateral VI  
(n=1,179)  
P value 
Age               
 
Mean ± SD 63.3 ± 10.2 
 
61.6 ± 9.9 
 













Monthly personal income (S$) 






























       
 
























Low socio-economic status 
















VA in the better-seeing eye 
       
 
Mean ± SD 0.30 ± 0.21 0.17 ± 0.09 
 
0.52 ± 0.19 
 
<0.0001 
Better eye-weighted mean VA 
      
 
Mean ± SD 0.40 ± 0.24 0.28 ± 0.12 
 
0.62 ± 0.23 
 
<0.0001 
Mean of VA in both eyes 
       
 
Mean ± SD 0.51 ± 0.30 0.38 ± 0.19 
 
0.73 ± 0.31 
 
<0.0001 
Worse eye-weighted mean VA 
      
 
Mean ± SD 0.61 ± 0.37 0.48 ± 0.28 
 
0.83 ± 0.4 
 
<0.0001 
VA in the worse-seeing eye 
       
 
Mean ± SD 0.71 ± 0.46 0.58 ± 0.38 
 
0.94 ± 0.50 
 
<0.0001 
EQ-5D index score 
       
 
Mean ± SD 0.84 ± 0.21 0.85 ± 0.20 
 
0.81 ± 0.23 
 
<0.0001 
SD = standard deviation; S$ = Singapore dollar; VA= visual acuity; VI = visual impairment    
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The linear regression coefficient estimated using data from all participants with bilateral VI 
was, from high to low in absolute value, -0.095 for WMVA, -0.089 for WVA, -0.078 for 
MVA, -0.070 for BMVA, and -0.056 for BVA. In subgroup analysis, the rank order of the 
VA measures in terms of their regression coefficient values remained the same in ethnic 
Chinese/Indian participants (Table 5.2), participants <65 years old (Table 5.3), and 
participants in high SES (Table 5.5); in contrast, the rank order of the VA measures, from 
high to low based on their regression coefficient values, was BMVA, BVA, MVA, WMVA, 
and WVA in Malay participants, participants ≥65 years old, and participants in low SES 
(Tables 5.2-5.4). Nevertheless, there was no difference in the rank order of the regression 
coefficients for the VA measures across the three ethnic groups after the study sample was 
stratified by age (Table 5.3) or SES (Table 5.4). WVA and BMVA were associated with 
larger regression coefficient values than BVA and BMVA in participants <65 years old or in 
high SES, while the opposite was the case in participants ≥65 years old or in low SES, 
regardless of ethnicity. Further analysis showed that BVA and BMVA were associated with 
larger effect values on HRQOL than WVA and WMVA only in participants ≥65 years old 
and in low SES (Table 5.6). The trend that WVA and WMVA were associated with larger 
regression coefficient values than BVA and BMVA was observed in all other subgroups 
defined by age and SES: ≥65 years old and in high SES, <65 years old and in low SES, and 
participants <65 years old and in high SES (Table 5.6).  
 
In participants with bilateral VI, the odds ratio (OR) of reporting problems was highest for 
WMVA/WVA, followed by, from high to low in OR, MVA, BMVA, and BVA. This was the 
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case for all the five health dimensions and also for all subgroups defined by age and SES 
except for participants ≥65 years old and in high SES (Table 5.6). For example, when all 
participants with bilateral VI were considered, the OR of reporting problems in mobility was 
3.27 for WVA, 3.48 for WMVA, 2.66 for MVA, 2.11 for BMVA, and 1.80 for BVA. In 
participants ≥65 years old and in low SES, the OR for reporting problems in performing usual 
activities was, from high to low, 10.30 for BVA, 6.30 for BMVA, 3.43 for MVA, 2.33 for 
WMVA, and 1.85 for WVA.  
  
Similar trends in the effect of the VA measures on the EQ-5D index scores and responses to 
the five health dimensions also exhibited in participants with unilateral VI (see Table 5.7-
5.11).   
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Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
BVA -0.056 -0.082 -0.029 
 
-0.048 -0.083 -0.012 
 
-0.055 -0.114 0.004 
 
-0.068 -0.131 -0.004 
 
BMVA -0.070 -0.103 -0.037 
 
-0.063 -0.107 -0.019 
 
-0.071 -0.145 0.002 
 
-0.077 -0.125 -0.029 
 
MVA -0.078 -0.121 -0.035 
 
-0.087 -0.143 -0.031 
 
-0.086 -0.182 0.011 
 
-0.045 -0.108 0.018 
 
WMVA -0.095 -0.134 -0.056 
 
-0.099 -0.159 -0.040 
 
-0.124 -0.242 -0.006 
 
-0.045 -0.094 0.003 
 
WVA -0.089 -0.135 -0.044 
 
-0.092 -0.138 -0.046 
 
-0.102 -0.192 -0.012 
 
-0.042 -0.085 0.002 
BVA = visual acuity in the better-seeing eye; BMVA = better eye-weighted mean visual acuity; CI = confidence interval; MVA = mean 
of visual acuity in both eyes; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity in the worse-seeing eye;  
















Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
≥65 years n=601 
   
n=149 
   
n=171 




  BVA -0.100 -0.181 -0.019 
 
-0.071 -0.174 0.032 
 
-0.097 -0.288 0.094 
 
-0.107 -0.209 -0.005 
  BMVA -0.127 -0.224 -0.030 
 
-0.076 -0.184 0.032 
 
-0.102 -0.321 0.118 
 
-0.146 -0.272 -0.021 
  MVA -0.092 -0.168 -0.015 
 
-0.065 -0.153 0.024 
 
-0.092 -0.239 0.055 
 
-0.097 -0.195 0.000 
  WMVA -0.080 -0.148 -0.011 
 
-0.041 -0.113 0.030 
 
-0.088 -0.217 0.041 
 
-0.044 -0.105 0.017 
  WVA -0.055 -0.110 0.001 
 
-0.034 -0.093 0.026 
 
-0.065 -0.156 0.026 
 
-0.031 -0.080 0.018 
<65 years n=578 
   
n=242 
   
n=191 




  BVA -0.024 -0.059 0.012 
 
-0.035 -0.079 0.010 
 
-0.023 -0.085 0.039 
 
-0.018 -0.089 0.053 
  BMVA -0.043 -0.088 0.002 
 
-0.055 -0.110 0.001 
 
-0.042 -0.117 0.033 
 
-0.031 -0.112 0.050 
  MVA -0.073 -0.142 -0.004 
 
-0.090 -0.162 -0.018 
 
-0.079 -0.180 0.023 
 
-0.045 -0.132 0.041 
  WMVA -0.116 -0.183 -0.050 
 
-0.108 -0.207 -0.009 
 
-0.131 -0.272 0.010 
 
-0.078 -0.202 0.047 
  WVA -0.095 -0.160 -0.031 
 
-0.098 -0.194 -0.002 
 
-0.118 -0.244 0.008 
 
-0.066 -0.172 0.040 
BVA = visual acuity in the better-seeing eye; BMVA = better eye-weighted mean visual acuity; CI = confidence interval; MVA = mean 
of visual acuity in both eyes; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity in the worse-seeing eye;  















Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
Low SES n=502 
   
n=165 
   
n=112 
   
n=225 
  
  BVA -0.101 -0.189 -0.013 
 
-0.117 -0.235 0.001 
 
-0.078 -0.282 0.127 
 
-0.087 -0.203 0.029 
  BMVA -0.122 -0.226 -0.019 
 
-0.127 -0.259 0.005 
 
-0.083 -0.326 0.160 
 
-0.132 -0.280 0.017 
  MVA -0.085 -0.151 -0.019 
 
-0.092 -0.186 0.002 
 
-0.056 -0.211 0.100 
 
-0.053 -0.140 0.034 
  WMVA -0.056 -0.108 -0.005 
 
-0.070 -0.144 0.003 
 
-0.040 -0.160 0.080 
 
-0.034 -0.102 0.033 
  WVA -0.036 -0.077 0.006 
 
-0.056 -0.113 0.001 
 
-0.030 -0.126 0.066 
 
-0.024 -0.079 0.031 
High SES n=677 
   
n=226 
   
n=249 
   
n=202 
  
  BVA -0.031 -0.071 0.009 
 
-0.041 -0.096 0.015 
 
-0.046 -0.150 0.058 
 
-0.019 -0.083 0.046 
  BMVA -0.043 -0.092 0.006 
 
-0.055 -0.124 0.013 
 
-0.065 -0.218 0.087 
 
-0.025 -0.077 0.027 
  MVA -0.064 -0.127 0.000 
 
-0.083 -0.169 0.004 
 
-0.095 -0.290 0.099 
 
-0.043 -0.126 0.041 
  WMVA -0.132 -0.237 -0.027 
 
-0.135 -0.269 -0.001 
 
-0.150 -0.434 0.134 
 
-0.104 -0.254 0.046 
  WVA -0.098 -0.182 -0.014 
 
-0.129 -0.241 -0.018 
 
-0.143 -0.392 0.105 
 
-0.062 -0.175 0.052 
BVA = visual acuity in the better-seeing eye; BMVA= better eye-weighted mean visual acuity; CI= confidence interval; MVA = mean 
of visual acuity in both eyes; SES = socio-economic status; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity 
in the worse-seeing eye;  








≥65 & low SES 
(n=289)  
<65 & low SES 
(n=213)  
≥65 & medium/high SES 
(n=312)  
<65 & medium/high SES 
(n=365) 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
  BVA -0.142 -0.266 -0.018 
 
-0.018 -0.112 0.075 
 
-0.024 -0.108 0.059 
 
-0.035 -0.084 0.014 
  BMVA -0.131 -0.248 -0.014 
 
-0.035 -0.149 0.079 
 
-0.042 -0.147 0.063 
 
-0.069 -0.164 0.027 
  MVA -0.096 -0.185 -0.008 
 
-0.064 -0.176 0.049 
 
-0.061 -0.166 0.043 
 
-0.097 -0.213 0.019 
  WMVA -0.070 -0.147 0.007 
 
-0.083 -0.190 0.024 
 
-0.086 -0.227 0.055 
 
-0.169 -0.301 -0.037 
  WVA -0.029 -0.072 0.014 
 
-0.088 -0.196 0.021 
 
-0.096 -0.249 0.057 
 
-0.138 -0.262 -0.013 
BVA = visual acuity in the better-seeing eye; BMVA= better eye-weighted mean visual acuity; CI= confidence interval; MVA = mean 
of visual acuity in both eyes; SES = socio-economic status; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity 
in the worse-seeing eye;  











≥65 & low SES (n=289) 
 























1.80 1.89 1.83 1.14 1.19   3.90 11.53 10.30 3.18 1.88   1.61 1.52 1.42 1.10 1.18 
(1.40-2.30) (1.24-2.88) (1.37-2.45) (0.90-1.44) (0.93-1.52)   (1.45-10.47) (2.75-48.32) (2.93-36.17) (1.01-10.03) (0.63-5.57)   (1.18-2.18) (0.77-3) (0.96-2.10) (0.83-1.46) (0.87-1.60) 
BMVA 
2.11 2.47 2.39 1.19 1.28   3.66 7.57 6.30 1.85 1.52   1.86 1.88 1.60 1.13 1.25 
(1.55-2.88) (1.46-4.16) (1.59-3.59) (0.89-1.59) (0.98-1.67)   (1.46-9.18) (2.26-25.36) (2.33-17.05) (0.75-4.55) (0.62-3.7)   (1.27-2.73) (0.82-4.33) (0.98-2.62) (0.80-1.60) (0.86-1.83) 
MVA 
2.66 3.60 2.75 1.31 1.45   2.67 5.14 3.43 1.32 1.27   2.36 2.98 2.39 1.29 1.54 
(1.78-3.98) (1.84-7.06) (1.72-4.40) (0.91-1.91) (1.04-2.03)   (1.32-5.37) (1.78-14.88) (1.63-7.21) (0.67-2.61) (0.64-2.52)   (1.42-3.90) (1.03-8.61) (1.26-4.54) (0.82-2.03) (0.94-2.52) 
WMVA 
3.48 5.58 4.83 1.56 1.80   2.09 2.53 2.33 1.13 1.15   3.62 6.86 7.25 1.80 1.92 
(2.12-5.72) (2.75-11.33) (2.85-8.19) (1.14-2.14) (1.27-2.55)   (1.18-3.68) (1.21-5.29) (1.31-4.15) (0.66-1.92) (0.67-1.98)   (1.83-7.14) (1.66-28.25) (2.49-21.12) (0.98-3.32) (0.99-3.70) 
WVA 
3.27 4.56 3.73 1.88 2.20   1.77 1.96 1.85 1.05 1.10   3.55 5.81 5.82 2.04 2.38 
(2.15-4.98) (2.41-8.66) (2.41-5.77) (1.37-2.58) (1.54-3.15)   (1.14-2.76) (1.01-3.80) (1.16-2.95) (0.75-1.47) (0.72-1.66)   (1.82-6.91) (1.55-21.87) (2.46-13.79) (0.99-4.20) (1.05-5.37) 
BVA: visual acuity in the better-seeing eye; BMVA: better eye-weighted mean visual acuity; MVA: mean of visual acuity in both eyes; SES: socio-economic 
status; WMVA: worse eye –weighted mean visual acuity; WVA: visual acuity in the worse-seeing eye;  
Boldness: P <0.05; 
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Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
  BVA -0.021 -0.043 0.002 
 
-0.019 -0.043 0.006 
 
-0.027 -0.081 0.026 
 
-0.102 -0.141 -0.063 
  BMVA -0.031 -0.061 -0.001 
 
-0.026 -0.059 0.007 
 
-0.039 -0.110 0.032 
 
-0.146 -0.198 -0.094 
  MVA -0.045 -0.089 -0.001 
 
-0.036 -0.084 0.012 
 
-0.063 -0.166 0.040 
 
-0.062 -0.136 0.012 
  WMVA -0.073 -0.108 -0.038 
 
-0.088 -0.142 -0.033 
 
-0.110 -0.226 0.006 
 
-0.034 -0.098 0.030 
  WVA -0.056 -0.106 -0.007 
 
-0.073 -0.114 -0.031 
 
-0.080 -0.167 0.006 
 
-0.023 -0.066 0.020 
BVA = visual acuity in the better-seeing eye; BMVA = better eye-weighted mean visual acuity; CI = confidence interval; MVA = mean 
of visual acuity in both eyes; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity in the worse-seeing eye;  














Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
≥65 n=840         n=252       n=227         n=361     
  BVA -0.124 -0.245 -0.002   -0.108 -0.259 0.043   -0.123 -0.334 0.087   -0.163 -0.323 -0.004 
  BMVA -0.116 -0.221 -0.011   -0.097 -0.239 0.045   -0.115 -0.320 0.091   -0.157 -0.309 -0.005 
  MVA -0.077 -0.147 -0.007   -0.072 -0.187 0.042   -0.098 -0.283 0.088   -0.059 -0.160 0.042 
  WMVA -0.050 -0.105 0.006   -0.047 -0.125 0.032   -0.073 -0.211 0.066   -0.029 -0.120 0.062 
  WVA -0.032 -0.074 0.010   -0.034 -0.093 0.025   -0.057 -0.161 0.047   -0.016 -0.062 0.031 
<65  n=1164       n=501         n=434       n=229      
  BVA -0.015 -0.046 0.017   -0.014 -0.065 0.036   -0.013 -0.076 0.051   -0.041 -0.107 0.024 
  BMVA -0.027 -0.062 0.008   -0.025 -0.080 0.029   -0.029 -0.113 0.056   -0.056 -0.144 0.031 
  MVA -0.038 -0.088 0.011   -0.032 -0.097 0.033   -0.049 -0.171 0.073   -0.066 -0.196 0.065 
  WMVA -0.090 -0.155 -0.025   -0.096 -0.181 -0.012   -0.131 -0.321 0.059   -0.088 -0.239 0.063 
  WVA -0.133 -0.214 -0.053   -0.155 -0.259 -0.050   -0.138 -0.344 0.068   -0.092 -0.254 0.070 
BVA = visual acuity in the better-seeing eye; BMVA = better eye-weighted mean visual acuity; CI = confidence interval; MVA = mean 
of visual acuity in both eyes; WMVA = worse eye –weighted mean visual acuity; WVA = visual acuity in the worse-seeing eye;  
















Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
Low SES  n=762       n=230         n=216       n=316      
  BVA -0.130 -0.256 -0.003   -0.087 -0.244 0.069   -0.183 -0.595 0.229   -0.190 -0.466 0.086 
  BMVA -0.105 -0.190 -0.019   -0.051 -0.140 0.038   -0.136 -0.427 0.155   -0.169 -0.376 0.039 
  MVA -0.050 -0.122 0.022   -0.041 -0.122 0.040   -0.066 -0.243 0.110   -0.076 -0.182 0.030 
  WMVA -0.030 -0.087 0.026   -0.035 -0.095 0.026   -0.040 -0.162 0.083   -0.022 -0.093 0.050 
  WVA -0.021 -0.063 0.021   -0.026 -0.071 0.020   -0.028 -0.121 0.066   -0.013 -0.067 0.041 
High SES  n=1,242        n=523       n=445         n=274     
  BVA -0.016 -0.044 0.012   -0.011 -0.040 0.018   -0.010 -0.074 0.054   -0.026 -0.075 0.023 
  BMVA -0.026 -0.063 0.012   -0.016 -0.054 0.023   -0.029 -0.115 0.057   -0.034 -0.100 0.032 
  MVA -0.032 -0.087 0.023   -0.027 -0.083 0.030   -0.041 -0.168 0.085   -0.048 -0.145 0.049 
  WMVA -0.125 -0.215 -0.034   -0.106 -0.200 -0.012   -0.151 -0.352 0.050   -0.063 -0.190 0.063 
  WVA -0.154 -0.260 -0.048   -0.191 -0.304 -0.078   -0.170 -0.383 0.044   -0.081 -0.230 0.069 
BVA = visual acuity in the better-seeing eye; BMVA= better eye-weighted mean visual acuity; CI= confidence interval; MVA= mean 
of visual acuity in both eyes; SES= socio-economic status; WMVA= worse eye –weighted mean visual acuity; WVA= visual acuity in 
the worse-seeing eye;  





Table 5.10 Unadjusted effects of VA measures on EQ-5D index score in participants with unilateral VI by socio-economic status and 
age group (n=2,004) 
VA measure 
≥65 & low SES 
(n=383)  
<65 & low SES 
(n=379)  
≥65 & medium/high SES 
(n=412)  
<65 & medium/high SES 
(n=830) 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
 
Beta 95 %CI 
  BVA -0.159 -0.318 0.001 
 
-0.012 -0.142 0.117 
 
-0.013 -0.170 0.144 
 
-0.046 -0.096 0.003 
  BMVA -0.145 -0.291 0.001 
 
-0.021 -0.126 0.084 
 
-0.016 -0.120 0.089 
 
-0.058 -0.120 0.003 
  MVA -0.092 -0.204 0.020 
 
-0.032 -0.143 0.080 
 
-0.028 -0.110 0.055 
 
-0.107 -0.187 -0.027 
  WMVA -0.025 -0.098 0.047 
 
-0.043 -0.168 0.083 
 
-0.054 -0.162 0.053 
 
-0.173 -0.280 -0.066 
  WVA -0.016 -0.075 0.043 
 
-0.049 -0.192 0.095 
 
-0.063 -0.188 0.063 
 
-0.169 -0.277 -0.061 
BVA = visual acuity in the better-seeing eye; BMVA= better eye-weighted mean visual acuity; CI= confidence interval; MVA= mean 
of visual acuity in both eyes; SES= socio-economic status; WMVA= worse eye –weighted mean visual acuity; WVA= visual acuity in 
the worse-seeing eye;  
Boldness: P <0.05; 
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≥65 & lowSES (n=383) 
 























1.60 1.78 1.86 1.22 1.14   5.00 3.97 8.14 1.78 1.85   1.41 1.58 1.49 1.19 1.04 
(1.22-2.11) (1.13-2.79) (1.42-2.44) (0.96-1.54) (0.88-1.47)   (1.12-22.36) (0.69-22.77) (2.07-31.97) (0.65-4.90) (0.62-5.50)   (1.01-1.97) (0.84-2.98) (0.93-2.39) (0.90-1.57) (0.76-1.42) 
BMVA 
1.99 2.17 2.34 1.35 1.22   4.43 4.34 8.87 1.86 1.90   1.70 2.03 2.14 1.32 1.09 
(1.48-2.67) (1.12-4.23) (1.53-3.57) (0.99-1.84) (0.87-1.71)   (1.04-18.84) (0.65-28.87) (2.22-35.39) (0.61-5.69) (0.60-6.05)   (1.09-2.63) (0.80-5.16) (1.06-4.33) (0.86-2.03) (0.72-1.65) 
MVA 
2.72 3.18 3.56 1.68 1.40   2.82 2.93 6.44 1.68 1.73   2.65 3.19 2.98 1.66 1.24 
(1.59-4.64) (1.10-9.21) (1.77-7.14) (0.89-3.16) (0.85-2.30)   (0.97-8.25) (0.59-14.67) (1.80-23.00) (0.69-4.10) (0.70-4.24)   (1.40-5.01) (0.82-12.36) (1.19-7.42) (0.80-3.45) (0.68-2.27) 
WMVA 
6.07 7.92 12.38 2.79 1.54   1.80 2.05 3.28 1.40 1.50   7.63 9.76 14.93 3.69 2.05 
(3.92-9.40) (2.22-28.24) (6.19-24.78) (2.05-3.81) (0.98-2.42)   (0.91-3.55) (0.54-7.84) (1.04-10.34) (0.76-2.56) (0.77-2.92)   (2.52-23.11) (1.47-75.92) (3.09-72.02) (1.49-9.16) (0.75-5.63) 
WVA 
4.30 5.08 7.64 3.35 1.84   1.48 1.71 2.37 1.27 1.37   6.55 6.98 9.69 6.66 4.13 
(2.49-7.44) (1.93-13.36) (4.69-12.44) (2.54-4.40) (1.40-2.40)   (0.78-2.81) (0.60-4.91) (0.91-6.20) (0.81-2.01) (0.80-2.34)   (2.33-18.37) (0.90-46.52) (2.09-44.9) (2.01-21.99) (1.07-15.92) 
BVA: visual acuity in the better-seeing eye; BMVA: better eye-weighted mean visual acuity; MVA: mean of visual acuity in both eyes; SES: socio-economic 
status; WMVA: worse eye –weighted mean visual acuity; WVA: visual acuity in the worse-seeing eye;  




Our study demonstrated that the VA of both eyes of visually impaired individuals had an effect 
on their HRQOL and, more importantly, that the relative effect size of the individuals’ better- 
and worse-seeing eyes varied with their socio-demographic characteristics. Specifically, while 
BVA had a larger effect than WVA on HRQOL in old individuals from low SES, WVA had a 
larger effect than BVA in young /middle-aged individuals and old individuals from high SES. To 
the best of our knowledge, this is the first time that the differential effect size of the better- and 
worse-seeing eyes on overall HRQOL is observed in the same study. Previous studies found that 
either BVA or WVA was more strongly associated than the other with utility-based HRQOL 
measures (Finger et al., 2013; Brown et al., 2001; Sahel et al., 2007; Nease et al., 2000; Jampel, 
2001).  
 
The differential effect size of the better- and worse-seeing eyes on the HRQOL of visually 
impaired individuals suggests that the effect of VA on an individual’s functions and wellbeing 
varies with the individual’s daily activities. The better-seeing eye is more important than the 
worse-seeing eye to old individuals in low SES could be because such individuals tend to do 
simple and easy daily activities such as household chores that rely more on the vision of their 
better-seeing eyes. On the other hand, the working young and old individuals in high SES may 
need a high level of vision acuity that is limited mainly by their worse-seeing eyes. Also, the 
worse-seeing eye should be a more important mental stressor than the better-seeing eye to such 
individuals because of their responsibilities and expectations. These hypotheses are supported by 
the differential association between the VA of both eyes and self-reported problems to the 
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individual EQ-5D health dimensions revealed in this study. The differential effect size of the two 
eyes may also reflect the temporal effect of visual impairment on individuals. It may be possible 
that when VA of the two eyes of an individual worsened in different degrees, the impact on 
HRQOL is mainly from the worse eye in the short term because of slow adaptation. However, 
the level of HRQOL is mainly determined by the better eye after the individual has leant how to 
live with his or her impaired vision.            
 
Our study suggests that the current practice of using BVA alone as the measure of VI severity is 
not optimal. Conventionally, only BVA is used to study the association between vision and 
patient-reported outcomes (Varma et al., 2006; McClure et al., 2009; Lin and Yu, 2012), 
although BVA alone does not reflect the binocular visual function which is also contributed by 
WVA. Our study might also have implications on the ophthalmologic clinical practice: while the 
better-seeing eye should be given higher priority because it is a more important determinant of 
visual function than the worse-seeing eye, the potential benefit of treating the worse-seeing eye 
or preventing it from further worsening cannot be underestimated. There has been evidence 
supporting the HRQOL benefits associated the treatment of the worse-seeing eye. For example, 
association between improved patient-reported outcomes and treatment of neovascular age-
related macular degeneration, regardless of the severity of the treated eye, was observed 
(Bressler et al., 2010; Finger et al., 2014); HRQOL benefits from the cataract surgery on the 
second eye, which is usually the worse-seeing eye are widely reported (Elliott et al., 2000; 
Castells et al., 2006; Desai et al., 1996; Lundstrom et al., 2001; Busbee et al., 2003). Moreover, 
by demonstrating that the worse-seeing eye might have a greater psychological effect than the 
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better-seeing eye, our study highlights the importance of psychosocial interventions to visually 
impaired patients (Senra et al., 2011; Senra et al., 2015).  
 
The main limitation of the study is the use of only one utility measure (i.e. the EQ-5D health 
index) in only ethnic Asians with VI. Studies using other utility measures such as HUI3 and SF-
6D and samples from other cultures are warranted to ascertain the generalizability of the findings 
reported in this paper. Moreover, the unmeasured variables other than age and SES are not tested 
in the study, though they could be the reason for the different impact of VA in the two eyes on 
the utility measure. 
 
In summary, our study suggested that the visual acuity of the worse-seeing eye may have greater 
impact than that of the better-seeing eye on the overall health utility of visually impaired 
individuals. Therefore, the VA of the better-seeing eye alone appears to be suboptimal for 










A Vision ‘Bolt-On’ Item could Increase the 





Addition of new items, also referred to as ‘bolt-on’ items, has been explored as a means to 
improving the EQ-5D questionnaire (Hoeymans et al., 2005; Arrons and Krabbe 2011; 
Jansses et al., 2013; Longworth et al., 2014; Swinburn et al., 2013; Yang et al., 2014). ‘Bolt-
on’ items usually take the same form of the EQ-5D items but target different health 
dimensions. The aim of this exercise is to increase the sensitivity of the EQ-5D in therapeutic 
areas where the performance of the standard version is suboptimal. For example, if the EQ-
5D is not sensitive to the impact of eye diseases, addition of an item assessing vision 
problems may mitigate the problem.  
 
Research on the ‘bolt-on’ items has focused on their measurement properties and valuation of 
the health states defined by the ‘bolt-on’ descriptive system. ‘Bolt-on’ items seem to enhance 
measurement. For example, studies showed that a cognition ‘bolt-on’ item captured 
additional health information when added to the EQ-5D (Hoeymans et al., 2005; Arrons and 
Krabbe, 2001). However, the effect of ‘bolt-on’ items on valuation of the resultant health 
states appeared to be complex (Jansses et al., 2013). While the utility values of all the 
possible health states (aka the ‘value set’) were successfully determined for a vision 
(Longworth et al., 2014) and a psoriasis (Swinburn et al., 2013) ‘bolt-on’ system, a sleep 
‘bolt-on’ item was found to add no value to the EQ-5D (Yang et al., 2014). It was because the 
sleep problems described by the item had little impact on overall health utility compared to 
the health problems captured by the existing EQ-5D items. Therefore, the additional 
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information captured by ‘bolt-on’ items may not necessarily translate into a more sensitive 
utility-based health index.  
 
One important question that has not yet been answered for the ‘bolt-on’ exercise is whether 
the utility-based index for the ‘bolt-on’ health states (hereafter referred to as ‘bolt-on’ index) 
is more sensitive than the standard EQ-5D index (hereafter referred to as ‘standard’ index) in 
empirical studies. The utility-based health index is a convenient outcome measure for 
medical decision making and cost-effectiveness analysis of health technologies, and it is a 
main reason for the popularity of the EQ-5D questionnaire. Like any new health-status 
measure, a ‘bolt-on’ index should be psychometrically validated before formal use. Therefore, 
the purpose of this study was to assess the discriminatory power or sensitivity to difference, 
of a vision ‘bolt-on’ index (Longworth et al., 2014) in terms of its ability to discriminate 
between individuals with different levels of vision problems. Through this study, we hope to 
evaluate the prospect of the ‘bolt-on’ exercise as an approach to developing new utility-based 
measures.   
 
6.2 Methods  
We used data from the burden-of-illness study for visual impairment (VI) in Singapore, 
which have been described in Chapter 2 and Chapter 3. In brief, health and economic burden 




For individuals with VI, consecutive patients attending the specialist outpatient clinics in 
Singapore National Eye Centre, a tertiary eye centre which manages about half of all eye 
conditions in Singapore, were recruited following the inclusion criteria. After informed 
consent was obtained, each patient or his/her caregiver was interviewed face-to-face in the 
hospital by a bilingual research assistant using a battery of standardized questionnaires 
including, in the order of administration, the (3-level) vision ‘bolt-on’ EQ-5D questionnaire, 
the 14-item visual function questionnaire (VF-14) (Steinberg et al., 1994), and a health 
services utilization and expenditure questionnaire.  
 
For individuals without VI, members of the general public who volunteered to be screened 
for eye diseases on the 2013 National Eye Care Day, which was conducted at the Singapore 
National Eye Centre, were recruited. Following informed consent, each subject was home 
visited and interviewed face-to-face by a trained interviewer using the same set of 
questionnaires for individuals with VI.  
 
Definition of VI 
In this study, VA was measured by a trained optometrist for each individual using a Snellen 
chart. VI was classified according to the VA in the better-seeing eye: (1) mild VI (VA ≤6/12 
to >6/18); (2) moderate VI (VA ≤6/18 to >6/60); (3) severe VI (VA ≤6/60 to >6/120); and (4) 







The vision ‘bolt-on’ EQ-5D questionnaire comprises two parts: the 3-level EQ-5D 
descriptive system and a vision item. The EQ-5D descriptive system consists of 5 items, each 
for a different dimension including mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Respondents were asked to describe their health status on the day of 
survey in those dimensions as no problems, some problems, or extreme problems. The vision 
item developed by Longworth and colleagues (Longworth et al., 2014) was used in this study. 
It consists of the heading of “Vision (using glasses or contact lenses if needed)” and the 
response options of “I have no problems seeing, I have some problems seeing, and I have 
extreme problems seeing”. The vision item followed the EQ-5D items in the questionnaire 
and was administered immediately after the EQ-5D items in this study. Both the English and 
Chinese versions of the EQ-5D questionnaire were validated in local patients undergoing 
cataract surgery (Ang et al., 2013) and those with AMD (Au et al., 2012).  
 
In this study, 4 published value sets were used to calculate EQ-5D index scores, including 
two value sets developed by Longworth and colleagues for predicting the vision ‘bolt-on’ 
index (EQ-5D[vision]) and the standard EQ-5D index (EQ-5D[core]), respectively, the value 
set developed in the UK’s Measurement and Valuation of Health study (EQ-5D[MVH]) 
(Fayers and Machin, 2000), and a value set estimated in Singapore (EQ-5D[SG]) (Vickrey et 
al., 1997). The rationales for choosing the three EQ-5D indices were: EQ-5D[core] and EQ-
5D[vision] were developed simultaneously using an identical study protocol; EQ-5D[MVH] 
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was developed using the health preferences of the same population as EQ-5D[vision]; EQ-
5D[SG] was developed using the health preferences of the population from which the study 




























Score range -0.072 – 1.000 
 
-0.015 – 1.000 
 
-0.594 – 1.000 
 
-0.769 – 1.000 









MVH, Measurement and Valuation of Health study; SG, Singapore.  
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EQ-5D[vision] and EQ-5D[core] were simultaneously developed using identical sampling, 
valuation, and data modeling procedures to study the impact of adding the vision dimension 
on the valuation of EQ-5D health states (Swinburn et al., 2013). Both value sets were 
estimated using time trade-off utility values of 20 health states directly measured from a 
general population sample drawn from Yorkshire, England (n=155 for EQ-5D[core] and 157 
for EQ-5D[vision]). The values of EQ-5D[vision] range from -0.072 for the worst health state 
to 1.018 for the best health state. In this study, the only one >1 value for the best health state 
was truncated to 1.000, in order to achieve comparability with other EQ-5D value sets used. 
The range of EQ-5D[core] values is -0.015 to 1.000.  
 
The EQ-5D[MVH] was estimated based on time trade-off valuation of 42 selected EQ-5D 
health states by a nationally representative sample (n=2,997) of the general UK population. 
The range of the values is -0.594 to 1.000. The EQ-5D[SG] was estimated using the time 
trade-off values from a general population sample (n=456) in Singapore. For estimating this 
value set, a total of 80 EQ-5D health states were valued using a modified MVH study 
protocol (Vickrey et al., 1997). The value range is -0.769 to 1.000. The main characteristics 
of the four EQ-5D index scores are summarized in Table 1. 
 
VF-14 
The VF-14 assesses the level of difficulty in performing activities of daily living due to 
vision problems. Each of the 14 items in this questionnaire measures one different vision 
problems using a 5-point Likert response scale ranging from 0 (no difficulty) to 4 (unable to 
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perform activity). The instrument has been validated in the Singaporean population 
previously (Lamoureux et al., 2009). 
 
Statistical analysis 
The discriminatory power of the ‘bolt-on’ index score was assessed by comparing the ability 
of the ‘bolt-on’ and standard index scores to discriminate between paired groups of 
individuals known to differ in VI severity or vision problems. For this purpose, 4 pairs of 
known groups were defined according to VI severity: no VI versus mild VI, mild VI versus 
moderate VI, moderate VI versus severe VI, and severe VI versus blindness; 12 pairs of 
known groups were defined using self-reported vision problems with VF-14, each pair for 
one different vision problem. Those vision problems included reading small print, reading 
newspapers, reading large print, recognizing people, seeing steps, reading traffic signs, doing 
handwork, filling forms, playing games, taking part in sports, cooking, and watching TV. 
Difficulty in car driving was assessed in VF-14 but was excluded from this analysis because 
very few participants drove or had driven a car. For each vision problem, the two known 
groups consisted of a group with problems (defined as reporting ‘a little’, ‘some’, or ‘a great 
deal’ of difficulty or ‘unable’ to perform the related activity) and a group without problems 
(defined as reporting ‘no’ difficulty in performing the related activity).   
 
Discriminatory power was first assessed using the absolute mean difference in the index 
scores between the known groups defined by participants’ VI severity and VF-14. A larger 
difference means greater utility gains and therefore a higher chance of drawing the 
108 
 
conclusion of cost-effectiveness when the index is used in a cost-utility analysis, thus 
indicating higher discriminatory power. Discriminatory power was also assessed in terms of 
the squared t-statistic derived from the two-sample t-test of the index scores between the 
known groups. The squared t-statistic (equivalent to the F-statistic from the ANOVA test in 
value) is widely used to assess the relative efficiency of patient-reported outcome measures 
(Fayers and Machin, 2000; Vickrey et al., 1997; Luo et al., 2009). A higher F-statistic value 
means higher likelihood for the measure to show statistical significance when used to 
compare groups. Hence, higher F-statistic values indicate higher discriminatory power. In this 
study, the F-statistic ratio of the two index scores was calculated for each pair of the known 
groups in such a way that a <1 ratio would mean that the ‘bolt-on’ index score is more 
discriminative. The ratio can be interpreted in terms of the relative sample size needed to 
achieve statistical significance (King et al., 2014). For example, a ratio of 0.5 means that the 
‘bolt-on’ index can achieve the same statistical power as the standard index with only half of 
the sample size for the latter when they are used to compare the two groups.   
 
The differences in the index scores between the known groups and their corresponding F-
statistics were also estimated using multiple linear regression models in which the effect of 
age and gender was adjusted. The adjusted difference and F-statistic are better indicators than 
the unadjusted estimates of the sensitivity to change (or responsiveness) of the index scores in 
longitudinal studies. I was responsible for data collection and data analyses in the chapter. All 
analyses were conducted using SAS for Windows (version 9.2, SAS Institute, Inc., Cary, NC) 






A total of 500 individuals with VI were recruited. The mean ± standard deviation (SD) age 
was 71.6 ± 9.8 years old and 47.6% was male. The majority of the individuals were Chinese 
(88.0%), with primary or no formal education (64.2%), not working (80.2%), and married 
(86.2%). The mean ± SD for EQ-5D[vision], EQ-5D[core], EQ-5D[MVH], and EQ-5D[SG] 
was 0.90 ± 0.15, 0.91 ± 0.15, 0.80 ± 0.27, and 0.74 ± 0.37, respectively. The full socio-
demographic and health characteristics of individuals with VI are shown in Table 6.2. 
 
A total of 336 individuals without VI participated in the study. The mean ± SD age was 63.1 
± 7.4 years old and 36.3% was male. The majority of them were Chinese (95.8%), with 
secondary education (68.2%), not working (58.3%), and married (77.4%). The mean ± SD for 
EQ-5D[vision], EQ-5D[core], EQ-5D[MVH], and EQ-5D[SG] was 0.97 ± 0.05, 0.96 ± 0.06, 
0.90 ± 0.14, and 0.91 ± 0.14, respectively. Compared with individuals with VI, those without 
VI were significantly younger, better educated, more likely to work, and healthier according 
to the EQ-5D (Table 6.2).  
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63.1 (7.4) <0.0001 
Gender 
        
 
 




36.3 (122) 0.0012 
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EQ-5D index score, mean (SD)         




0.97 (0.05) <0.0001 




0.96 (0.06) <0.0001 




0.90 (0.14)  <0.0001 








        
 
 



















        
 
 



















        
 
 



















        
 
 



















        
 
 



















        
 
 


















Note: the number inside the parentheses is the frequency and the number outside them is the 
proportion, unless otherwise specified. 
*T-test or Chi-square test for the difference between individuals with VI and individuals 
without VI 




Absolute mean differences between known groups 
All EQ-5D index scores decreased monotonically with increasing VI severity (Table 6.3). 
The mean differences in EQ-5D[SG] (range: 0.041 to 0.126) and EQ-5D[MVH] (range 0.028 
to 0.070) for the 4 pairs of VI groups were larger than those in EQ-5D[vision] (range: 0.015 
to 0.055) which were similar to or slightly larger than those in EQ-5D[core] (range: 0.017 to 
0.036) (Figure 6.1). Similarly, the mean scores for individuals with a particular vision 
problem assessed by VF-14 were lower than those for individuals without that problem for all 
the four EQ-5D indices (Table 6.4). All the 12 vision problems are considered, the mean 
differences in EQ-5D[SG] (range: 0.178 to 0.387) and EQ-5D[MVH] (range 0.129 to 0.252) 
between the groups with and without a problem were larger than those in EQ-5D[vision] 
(range: 0.074 to 0.155) which were slightly but uniformly larger than those in EQ-5D[core] 
(range: 0.061 to 0.135) (Figure 6.3).  
 
The trends in the mean between-group differences in the EQ-5D indices remained the same 
after adjusting for age and gender, although attenuated (Figures 6.2 and 6.4). 
 
F-statistic ratios for known groups 
The F-statistic ratio of EQ-5D[core], EQ-5D[MVH], and EQ-5D[SG] versus EQ-5D[vision] 
in the ANOVA tests for the groups known to differ in VI severity ranged from 0.415 to 0.667, 




Similarly, the F-statistic ratios derived from the comparisons of individuals with and without 
a vision problem were < 1 for all 12 vision problems for EQ-5D[core] and EQ-5D[MVH] 
versus EQ-5D; the F-statistic ratios for EQ-5D[SG] versus EQ-5D[vision] ranged from 0.829 
to 1.006 (Figure 6.6). The F-statistic ratio values became smaller in all but one known-group 
comparisons after adjusting for the effect of age and gender (Figure 6.7 and 6.8); in the 
comparison of individuals with severe VI and those who were blind, the adjusted F-statistic 




Table 6.3 Mean (SD) EQ-5D index scores for different visual impairment groups (n=836) 
























































MVH, Measurement and Valuation of Health study; VI, visual impairment; SD, standard deviation.
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Table 6.4. Mean (SD) EQ-5D index scores for groups with and without a vision problem assessed by VF-14 (n=836) 







Reading Small Print 
            
 
Without problems 337  0.970 (0.090) 
 






With problems 499  0.896 (0.133) 
 







           
 
Without problems 442  0.964 (0.089) 
 






With problems 391  0.882 (0.141) 
 









        
 
Without problems 674  0.952 (0.085) 
 






With problems 162  0.815 (0.183) 
 









        
 
Without problems 696  0.949 (0.090) 
 






With problems 140  0.811 (0.186) 
 







     
 
     
 
Without problems 671  0.953 (0.086) 
 






With problems 165  0.815 (0.178) 
 





Reading traffic signs 
            
 
Without problems 668  0.951 (0.089) 
 






With problems 168  0.823 (0.177) 
 










Without problems 509  0.959 (0.078) 
 






With problems 275  0.854 (0.165) 
 






             
 
Without problems 556  0.958 (0.083) 
 






With problems 272  0.859 (0.161) 
 






             
 
Without problems 547  0.946 0.095 
 






With problems 168  0.829 0.179 
 





Taking Part in Sports 
            
 
Without problems 535  0.943 0.098 
 






With problems 166  0.831 0.177 
 






             
 
Without problems 672  0.947 0.092 
 






With problems 126  0.792 0.183 
 






             
 
Without problems 629  0.954 0.084 
 





  With problems 207   0.838 0.172 
 





MVH, Measurement and Valuation of Health study; SD, standard deviation; SG, Singapore.
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Figure 6.1 Unadjusted mean differences in EQ-5D index scores between different visual 
impairment groups 
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Figure 6.2 Adjusted mean differences in EQ-5D index scores between different VI groups 
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Figure 6.3 Unadjusted mean differences in EQ-5D index scores between groups with and 
without a vision problem assessed by the VF-14  













































Figure 6.4 Adjusted mean differences in EQ-5D index scores between groups with and 
without a vision problem assessed by the VF-14  
 












































Figure 6.5 F-statistic ratios of unadjusted mean difference in EQ-5D index scores between 
different visual impairment groups 
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Figure 6.6 F-statistic ratio of adjusted mean difference in EQ-5D index scores between 
different VI groups 
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Figure 6.7 F-statistic ratios of unadjusted mean differences in EQ-5D index scores between 
groups with and without a vision problem assessed by the VF-14 
 




























Figure 6.8 F-statistic ratio of adjusted mean differences in EQ-5D index scores between 
groups with and without a vision problem assessed by the VF-14  
 












































In this study, we found that the vision ‘bolt-on’ EQ-5D index score was more discriminative 
than the standard EQ-5D index score to different levels of visual problems. To the best of our 
knowledge, this is the first empirical study showing that a ‘bolt-on’ EQ-5D index score had 
higher discriminatory power than the standard EQ-5D index score. A previous study found 
that a cognition ‘bolt-on’ item might increase the sensitivity of the EQ-5D to change (or 
responsiveness) in the elderly population (Arrons and Krabbe, 2011). However, the 
preference-based EQ-5D index score was not assessed in that study. Hence, our study 
provided the first evidence for the value of the ‘bolt-on’ exercise in developing utility-based 
measures with better measurement properties.  
 
The vision ‘bolt-on’ EQ-5D exhibited a larger difference than the standard EQ-5D in 14 of 16 
comparisons of groups known to differ in vision status, suggesting that it would demonstrate 
greater gains than the latter for interventions that can improve vision acuity or function. 
Although the advantage in utility gains as indicated by adjusted mean absolute differences 
was small, it may still increase the chance of showing positive results in economic evaluation 
studies. For example, the utility gains of the EQ-5D[vision] and EQ-5D[core] were only 
between 0.01 and 0.03. If a new intervention can improve mildly impaired vision to normal 
vision and maintain it for 10 years, the incremental gains in QALYs for an individual treated 
by the intervention as compared to the usual care which can only maintain the current vision 
would be 0.48 and 0.30 based on the vision ‘bolt-on’ and standard EQ-5D, respectively, 
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according to our study. Assuming the incremental costs for the intervention as compared to 
usual care are $15,000, the point estimate of the incremental cost-effectiveness ratio (ICER) 
based on the ‘bolt-on’ and standard EQ-5D would be $31,250/QALY and $50,000/QALY, 
respectively. If the decision maker’s willingness-to-pay threshold is $40,000/QALY, the use 
of the two index scores would lead to completely different conclusions. Therefore, the 
seemingly small advantage of the vision ‘bolt-on’ EQ-5D over the standard EQ-5D in 
economic evaluations should not be underestimated.  
 
It should be noted that the ‘bolt-on’ index score may not always be advantageous to the 
standard EQ-5D index score in economic evaluations. In comparison of the EQ-5D[MVH, 
EQ-5D[SG] and EQ-5D[vision], the vision ‘bolt-on’ EQ-5D was not superior to the standard 
EQ-5D in generating larger between-group differences when the UK and Singapore value 
sets were used. An obvious reason for this result is the much wider ranges of the UK and 
Singapore value sets (Table 4.1). However, the result remained the same even after the two 
value sets were rescaled to the range of the vision ‘bolt-on’ value set. Therefore, the non-
superiority of the vision ‘bolt-on’ system must have to do with the different ways in which 
those value sets were estimated. The design of the MVH, Singapore, and vision ‘bolt-on’ 
valuation studies differed in many important aspects such as target population, valuation 
procedure, and modeling strategy. Those have been shown to affect valuation of EQ-5D 
health states (Johnson et al., 2005; Rand-Hendriksen et al., 2012; Wang et al., 2014). Hence, 
an important implication of this result is that a ‘bolt-on’ EQ-5D might not necessarily result 
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in more positive cost-effectiveness outcomes than the standard EQ-5D when used in 
economic evaluations. How to increase the sensitivity of a ‘bolt-on’ system from its core 
system then? Our study suggests that one way to do it might be to estimate the value set of 
the new system using the same study protocol for the core system. Moreover, in two 
comparisons of individuals with different levels of VI, the absolute difference quantified by 
EQ-5D[vision] and EQ-5D[core] differed by only 0.002, with the standard EQ-5D being the 
more discriminative one. Although the difference is too small to affect the outcomes of 
economic evaluations, this result suggests that the vision ‘bolt-on’ item may not always 
increase the discriminatory power of the index score, especially when the difference between 
the groups and the sample size of the groups are both small. Despite this result, the ‘bolt-on’ 
EQ-5D is the first choice for use in economic evaluations since it is not disadvantaged in any 
condition.  
 
Our study suggests that the ‘bolt-on’ index score would be more discriminative than the 
standard EQ-5D index score when they are used in studies aiming to detect statistically 
significant difference. Based on the F-statistic ratios, the ‘bolt-on’ index score is more likely 
than the standard EQ-5D index score (EQ-5D[MVH], EQ-5D[SG], and EQ-5D[core]) to 
show statistically significant results, which means a smaller sample size is needed when the 
‘bolt-on’ index substitutes the standard EQ-5D index as the primary outcome measure in a 
clinical trial. This advantage of the ‘bolt-on’ index score was present in all the known-groups 
comparisons, including the two comparisons where the standard EQ-5D index score 
128 
 
demonstrated a lager absolute mean difference. This is not surprising as the F-statistic is a 
function of both the mean difference between groups and the standard deviation of the index 
scores (Fayers and Machin et al., 2000). When the mean difference is relatively small, a 
relatively higher F-statistic value is still possible if the corresponding standard deviation is 
small. The standard deviation of the ‘bolt-on’ index score was smaller than that for the 
standard EQ-5D index score for almost all of the comparison groups in this study. As the two 
indices use the common scale anchored by 0 (dead) and 1 (full health), this result means the 
‘bolt-on’ index score could provide measurements with less error or higher reliability for the 
comparison groups. The higher F-statistic values suggest that, not only the vision ‘bolt-on’ 
item captured unique difference between known groups, it also meaningfully impacted on the 
index score. The F-statistic ratios also suggest that the advantage of the ‘bolt-on’ index score 
to the standard EQ-5D index score is greater in discriminating between different levels of VI 
than vision problems. This could be due to the fact that certain standard EQ-5D items such as 
the usual activities and the VF-14 captured some common information. As a result, the added 
value of the vision item to the EQ-5D is less when the target of measurement is defined by 
the VF-14. Taken all together, our study suggested that it would be more advantageous to use 
the vision ‘bolt-on’ EQ-5D than the standard EQ-5D in hypothesis-testing studies. This is 
good news as the performance of the standard EQ-5D in visual disorder was found to be 




The main limitation of this study is the use of experimental value sets which were estimated 
using a relatively small general population sample. There is currently no an official ‘bolt-on’ 
value set. Therefore, what we showed in the study is just the potential of the vision ‘bolt-on’ 
item in empirical studies, and the utility values reported in this paper should not be used in 
any formal economic evaluation. Secondly, it should be noted that discriminatory power is 
sensitivity to difference but not sensitivity to change or responsiveness, although higher 
discriminatory power may be a sign of better responsiveness. Hence, future studies are 
needed to assess the relative sensitivity of the ‘bolt-on’ and standard EQ-5D in interventional 
studies. Thirdly, this study was based on observation of a vision ‘bolt-on’ item in Asians with 
and without vision problems. Hence, the study findings might not be generalizable to other 
populations or ‘bolt-on’ items. Nevertheless, this study is well powered by a large sample of 
individuals and it has provided the first information about the potential of the ‘bolt-on’ 
exercise in the real world. Lastly, the “bolt-on” EQ-5D questionnaire only differs from the 
standard EQ-5D questionnaire by 1 question. Hence, its potential usefulness and clinical 
impact need to be explored further.  
 
In conclusion, the vision ‘bolt-on’ EQ-5D appears to be more discriminative than the 
standard EQ-5D in measurement of vision problems. Future studies should investigate the 
extent to which the vision ‘bolt-on’ item can increase the sensitivity of the EQ-5D to vision 











7.1 Major findings 
Five studies were conducted to determine the health and economic burden of visual impairment 
(VI) in Singapore. The major findings of these studies are as follows: 
1. VI imposes considerable direct medical costs to the healthcare system now and in the next 
few decades in Singapore. AMD has the largest direct medical costs in both the individual 
and population levels, compared with the cataract, glaucoma, and diabetic retinopathy (DR). 
 
2. VI also causes considerable out-of-pocket (OOP) expenditure and productivity loss in 
Singapore. Outpatient service is the main cause of medical service utilization and OOP 
expenditure. The productivity loss of caregivers is higher than that of the patients.  
 
3. VI exerts substantial health burden in all three Asian ethnicities in Singapore. VI has a 
significant impact on health-related quality of life (HRQOL) and the health burden of VI 
measured by quality-adjusted life years (QALYs) per 100,000 people is higher than that of 
other health conditions.  
 
4. The relative effect size of visual acuity (VA) in better-seeing and worse-seeing eye on the 
overall health utility is mediated by age and socio-economic status. VA in the better-seeing 
eye has a larger effect than VA in the worse-seeing eye only in those old (>65 years) and in 
low SES. Therefore, considering VA in the better-seeing eye alone in the HRQOL research 




5. The vision ‘bolt-on’ EQ-5D seems to be more discriminative than the standard EQ-5D in the 
measurement of vision problems.   
 
7.2 Contributions 
The main contributions of the thesis to understanding the economic costs and health burden in 
Singapore are summarized as follows: 
1. The economic burden and health burden of VI provide a comprehensive picture of the 
disease burden of VI in Singapore. The findings provide useful information for health 
professionals and policy makers to design and implement appropriate programs and 
strategies to prevent VI and reduce the disease burden of VI. Meanwhile, findings about 
the impact of VI on the health utilities and costs of VI could also be used in future cost-
utility analysis of eye disease interventions. 
 
2. The effect of VA in the better-seeing and worse-seeing eye on health utility in visually 
impaired individuals provides useful information for future the HRQOL research of 
vision problems. VA in the worse-seeing eye may be a more valuable measure in the 
HRQOL research of vision problems, compared with VA in the better-seeing eye. 
 
3. The vision ‘bolt-on’ EQ-5D shows better discriminative power than the standard EQ-5D 
in the measurement of vision problems. The finding supports further development and 
testing of the vision ‘bolt-on’ EQ-5D in the cost-utility analysis of interventions for 




7.3 Future studies 
New research questions from the findings and limitations in the studies are as follows: 
1. Future studies need to estimate the direct medical costs of VI occurred in the medical 
centers  apart from Singapore National Eye Center; 
2. Future studies need to estimate the OOP expenditure and productivity loss of VI using 
more reliable data and more representative sample of individuals without VI as the 
control group.  
3. Future studies need to study the impact of more health conditions on health utilities and 
compare it with VI in Singapore. 
4. Future studies need to assess the effect of VA measures based on VA in the better-seeing 
and worse-seeing eye on utility measure in populations other than Asians.  
5. Future studies need to build up an official ‘bolt-on’ value set based on the Singapore 
general population and assess the sensitivity of the ‘bolt-on’ EQ-5D to change or 
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The vision “bolt-on” EQ-5D-3L questionnaire 
I am now going to ask you some questions regarding your state of health today. 
J1 In terms of mobility, would you 
say you…(READ OUT)? 
Have no problems in walking about 1 
Have some problems in walking about 2 
Are confined to bed 3 
 
J2 In terms of self-care, would you 
say you…(READ OUT)? 
Have no problems with self-care 1 
Have some problems washing or dressing 
yourself 
2 
Are unable to wash or dress yourself 3 
 
J3 In terms of usual activities (e.g. 
work, study, housework, family or 
leisure activities), would you say 
you…(READ OUT)? 
Have no problems with performing your 
usual activities 
1 
Have some problems with performing your 
usual activities 
2 
Are unable to perform your usual activities 3 
 
J4 In terms of pain or discomfort 
would you say you…(READ 
OUT)? 
Have no pain or discomfort 1 
Have moderate pain or discomfort 2 
Have extreme pain or discomfort 3 
 
J5 In terms of anxiety or depression 
would you say you are…(READ 
OUT)? 
Not anxious or depressed 1 
Moderately anxious or depressed 2 
Extremely anxious or depressed 3 
 
J6 In terms of vision, using glasses or 
contact lens if needed, would you 
say you have…(READ OUT)? 
No problems seeing 1 
Some problems seeing 2 
Extremely problems seeing 3 
SHOWCARD J7 
J7 Using this scale where 0 means the 
worst state of health and 100 means 
the best state of health, how would 
you rate your own state of health 
today? 
























The VF-14 questionnaire 
I am now going to ask you a list of questions related to your vision (eyesight). 
K1 Do you have any difficulty, even with 
glasses (i.e. spectacles) reading small 
print, such as labels on medicine bottles, 
telephone book or food labels? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 





K2 Do you have any difficulty, even with 
glasses (i.e. spectacles) reading a 
newspaper or a book? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K3 Do you have any difficulty, even with 
glasses (i.e. spectacles) reading a large-
print book or a large-print newspaper 
or numbers on a telephone? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K4 Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
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Do you have any difficulty, even with 
glasses (i.e. spectacles) recognizing 
people when they are close to you? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
No 5 




K5 Do you have any difficulty, even with 
glasses (i.e. spectacles) seeing steps, 
stairs or curbs (kerbs)? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 
Not applicable 6 
  
  
K6 Do you have any difficulty, even with 
glasses (i.e. spectacles) reading traffic 
signs, street signs or store signs? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K7 Do you have any difficulty, doing fine 
handwork like sewing, knitting or 
carpentry because of your vision, even 
with glasses (i.e. spectacles)? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 





If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 




K8 Do you have any difficulty, writing 
cheques or filling forms because of your 
vision, even with glasses (i.e. spectacles)? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K9 Do you have any difficulty playing games 
such as chess, card games, mahjong 
because of your vision, even with glasses 
(i.e. spectacles)? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K10 Do you have any difficulty taking part in 
sports like bowling, tennis, badminton, 
golf because of your vision, even with 
glasses? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 






K11 Do you have any difficulty cooking 
because of your vision, even with glasses? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K12 Do you have any difficulty, even with 
glasses (i.e. spectacles), watching 
television? 
 
If YES, PROBE: How much difficulty do 
you currently have? A little difficulty, a 
moderate amount of difficulty, a great 
deal of difficulty or unable to do the 
activity? 
Yes, a little difficulty 1 
Yes, a moderate amount of difficulty 2 
Yes, a great deal of difficulty 3 
Yes, unable to do the activity 4 
No 5 




K13 Do you currently drive a car? Yes 1 GO TO K14 
No 2 GO TO K16 
 
K14 How much difficulty do you have driving 
during the day because of your vision? 
Do you have…(READ OUT)? 
No  difficulty 1 
A little difficulty 2 
A moderate amount of difficulty 3 
A great deal of difficulty 4 
 
K15 How much difficulty do you have driving 
at night because of your vision? 
Do you have…(READ OUT)? 
No  difficulty 1 
A little difficulty 2 
A moderate amount of difficulty 3 
A great deal of difficulty 4 
 
 
K16 Have you ever driven a car? 
 








K17 How long ago did you stop driving? Was 
it…(READ OUT)? 
Less than 6 months ago 1 
6 to 12 months ago  2 
More than 12 months ago 3 
 
K18 Why did you stop driving? Was it because 
of eyesight problem? 
Vision 1 
Other illness 2 





The healthcare utilization, expenditure and employment questionnaire 
INTRODUCTION: Good morning/afternoon/evening, I am __________, from Singapore National Eye Center 
(SHOW INTERVIEWER CARD). On behalf of the Singapore Eye Research Institute (SERI), we are conducting a 
survey on the healthcare utilization and expenditure of Singaporeans with and without eye diseases (SHOW LETTER 
FROM SERI). We would appreciate it if you could help us by providing us the required information. Please be 
assured that all responses provided by you will be kept strictly confidential. 
 
HEALTH SCHEMES & INSURANCE 
A1 Do you have a Medisave account? Yes 1  
No 2  
Don’t Know (DO NOT READ OUT) 97  
Refused (DO NOT READ OUT) 99  
 
A2 Are you currently covered 
by…(READ OUT)? 
Medishield 1 GO TO A3a 
Private Shield Plan such as  
Incomeshield, PruShield 
2 GO TO A3b 
Not covered by any Shield Plan 3 
GO TO A3a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
 
A3a Are you currently covered by 
any…(READ OUT)? 
Private Healthcare Insurance Plan that covers cost of 
inpatient services 
1 
Private Healthcare Insurance Plan that covers cost of 
outpatient services 
2 
Private Healthcare Insurance Plan that covers both cost of  
inpatient and outpatient services 
3 
Have such Private Healthcare Insurance Plan but not sure of 
the coverage  
4 
Not covered by such Private Healthcare Insurance Plan 5 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
 
A3b Apart from Private Shield Plan, 
are you currently covered by 
other …(READ OUT)? 
Private Healthcare Insurance Plan that covers cost of 
inpatient services 
1 
Private Healthcare Insurance Plan that covers cost of 
outpatient services 
2 
Private Healthcare Insurance Plan that covers both cost of  
inpatient and outpatient services 
3 
Have such Private Healthcare Insurance Plan but not sure of 
the coverage  
4 
Not covered by such Private Healthcare Insurance Plan 5 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
A4 Yes 1 
No 2 
Don’t Know (DO NOT READ OUT) 97 
GO TO A4 
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Are you currently covered by 
ElderShield? 
Refused (DO NOT READ OUT) 
99 
 
A5 Are you currently a holder of the 
Civil Service Card (CSC)? 
Yes 1 
No 2 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 




Don’t Know (DO NOT READ OUT) 97 





ACUTE CARE HOSPITAL/COMMUNITY HOSPITAL 
B1 Did you at any time during the past 3 
months stay at least one night in a 
hospital because of health problems? 
Yes 1 GO TO B2 
No 2 
GO TO C1 Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
B2 How many times did you stay in a 
hospital (for at least one night for health 
problems) in the past 3 months? 
RECORD NO: ___ GO TO B3 
DK (DO NOT READ OUT) 97  
GO TO C1 RF (DO NOT READ OUT) 99 
 
B3 I would like to know more details 
about each of your hospital 
admission in the past 3 months.  
Let’s talk about your hospital 
admission. How many nights did 
you stay at the hospital? 
 Most  
Recent 
2nd Most  
Recent 
3rd Most  
Recent  
    
RECORD NUMBER _______ _______ ________ 
 
   
 
B4 For this admission, which 
hospital did you stay in? 








   
Alexandra Hospital  1 1 1 
Changi General Hospital  2 2 2 
Institute of Mental Health  3 3 3 
Khoo Teck Puat Hospital  4 4 4 
KK Women’s and Children’s 
Hospital 
5 5 5 
National University Hospital 6 6 6 
Singapore General Hospital  7 7 7 
Tan Tock Seng Hospital  8 8 8 
National Heart Centre 9 9 9 
Community Hospital    
Bright Vision Hospital 10 10 10 
Kwong Wai Shiu Hospital 11 11 11 
Ren Ci Hospital 12 12 12 
St Andrew’ s Community Hospital 13 13 13 
St Luke’s Hospital 14 14 14 

















DK 97 97 97 
RF 99 99 99 
 
 
IF GOVERNMENT RESTRUCTURED HOSPITAL (B4=1-9) – SEE SHADED AREA, GO TO B5 




B5 What class of ward 
did you stay in? 
 Most Recent 2nd Most Recent 3rd Most Recent  
A Class 1 1 1 
B1 Class 2 2 2 
B2 Class 3 3 3 
C Class 4 4 4 
DK (Do Not Read Out) 97 97 97 
RF (Do Not Read Out) 99 99 99 
 
B6 How did you 
travel to the 
hospital? 
 Most Recent 2nd Most Recent 3rd Most Recent 
 Yes No Yes No Yes No 
Ambulance 1 2 1 2 1 2 
Taxi 1 2 1 2 1 2 
Bus 1 2 1 2 1 2 
MRT 1 2 1 2 1 2 
Car 1 2 1 2 1 2 
Walk 1 2 1 2 1 2 
Others (Specify) 





DK 1 2 1 2 1 2 
RF 1 2 1 2 1 2 
 
B7 How much was 
spent on the 
transportation to 
the hospital? 
 Most Recent 
 
2nd Most Recent 
 
3rd Most Recent  
RECORD AMOUNT $_________ $__________ $__________ 
    
 
B8 What were the 
medical conditions 
for which you sought 
treatment at the 
hospital? 





 Recent  
 Y N Y N Y N 
Diabetes 1 2 1 2 1 2 
High blood pressure 1 2 1 2 1 2 
High blood cholesterol 1 2 1 2 1 2 
Heart attack /heart failure/  
uneven heart rhythm 
1 2 1 2 1 2 
Stroke 1 2 1 2 1 2 
Asthma 1 2 1 2 1 2 
Chronic obstructive pulmonary  
disease (COPD) 
1 2 1 2 1 2 
 Pneumonia 1 2 1 2 1 2 
Cough, cold, sore throat, fever 1 2 1 2 1 2 
Lower back pain 1 2 1 2 1 2 
Osteoporosis 1 2 1 2 1 2 
Rheumatism and arthritis 1 2 1 2 1 2 
Joint conditions 1 2 1 2 1 2 
Fractures 1 2 1 2 1 2 
Physical injuries 1 2 1 2 1 2 
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Cataract 1 2 1 2 1 2 
Glaucoma 1 2 1 2 1 2 
Eye infection 1 2 1 2 1 2 
Hearing loss 1 2 1 2 1 2 
Schizophrenia 1 2 1 2 1 2 
Alzheimer’s & other dementia 1 2 1 2 1 2 
Anxiety & depression 1 2 1 2 1 2 
Non cancer (benign) growth 1 2 1 2 1 2 
Cancer 1 2 1 2 1 2 










DK 1 2 1 2 1 2 
RF 1 2 1 2 1 2 
B9 How much was your hospital bill, excluding government subsidy? 
 
B10 How did you pay the hospital bill? 
 
IF YES TO ANY HEALTH SCHEME/INSURANCE 
B11 You mentioned that your hospital bill was paid using…(READ OUT HEALTH SCHEME/INSURANCE 
USED). How much was paid using these health scheme/insurance? 
 
IF  YES TO OUT-OF-POCKET USING CASH OR CREDIT CARD 
B12 You mentioned that your hospital bill was paid out-of-pocket using cash or credit card. How much was 
paid using cash or credit card? 
 
IF  YES TO OTHERS 
B13 How much was paid using ….(READ OUT OTHERS)? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
Hospital Bill B9  $__________   B9  $__________   B9  $__________   
       
 B10 B11 B10 B11 B10 B11 
 Y N  Y N  Y N  
Health Scheme/Insurance         
$_______ 
(A) 







Medishield 1 2 1 2 1 2 
Private Insurance  1 2 1 2 1 2 
Medifund 1 2 1 2 1 2 















   B12   B12   B12 
Out-of-Pocket  
Using Cash or Credit 
Card 
         
         









Family Member/Relative 1 2 1 2 1 2 
Friend 1 2 1 2 1 2 
























DK 1 2  1 2  1 2  
RF 1 2  1 2  1 2  
          
TOTAL (A+B+C)  $______  $______  $______ 
 
INTERVIEWER TO CHECK : TOTAL (A+B+C)=B9  
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EMERGENCY DEPARTMENT SERVICES 
C1 Let’s now talk about emergency 
department in a hospital. Did you at any 
time during the past 3 months receive 
medical care in a hospital emergency 
department that did not result in 
hospitalization (i.e. not directly admitted  
to hospital)? 
Yes 1 GO TO C2 
No 2 
GO TO D1 Don’t Know (DO NOT READ OUT) 97 




C2 In the past 3 months, how many times did 
you receive medical care in a hospital 
emergency department that did not result in 
hospitalization? 
RECORD NO: ___ GO TO C3 
DK (DO NOT READ 
OUT) 
97  
GO TO D1 
RF (DO NOT READ 
OUT) 
99 
    
 
C3 I would like to know more details 
about each of your visit to the 
hospital emergency department 




Let’s talk about your…….(READ 
OUT RECENCY) visit to the 
hospital emergency department. 
Which hospital emergency 









   
Alexandra Hospital  1 1 1 
Changi General Hospital  2 2 2 
Institute of Mental Health  3 3 3 
Khoo Teck Puat Hospital  4 4 4 
KK Women’s and Children’s 
Hospital 
5 5 5 
National University Hospital 6 6 6 
Singapore General Hospital 7 7 7 

















DK 97 97 97 
RF 99 99 99 
 









 Y N Y N Y N 
Ambulance 1 2 1 2 1 2 
Taxi 1 2 1 2 1 2 
Bus 1 2 1 2 1 2 
MRT 1 2 1 2 1 2 
Car 1 2 1 2 1 2 











DK 1 2 1 2 1 2 




C5 How much was spent on the 
transportation to the hospital 









    
RECORD AMOUNT $_______ $_______ $_______ 
    
 
C6 What were the 
medical conditions 
for which you sought 
treatment at the 
hospital emergency 
department? 
 Most  
Recent 




 Yes No Yes No Y N 
Diabetes 1 2 1 2 1 2 
High blood pressure 1 2 1 2 1 2 
High blood cholesterol 1 2 1 2 1 2 
Heart attack /heart failure/ 
uneven heart rhythm 
1 2 1 2 1 2 
Stroke 1 2 1 2 1 2 
Asthma 1 2 1 2 1 2 
Chronic obstructive 
pulmonary disease (COPD) 
1 2 1 2 1 2 
 Pneumonia 1 2 1 2 1 2 
Cough, cold, sore throat, 
fever 
1 2 1 2 1 2 
Lower back pain 1 2 1 2 1 2 
Osteoporosis 1 2 1 2 1 2 
Rheumatism and arthritis 1 2 1 2 1 2 
Joint conditions 1 2 1 2 1 2 
Fractures 1 2 1 2 1 2 
Physical injuries 1 2 1 2 1 2 
Cataract 1 2 1 2 1 2 
Glaucoma 1 2 1 2 1 2 
Eye infection 1 2 1 2 1 2 
Hearing loss 1 2 1 2 1 2 
Schizophrenia 1 2 1 2 1 2 
Alzheimer’s & other 
dementia 
1 2 1 2 1 2 
Anxiety & depression 1 2 1 2 1 2 
Non cancer (benign) growth 1 2 1 2 1 2 
Cancer 1 2 1 2 1 2 









DK 1 2 1 2 1 2 
RF 1 2 1 2 1 2 
 





C8 How did you pay the bill? 
 
IF YES TO ANY HEALTH SCHEME/INSURANCE 
C9 You mentioned that the bill was paid using…(READ OUT HEALTH SCHEME/INSURANCE USED). 
How much was paid using these health scheme/insurance? 
 
IF  YES TO OUT-OF-POCKET USING CASH OR CREDIT CARD 
C10 You mentioned that the bill was paid out-of-pocket using cash or credit card. How much was paid using 
cash or credit card? 
 
IF  YES TO OTHERS 
C11 How much was paid using ….(READ OUT OTHERS)? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
Emergency Dept Bill C7  $__________ C7  $__________ C7  $__________ 
       
 C8 C9 C8 C9 C8 C9 
 Y N  Y N  Y N  
Health Scheme/Insurance         
$______ 
 (A) 




















          
Out-of-Pocket  
Using Cash or Credit 
Card 
         
  C10   C10   C10 









Family Member/Relative 1 2 1 2 1 2 



























DK 1 2  1 2  1 2  
RF 1 2  1 2  1 2  
          
TOTAL (A+B+C)  $_______  $_______  $_______ 




D1 Let’s now talk about visits to government 
polyclinics and private GP clinics. Did 
you at any time in the past 3 months 
receive medical care at a polyclinic or 
private GP clinic? 




Don’t Know (DO NOT READ OUT) 97 




D2 In the past 3 months, how many times 
did you visit a polyclinic or private GP 
clinic to receive medical care? 
RECORD NO: ___ GO TO D3 
DK (DO NOT READ OUT) 97  
GO TO D13 
RF (DO NOT READ OUT) 99 
    
 
D3 I would like to know more details about 
each of your visit to a polyclinic/private 
GP clinic in the past 3 months.  Let’s 
talk about your…(READ OUT 
RECENCY) visit.  For this visit, did 
you receive medical care at a polyclinic 







Polyclinic 1 1 1 
Private GP Clinic 2 2 2 
DK (DO NOT READ OUT) 97 97 97 




D4 For your visit to the private GP 
clinic, did you enjoy subsidized 
rate on your bill under the 








Yes 1 1 1 
No 2 2 2 
DK (DO NOT READ OUT) 97 97 97 
RF (DO NOT READ OUT) 99 99 99 
 
D5 How did you travel to the 
polyclinic/private GP 
clinic (INTERVIEWER 
TO READ OUT 
ACCORDINGLY)? 
 Most  
Recent 




 Y N Y N Y N 
Ambulance 1 2 1 2 1 2 
Taxi 1 2 1 2 1 2 
Bus 1 2 1 2 1 2 
MRT 1 2 1 2 1 2 
Car 1 2 1 2 1 2 










DK (DO NOT READ 
OUT) 
1 2 1 2 1 2 
RF (DO NOT READ OUT) 1 2 1 2 1 2 
 
 






IF PRIVATE GP CLINIC – SEE SHADED AREA, GO TO D4, 




D6 How much was spent on the 
transportation to travel to the 
polyclinic/private GP clinic 
(INTERVIEWER TO READ OUT 
ACCORDINGLY)?  
    
RECORD AMOUNT $_____ $_____ $_______ 
 
   
 
 
D7 What were the 
medical conditions 
for which you sought 












 Y N Y N Y N 
Diabetes 1 2 1 2 1 2 
High blood pressure 1 2 1 2 1 2 
High blood cholesterol 1 2 1 2 1 2 
Heart attack /heart failure/ 
uneven heart rhythm 
1 2 1 2 1 2 
Stroke 1 2 1 2 1 2 
Asthma 1 2 1 2 1 2 
Chronic obstructive pulmonary 
disease (COPD) 
1 2 1 2 1 2 
 Pneumonia 1 2 1 2 1 2 
Cough, cold, sore throat, fever 1 2 1 2 1 2 
Lower back pain 1 2 1 2 1 2 
Osteoporosis 1 2 1 2 1 2 
Rheumatism and arthritis 1 2 1 2 1 2 
Joint conditions 1 2 1 2 1 2 
Fractures 1 2 1 2 1 2 
Physical injuries 1 2 1 2 1 2 
Cataract 1 2 1 2 1 2 
Glaucoma 1 2 1 2 1 2 
Eye infection 1 2 1 2 1 2 
Hearing loss 1 2 1 2 1 2 
Schizophrenia 1 2 1 2 1 2 
Alzheimer’s & other dementia 1 2 1 2 1 2 
Anxiety & depression 1 2 1 2 1 2 
Non cancer (benign) growth 1 2 1 2 1 2 
Cancer 1 2 1 2 1 2 









DK 1 2 1 2 1 2 
RF 1 2 1 2 1 2 
 
D8 For your visit to the polyclinic/private GP clinic (INTERVIEWER TO READ OUT ACCORDINGLY), 
how much was your bill, excluding government subsidy? 
 




IF YES TO ANY HEALTH SCHEME/INSURANCE 
D10 You mentioned that your bill was paid using…(READ OUT HEALTH SCHEME/INSURANCE USED). 
How much was paid using these health scheme/insurance? 
 
IF YES TO OUT-OF-POCKET USING CASH OR CREDIT CARD 
D11 You mentioned that your bill was paid out-of-pocket using cash or credit card. How much was paid 
using cash or credit card? 
 
IF YES TO OTHERS 
D12 How much was paid using ….(READ OUT OTHERS)? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
  Amount of Bill  D8 $__________  D8 $__________   D8 $__________ 
       
 D9 D10 D9 D10 D9 D10 
 Y N  Y N  Y N  
Health Scheme/Insurance         
$______ 
 (A) 







Private Insurance  1 2 1 2 1 2 
Medifund 1 2 1 2 1 2 













          
Out-of-Pocket Using Cash 
(including Credit Card) 
         
  D11   D11   D11 









Family Member/Relative 1 2 1 2 1 2 
Friend 1 2 1 2 1 2 

























DK 1 2  1 2  1 2  
RF 1 2  1 2  1 2  
          
TOTAL (A+B+C)  $________  $________  $_______ 
INTERVIEWER TO CHECK: TOTAL (A+B+C) =D8 
 
D13 Let’s now talk about visits to specialist 
outpatient clinics. Did you at any time 
Yes 1 GO TO 
D14 
No 2 GO TO E1 
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during the past 3 months receive medical 
care at a specialist outpatient clinic? 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
   
 
D14 In the past 3 months, how many times did 
you receive medical care at a specialist 
outpatient clinic? 
RECORD NO: ___ GO TO D15 
DK (DO NOT READ 
OUT) 
97  
GO TO E1 
RF (DO NOT READ 
OUT) 
99 
    
 
D15 I would like to know more 
details about each of your visit 
to the specialist outpatient clinic 
in the past 3 months.  Let’s talk 
about your…(READ OUT 
RECENCY) visit to a specialist 
outpatient clinic.  Which 
hospital or medical centre is the 












   
Alexandra Hospital  1 1 1 
Changi General Hospital  2 2 2 
Institute of Mental Health 3 3 3 
Khoo Teck Puat Hospital  4 4 4 
KK Women’s and Children’s 
Hospital 
5 5 5 
National University Hospital 6 6 6 
Singapore General Hospital  7 7 7 
Tan Tock Seng Hospital 8 8 8 
National Cancer Centre 9 9 9 
National Heart Centre 10 10 10 
Singapore National Eye Centre 11 11 11 

















DK (DO NOT READ OUT) 97 97 97 
RF (DO NOT READ OUT) 99 99 99 
    
 
D16 How did you  travel 
to the specialist 
outpatient clinic 
located at…(READ 
OUT ANSWER IN 
D15)? 
 Most  
Recent 




 Y N Y N Y N 
Ambulance 1 2 1 2 1 2 
Taxi 1 2 1 2 1 2 
Bus 1 2 1 2 1 2 
MRT 1 2 1 2 1 2 
Car 1 2 1 2 1 2 









DK (DO NOT READ OUT) 1 2 1 2 1 2 





D17 How much was spent on the 
transportation to the specialist 
outpatient clinic?  








$______ $_____ $______ 
 
 
D18 What were the 
medical conditions 
for which you sought 
treatment at the 
specialist outpatient 
clinic? 






 Y N Y N Y N 
Diabetes 1 2 1 2 1 2 
High blood pressure 1 2 1 2 1 2 
High blood cholesterol 1 2 1 2 1 2 
Heart attack /heart failure/ 
uneven heart rhythm 
1 2 1 2 1 2 
Stroke 1 2 1 2 1 2 
Asthma 1 2 1 2 1 2 
Chronic obstructive 
pulmonary disease (COPD) 
1 2 1 2 1 2 
 Pneumonia 1 2 1 2 1 2 
Cough, cold, sore throat, 
fever 
1 2 1 2 1 2 
Lower back pain 1 2 1 2 1 2 
Osteoporosis 1 2 1 2 1 2 
Rheumatism and arthritis 1 2 1 2 1 2 
Joint conditions 1 2 1 2 1 2 
Fractures 1 2 1 2 1 2 
Physical injuries 1 2 1 2 1 2 
Cataract 1 2 1 2 1 2 
Glaucoma 1 2 1 2 1 2 
Eye infection 1 2 1 2 1 2 
Hearing loss 1 2 1 2 1 2 
Schizophrenia 1 2 1 2 1 2 
Alzheimer’s & other 
dementia 
1 2 1 2 1 2 
Anxiety & depression 1 2 1 2 1 2 
Non cancer (benign) growth 1 2 1 2 1 2 
Cancer 1 2 1 2 1 2 










DK (DO NOT READ OUT) 1 2 1 2 1 2 
RF (DO NOT READ OUT) 1 2 1 2 1 2 
 
 
D19 For your visit to the specialist outpatient clinic, how much was the bill, excluding government subsidy? 
 





IF YES TO ANY HEALTH SCHEME/INSURANCE 
D21 You mentioned that the bill was paid using…(READ OUT HEALTH SCHEME/INSURANCE USED). 
How much was paid using these health scheme/insurance? 
 
IF YES TO OUT-OF-POCKET USING CASH OR CREDIT CARD 
D22 You mentioned that the bill was paid out-of-pocket using cash or credit card. How much was paid using 
cash or credit card? 
 
IF YES TO OTHERS 
D23 How much was paid using ….(READ OUT OTHERS)? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
  Amount of Bill  D19 $__________ D19 $__________ D19 $__________ 
 D20 D21 D20 D21 D20 D21 
 Y N  Y N  Y N  
Health Scheme/Insurance         
$_______ 





Private Insurance  1 2 1 2 1 2 
Medifund 1 2 1 2 1 2 













          
Out-of-Pocket  
Using Cash or Credit 
Card) 
         
  D22   D22   D22 






Family Member/Relative 1 2 1 2 1 2 
Friend 1 2 1 2 1 2 
Others (Specify) 1 
(____) 
2 1 (____) 2 1 (__) 2 


















DK 1 2  1 2  1 2  
RF 1 2  1 2  1 2  
          
TOTAL (A+B+C)  $_______   $_______   $_______ 
INTERVIEWER TO CHECK: TOTAL (A+B+C)=D19 
HEALTH SUPPLEMENTS/TREATMENT 
E1 Yes 1 
No 2 
Don’t Know (DO NOT READ OUT) 97 
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In the past 3 months, did you take any 
health supplements or herbal medicine 
(e.g. vitamins, cordyceps)? 
Refused (DO NOT READ OUT) 
99 
 
E2a In the past 3 months, did you visit a 
TCM (Traditional Chinese Medicine) 
physician? 
Yes 1 GO TO E2b 
No 2 
GO TO E3a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
E2b In the past 3 months, how many times 
did you visit a TCM physician? 
RECORD: _____ time(s) 
   
 
E2c On average, how much was the cost for 
each visit to the TCM physician, 




E3a In the past 3 months, did you go for 
acupuncture? 
Yes 1 GO TO E3b 
No 2 
GO TO E4a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
E3b In the past 3 months, how many times 
did you go for acupuncture? 
RECORD: _____ time(s) 
   
 
E3c On average, how much was the cost for 




E4a In the past 3 months, did you go for 
massage? 
Yes 1 GO TO E4b 
No 2 
GO TO E5a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
E4b In the past 3 months, how many times 
did you go for massage? 
RECORD: _____ time(s) 
   
 
E4c On average, how much was the cost for 
each massage session? 
RECORD: $____________ 
 
E5a Yes 1 GO TO E5b 
No 2 GO TO E6a 
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In the past 3 months, did you go for Tui-
Na/Bone-setting? 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 
99 
 
E5b In the past 3 months, how many times 
did you go for Tui-Na/Bone-setting? 
RECORD: _____ time(s) 
   
 
E5c On average, how much was the cost for 
each Tui-Na/bone-setting treatment? 
RECORD: $____________ 
 
E6a In the past 3 months, did you go for foot 
reflexology? 
Yes 1 GO TO E6b 
No 2 
GO TO F1a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
E6b In the past 3 months, how many times 
did you go for foot reflexology? 
RECORD: _____ time(s) 
   
 
E6c On average, how much was the cost for 








F1a Let’s now talk about health 
aids/equipment. 
In the past 3 months, did you use a 
magnifier? 
Yes 1 GO TO F1b 
No 2 
GO TO F2a 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F1b Is the magnifier purchased, on loan or 
donated by someone? 
Purchased 1 GO TO F1c 
On loan 2 
GO TO F2a 
Donated by someone 3 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F1c How much does the magnifier cost? 
RECORD : $ _____________ 
 
F1d Who paid for the magnifier? Was 
it..(READ OUT)? 
 Yes No 
Yourself 1 2 
Family member/relative 1 2 
Friend 1 2 
Others (Specify:_____ ) 1 2 
 
F2a In the past 3 months, did you use a 
walking frame or a walking stick?   
Yes 1 GO TO F2b 
No 2 
GO TO F3a Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F2b Is the walking frame/walking stick 
purchased, rented, on loan or donated 
by someone? 
Purchased 1 GO TO F2c 
Rented 2 GO TO F2e 
On loan 3 
GO TO F3a 
Donated by someone 4 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F2c How much does the walking 
frame/walking stick cost? RECORD : $ _____________ 
 
F2d Who paid for the walking 
frame/walking stick? Was it..(READ 
OUT)? 
 Yes No 
GO TO F3a 
Yourself 1 2 
Family member/relative 1 2 
Friend 1 2 
Others (Specify:_____ ) 1 2 
 
F2e $_______ per hour 1 
$ ______ per day 2 
$ ______ per week 3 
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How much is the rental of the walking 
frame/walking stick? 
$ ______ per month 
4 
 
F3a In the past 3 months, did you use a 
wheelchair?   
Yes 1 GO TO F3b 
No 2 
GO TO G1 Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F3b Is the wheelchair purchased, rented, 
on loan or donated by someone? 
Purchased 1 GO TO F3c 
Rented 2 GO TO F3e 
On loan 3 
GO TO G1 
Donated by someone 4 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
F3c How much does the wheelchair cost? RECORD : $ _____________ 
 
F3d Who paid for the wheelchair? Was 
it..(READ OUT)? 
 Yes No 
GO TO G1 
Yourself 1 2 
Family member/relative 1 2 
Friend 1 2 
Others (Specify:_____ ) 1 2 
 
F3e How much is the rental of the 
wheelchair? 
$_______ per hour 1 
$ ______ per day 2 
$ ______ per week 3 





EMPLOYMENT STATUS (RESPONDENT) 
G1 Are you currently…(READ 
OUT)? 
Working  1 GO TO G2 
Not working 2 GO TO G9a 
 
G2 What is your occupation? RECORD:  ____________ 
 
G3 Could you please tell me how 
much you earn per month? 
Below $1,000 1 
$1,000 to $1,999 2 
$2,000 to $2,999 3 
$3,000 to $3,999 4 
$4,000 to $4,999 5 
$5,000 to $5,999 6 
$6,000 to $6,999 7 
$7,000 to $7,999 8 
$8,000 to $8,999 9 
$9,000 to $9,999 10 
$10,000 & above 11 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
G4 How many days do you work in a week? RECORD : ________ days  
 
 
G5 How many hours do you work per day? RECORD : ________ hours 
 
 
G6 In the past month, how many hours did 
you miss work because of health problem?  
(Include hours missed on sick days, MC, time 
off, leave, times when went in late, left early etc. 
because of health problem) 




G7 In the past month, how many extra hours 
did you have to work to catch up on tasks 
that you were unable to complete during 
normal working hours due to health 
problem? 




G8a In the past 3 months, did you change job 
because of health problem? 
Yes 1 GO  TO G8b 
No 




G8b In the past 3 months, how many times did you 
change job because of health problem?  
RECORD :  ________ times 
 
 
G8c How much did you earn per month for your previous job (s)? Let’s talk about your…..(READ OUT 
RECENCY) previous job. How much did you earn per month for this job? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
Below $1,000 1 1 1 
$1,000 to $1,999 2 2 2 
$2,000 to $2,999 3 3 3 
$3,000 to $3,999 4 4 4 
$4,000 to $4,999 5 5 5 
$5,000 to $5,999 6 6 6 
$6,000 to $6,999 7 7 7 
$7,000 to $7,999 8 8 8 
$8,000 to $8,999 9 9 9 
$9,000 to $9,999 10 10 10 
$10,000 & above 11 11 11 
Don’t Know (DO NOT READ OUT) 97 97 97 
Refused (DO NOT READ OUT) 99 99 99 
 
G9a You mentioned that you are currently not 
working. Did you quit your job during the 
past 3 months because of health problem? 
Yes 1 GO TO G9b 
No 2 GO TO H1 
 
G9b How long ago did you quit your job? 
Was it…(READ OUT)? 
1 week or less ago 1 
Over 1 to 2 weeks ago 2 
Over 2 to 4 weeks ago 3 
Over 1 to 2 months ago 4 
Over 2 months ago 5 
 
G9c What was your occupation before you 
quitted the job? 
RECORD :  ____________ 
 
G9d Could you please tell me how much you 
earn per month for this job? 
Below $1,000 1 
$1,000 to $1,999 2 
$2,000 to $2,999 3 
$3,000 to $3,999 4 
$4,000 to $4,999 5 
$5,000 to $5,999 6 
$6,000 to $6,999 7 
$7,000 to $7,999 8 
$8,000 to $8,999 9 
GO TO H1 
182 
 
$9,000 to $9,999 10 
$10,000 & above 11 
Don’t Know (DO NOT READ OUT) 97 







H1 In the past 3 months, did anyone help you with any of the following daily activities because of your health 
problem? (INTERVIEWER TO READ OUT THE FOLLOWING ACTIVITIES, ONE AT A TIME) 
 
 Yes No DK RF   
Accompanying you to see a doctor 1 2 3 4  IF YES TO ANY, 
GO TO H2a 
 
ELSE, GO TO J1 
Doing light housework 1 2 3 4 
Assisting you with some routine activities e.g. getting in 
and out of bed or chair, bathing, dressing, using toilet 
1 2 3 4 
Taking medicine 1 2 3 4 
Others (Specify: _______ ) 1 2 3 4 
 
H2a Who helped you with these daily activities because of your health problem?  





H2b You mentioned that your…(READ OUT ANSWER IN H2a)  helped you with these daily activities 
because of your health problem. Who spends most time helping you with these daily activities? 
 
 H2a.  H2b. Main Caregiver 
 Yes No  
Maid 1 2 1 
Spouse 1 2 2 
Child 1 2 3 
Grandchild 1 2 4 
Brother 1 2 5 
Sister 1 2 6 
Neighbour/friend 1 2 7 
Others (Specify:_____ ) 1 2 8 
 
  
IF ONLY MAID MENTIONED, TRANSFER ANSWER TO H2b - GO TO J1 
IF ONLY ONE FAMILY MEMBER/RELATIVE/FRIEND MENTIONED, TRANSER ANSWER TO H2b - GO TO I1 
IF MORE THAN ONE FAMILY MEMBER/RELATIVE/FRIEND MENTIONED, ASK H2b 
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EMPLOYMENT STATUS (CAREGIVER) 
I1 Let’s now talk about your caregiver, that 
is, your….(READ OUT ANSWER IN 
H2b). Is he/she currently…(READ 
OUT)? 
Working  1 GO TO I2 
Not working 2 GO TO I9a 
 
I2 What is his/her occupation? RECORD:  ____________ 
 
I3 Could you please tell me how much he/she 
earns per month? 
Below $1,000 1 
$1,000 to $1,999 2 
$2,000 to $2,999 3 
$3,000 to $3,999 4 
$4,000 to $4,999 5 
$5,000 to $5,999 6 
$6,000 to $6,999 7 
$7,000 to $7,999 8 
$8,000 to $8,999 9 
$9,000 to $9,999 10 
$10,000 & above 11 
Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
I4 How many days does he/she work in a 
week? 
RECORD : ________ days  
 
 
I5 How many hours does he/she work per 
day? 
RECORD : ________ hours 
 
 
I6 In the past month, how many hours did 
he/she miss work because of taking care of 
you and helping you with your activities? 
(Include time off, leave, times when went in 
late, left early etc. because of your health 
problem) 




I7 In the past month, how many extra hours 
did he/she has to work to catch up on tasks 
that he/she was unable to complete during 
normal working hours due to taking care of 
you and helping you with your activities? 






I8a In the past 3 months, did he/she change job 
because of taking care of you and helping 
you with your activities? 
Yes 1 GO  TO I8b 
No 2 GO TO J1 
 
I8b In the past 3 months, how many times did 
he/she change job because of taking care 
of you and helping you with your 
activities? 




I8c How much did he/she earn per month for his/her previous job (s)? Let’s talk about his/her…..(READ 
OUT RECENCY) previous job. How much did he/she earn per month for this job? 
 
 Most Recent 2nd Most Recent 3rd Most Recent 
Below $1,000 1 1 1 
$1,000 to $1,999 2 2 2 
$2,000 to $2,999 3 3 3 
$3,000 to $3,999 4 4 4 
$4,000 to $4,999 5 5 5 
$5,000 to $5,999 6 6 6 
$6,000 to $6,999 7 7 7 
$7,000 to $7,999 8 8 8 
$8,000 to $8,999 9 9 9 
$9,000 to $9,999 10 10 10 
$10,000 & above 11 11 11 
Don’t Know (DO NOT READ OUT) 97 97 97 
Refused (DO NOT READ OUT) 99 99 99 
 
I9a You mentioned that your caregiver is 
currently not working. Did he/she quit 
his/her job during the past 3 months 
because of taking care of you and 
helping you with your activities? 
Yes 1 GO TO I9b 
No 2 GO TO J1 
   
 
I9b How long ago did he/she quit his/her job? 
Was it…(READ OUT)? 
1 week or less ago 1 
Over 1 to 2 weeks ago 2 
Over 2 to 4 weeks ago 3 
Over 1 to 2 months ago 4 
Over 2 months ago 5 
 
I9c What was his/her occupation before 
he/she quitted the job? 
RECORD :  ________  




I9d Could you please tell me how much 
he/she earns per month for this job? 
Below $1,000 1 
$1,000 to $1,999 2 
$2,000 to $2,999 3 
$3,000 to $3,999 4 
$4,000 to $4,999 5 
$5,000 to $5,999 6 
$6,000 to $6,999 7 
$7,000 to $7,999 8 
$8,000 to $8,999 9 
$9,000 to $9,999 10 
$10,000 & above 11 
Don’t Know (DO NOT READ OUT) 97 





L1 What is your current marital 
status? 
 




Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 
L2 What is your highest educational 
qualification attained? 
 
No formal qualification/Lower Primary 1 
Primary 2 
Lower Secondary 3 
Secondary 4 
Upper Secondary 5 
Polytechnic Diploma  6 




L3 Do you currently smoke 
regularly, that is, at least once a 
week? 
 
Yes 1 GO TO L5 
No 2 GO TO L4 
Don’t Know (DO NOT READ 
OUT) 
97  
GO TO L5 
Refused (DO NOT READ OUT) 99 
 
L4 Did you smoke regularly before, 




Don’t Know (DO NOT READ OUT) 97 
Refused (DO NOT READ OUT) 99 
 







English & Mandarin 5 
English & Malay 6 
English & Tamil 7 
Others (Specify:__________) 8 
 
Name of Respondent:  IRID :     
    
Address:  
         
Contact Number :  Date of Interview:   INT_ID     
 
